'Sen1' An O
'Sen1' episode O
'Sen1' of O
'Sen1' subacute O
'Sen1' encephalopathy O
'Sen1' after O
'Sen1' the O
'Sen1' infusion O
'Sen1' of O
'Sen1' a O
'Sen1' moderate O
'Sen1' dose O
'Sen1' of O
'Sen1' methotrexate U-DRUG
'Sen1' ( O
'Sen1' 1500 B-DOSAGE
'Sen1' mg I-DOSAGE
'Sen1' / I-DOSAGE
'Sen1' m2 L-DOSAGE
'Sen1' ) O
'Sen1' ( O
'Sen1' MTX O
'Sen1' ) O
'Sen1' is O
'Sen1' reported O
'Sen1' in O
'Sen1' a O
'Sen1' young O
'Sen1' adult O
'Sen1' with O
'Sen1' metastastic O
'Sen1' gastric O
'Sen1' cancer O
'Sen1' . O

'Sen2' She O
'Sen2' continued O
'Sen2' to O
'Sen2' receive O
'Sen2' regular O
'Sen2' insulin U-DRUG
'Sen2' 4 B-DOSAGE
'Sen2' times I-DOSAGE
'Sen2' per I-DOSAGE
'Sen2' day L-DOSAGE
'Sen2' over O
'Sen2' the O
'Sen2' following O
'Sen2' 3 O
'Sen2' years O
'Sen2' with O
'Sen2' only O
'Sen2' occasional O
'Sen2' hives O
'Sen2' . O

'Sen3' A O
'Sen3' 5-month O
'Sen3' - O
'Sen3' old O
'Sen3' infant O
'Sen3' became O
'Sen3' lethargic O
'Sen3' and O
'Sen3' poorly O
'Sen3' responsive O
'Sen3' after O
'Sen3' receiving O
'Sen3' 1 B-DOSAGE
'Sen3' drop L-DOSAGE
'Sen3' of O
'Sen3' brimonidine U-DRUG
'Sen3' in O
'Sen3' each O
'Sen3' eye O
'Sen3' . O

'Sen4' The O
'Sen4' presented O
'Sen4' patient O
'Sen4' was O
'Sen4' treated O
'Sen4' with O
'Sen4' 200 B-DOSAGE
'Sen4' mg L-DOSAGE
'Sen4' TCA O
'Sen4' and O
'Sen4' developed O
'Sen4' Cushing O
'Sen4' 's O
'Sen4' syndrome O
'Sen4' 6 O
'Sen4' weeks O
'Sen4' later O
'Sen4' ( O
'Sen4' cortisol O
'Sen4' and O
'Sen4' ACTH O
'Sen4' concentrations O
'Sen4' were O
'Sen4' below O
'Sen4' limits O
'Sen4' of O
'Sen4' detection O
'Sen4' , O
'Sen4' TCA U-DRUG
'Sen4' concentrations O
'Sen4' were O
'Sen4' > O
'Sen4' 3 O
'Sen4' micrograms O
'Sen4' / O
'Sen4' l O
'Sen4' ) O
'Sen4' . O

'Sen5' Central O
'Sen5' nervous O
'Sen5' system O
'Sen5' manifestations O
'Sen5' of O
'Sen5' an O
'Sen5' ibuprofen U-DRUG
'Sen5' overdose U-DOSAGE
'Sen5' reversed O
'Sen5' by O
'Sen5' naloxone O
'Sen5' . O

'Sen6' Ibuprofen U-DRUG
'Sen6' overdose U-DOSAGE
'Sen6' is O
'Sen6' usually O
'Sen6' characterized O
'Sen6' by O
'Sen6' GI O
'Sen6' upset O
'Sen6' , O
'Sen6' dizziness O
'Sen6' , O
'Sen6' and O
'Sen6' mild O
'Sen6' sedation O
'Sen6' . O

'Sen7' In O
'Sen7' this O
'Sen7' case O
'Sen7' , O
'Sen7' it O
'Sen7' was O
'Sen7' suspected O
'Sen7' that O
'Sen7' a O
'Sen7' combination O
'Sen7' of O
'Sen7' cigarette O
'Sen7' smoking O
'Sen7' , O
'Sen7' pulmonary O
'Sen7' fibrosis O
'Sen7' , O
'Sen7' and O
'Sen7' low U-DOSAGE
'Sen7' - O
'Sen7' dose O
'Sen7' methotrexate U-DRUG
'Sen7' therapy O
'Sen7' might O
'Sen7' have O
'Sen7' promoted O
'Sen7' the O
'Sen7' development O
'Sen7' of O
'Sen7' lung O
'Sen7' cancer O
'Sen7' . O

'Sen8' A O
'Sen8' case O
'Sen8' of O
'Sen8' normotensive O
'Sen8' scleroderma O
'Sen8' renal O
'Sen8' crisis O
'Sen8' after O
'Sen8' high U-DOSAGE
'Sen8' - O
'Sen8' dose O
'Sen8' methylprednisolone U-DRUG
'Sen8' treatment O
'Sen8' . O

'Sen9' A O
'Sen9' 60 O
'Sen9' year O
'Sen9' - O
'Sen9' old O
'Sen9' woman O
'Sen9' with O
'Sen9' chronic O
'Sen9' renal O
'Sen9' failure O
'Sen9' developed O
'Sen9' acute O
'Sen9' proximal O
'Sen9' muscle O
'Sen9' weakness O
'Sen9' after O
'Sen9' receiving O
'Sen9' a O
'Sen9' regular U-DOSAGE
'Sen9' dosage O
'Sen9' of O
'Sen9' colchicine U-DRUG
'Sen9' . O

'Sen10' The O
'Sen10' intramuscular O
'Sen10' challenge O
'Sen10' test O
'Sen10' with O
'Sen10' 25 B-DOSAGE
'Sen10' UI L-DOSAGE
'Sen10' of O
'Sen10' Miacalcic U-DRUG
'Sen10' was O
'Sen10' positive O
'Sen10' with O
'Sen10' an O
'Sen10' immediate O
'Sen10' anaphylactic O
'Sen10' reaction O
'Sen10' . O

'Sen11' On O
'Sen11' the O
'Sen11' fifth O
'Sen11' day O
'Sen11' after O
'Sen11' administration O
'Sen11' of O
'Sen11' a O
'Sen11' high O
'Sen11' dose O
'Sen11' of O
'Sen11' ARA B-DRUG
'Sen11' - I-DRUG
'Sen11' C L-DRUG
'Sen11' ( O
'Sen11' 2 B-DOSAGE
'Sen11' g I-DOSAGE
'Sen11' / I-DOSAGE
'Sen11' m2 I-DOSAGE
'Sen11' intravenously I-DOSAGE
'Sen11' every I-DOSAGE
'Sen11' 12 I-DOSAGE
'Sen11' hours L-DOSAGE
'Sen11' ) O
'Sen11' , O
'Sen11' she O
'Sen11' developed O
'Sen11' bullous O
'Sen11' lesions O
'Sen11' on O
'Sen11' the O
'Sen11' hands O
'Sen11' and O
'Sen11' soles O
'Sen11' that O
'Sen11' disseminated O
'Sen11' , O
'Sen11' evolving O
'Sen11' to O
'Sen11' necrosis O
'Sen11' , O
'Sen11' sepsis O
'Sen11' , O
'Sen11' and O
'Sen11' death O
'Sen11' on O
'Sen11' the O
'Sen11' 22nd O
'Sen11' day O
'Sen11' . O

'Sen12' On O
'Sen12' the O
'Sen12' fifth O
'Sen12' day O
'Sen12' after O
'Sen12' administration O
'Sen12' of O
'Sen12' a O
'Sen12' high U-DOSAGE
'Sen12' dose O
'Sen12' of O
'Sen12' ARA B-DRUG
'Sen12' - I-DRUG
'Sen12' C L-DRUG
'Sen12' ( O
'Sen12' 2 O
'Sen12' g O
'Sen12' / O
'Sen12' m2 O
'Sen12' intravenously O
'Sen12' every O
'Sen12' 12 O
'Sen12' hours O
'Sen12' ) O
'Sen12' , O
'Sen12' she O
'Sen12' developed O
'Sen12' bullous O
'Sen12' lesions O
'Sen12' on O
'Sen12' the O
'Sen12' hands O
'Sen12' and O
'Sen12' soles O
'Sen12' that O
'Sen12' disseminated O
'Sen12' , O
'Sen12' evolving O
'Sen12' to O
'Sen12' necrosis O
'Sen12' , O
'Sen12' sepsis O
'Sen12' , O
'Sen12' and O
'Sen12' death O
'Sen12' on O
'Sen12' the O
'Sen12' 22nd O
'Sen12' day O
'Sen12' . O

'Sen13' Toxic O
'Sen13' epidermal O
'Sen13' necrolysis O
'Sen13' after O
'Sen13' the O
'Sen13' use O
'Sen13' of O
'Sen13' high U-DOSAGE
'Sen13' - O
'Sen13' dose O
'Sen13' cytosine B-DRUG
'Sen13' arabinoside L-DRUG
'Sen13' . O

'Sen14' We O
'Sen14' report O
'Sen14' a O
'Sen14' fatal O
'Sen14' case O
'Sen14' of O
'Sen14' toxic O
'Sen14' epidermal O
'Sen14' necrolysis O
'Sen14' ( O
'Sen14' TEN O
'Sen14' ) O
'Sen14' resulting O
'Sen14' from O
'Sen14' a O
'Sen14' high U-DOSAGE
'Sen14' dose O
'Sen14' of O
'Sen14' cytosine O
'Sen14' arabinoside O
'Sen14' ( O
'Sen14' ARA B-DRUG
'Sen14' - I-DRUG
'Sen14' C L-DRUG
'Sen14' ) O
'Sen14' . O

'Sen15' We O
'Sen15' report O
'Sen15' a O
'Sen15' fatal O
'Sen15' case O
'Sen15' of O
'Sen15' toxic O
'Sen15' epidermal O
'Sen15' necrolysis O
'Sen15' ( O
'Sen15' TEN O
'Sen15' ) O
'Sen15' resulting O
'Sen15' from O
'Sen15' a O
'Sen15' high U-DOSAGE
'Sen15' dose O
'Sen15' of O
'Sen15' cytosine B-DRUG
'Sen15' arabinoside L-DRUG
'Sen15' ( O
'Sen15' ARA O
'Sen15' - O
'Sen15' C O
'Sen15' ) O
'Sen15' . O

'Sen16' The O
'Sen16' day O
'Sen16' after O
'Sen16' clozapine O
'Sen16' was O
'Sen16' stopped O
'Sen16' , O
'Sen16' while O
'Sen16' he O
'Sen16' was O
'Sen16' still O
'Sen16' receiving O
'Sen16' clomipramine U-DRUG
'Sen16' 150 B-DOSAGE
'Sen16' mg I-DOSAGE
'Sen16' / I-DOSAGE
'Sen16' d L-DOSAGE
'Sen16' , O
'Sen16' he O
'Sen16' began O
'Sen16' behaving O
'Sen16' oddly O
'Sen16' , O
'Sen16' started O
'Sen16' sweating O
'Sen16' profusely O
'Sen16' , O
'Sen16' shivering O
'Sen16' , O
'Sen16' and O
'Sen16' became O
'Sen16' tremulous O
'Sen16' , O
'Sen16' agitated O
'Sen16' , O
'Sen16' and O
'Sen16' confused O
'Sen16' . O

'Sen17' The O
'Sen17' day O
'Sen17' after O
'Sen17' clozapine U-DRUG
'Sen17' was O
'Sen17' stopped O
'Sen17' , O
'Sen17' while O
'Sen17' he O
'Sen17' was O
'Sen17' still O
'Sen17' receiving O
'Sen17' clomipramine O
'Sen17' 150 B-DOSAGE
'Sen17' mg I-DOSAGE
'Sen17' / I-DOSAGE
'Sen17' d L-DOSAGE
'Sen17' , O
'Sen17' he O
'Sen17' began O
'Sen17' behaving O
'Sen17' oddly O
'Sen17' , O
'Sen17' started O
'Sen17' sweating O
'Sen17' profusely O
'Sen17' , O
'Sen17' shivering O
'Sen17' , O
'Sen17' and O
'Sen17' became O
'Sen17' tremulous O
'Sen17' , O
'Sen17' agitated O
'Sen17' , O
'Sen17' and O
'Sen17' confused O
'Sen17' . O

'Sen18' We O
'Sen18' describe O
'Sen18' a O
'Sen18' patient O
'Sen18' who O
'Sen18' presented O
'Sen18' with O
'Sen18' bloody O
'Sen18' diarrhoea O
'Sen18' after O
'Sen18' 15 B-DOSAGE
'Sen18' mg L-DOSAGE
'Sen18' meloxicam U-DRUG
'Sen18' daily O
'Sen18' for O
'Sen18' 10 O
'Sen18' days O
'Sen18' for O
'Sen18' osteoarthritis O
'Sen18' . O

'Sen19' Pheripheral O
'Sen19' edema O
'Sen19' was O
'Sen19' observed O
'Sen19' in O
'Sen19' five O
'Sen19' female O
'Sen19' patients O
'Sen19' after O
'Sen19' taking O
'Sen19' proton O
'Sen19' pump O
'Sen19' inhibitors O
'Sen19' omeprazole O
'Sen19' , O
'Sen19' lansoprazole U-DRUG
'Sen19' , O
'Sen19' or O
'Sen19' pantoprazole O
'Sen19' for O
'Sen19' 7 O
'Sen19' - O
'Sen19' 15 O
'Sen19' days O
'Sen19' for O
'Sen19' peptic O
'Sen19' acid O
'Sen19' diseases O
'Sen19' in O
'Sen19' recommended O
'Sen19' standard U-DOSAGE
'Sen19' doses O
'Sen19' . O

'Sen20' Pheripheral O
'Sen20' edema O
'Sen20' was O
'Sen20' observed O
'Sen20' in O
'Sen20' five O
'Sen20' female O
'Sen20' patients O
'Sen20' after O
'Sen20' taking O
'Sen20' proton O
'Sen20' pump O
'Sen20' inhibitors O
'Sen20' omeprazole U-DRUG
'Sen20' , O
'Sen20' lansoprazole O
'Sen20' , O
'Sen20' or O
'Sen20' pantoprazole O
'Sen20' for O
'Sen20' 7 O
'Sen20' - O
'Sen20' 15 O
'Sen20' days O
'Sen20' for O
'Sen20' peptic O
'Sen20' acid O
'Sen20' diseases O
'Sen20' in O
'Sen20' recommended O
'Sen20' standard U-DOSAGE
'Sen20' doses O
'Sen20' . O

'Sen21' Pheripheral O
'Sen21' edema O
'Sen21' was O
'Sen21' observed O
'Sen21' in O
'Sen21' five O
'Sen21' female O
'Sen21' patients O
'Sen21' after O
'Sen21' taking O
'Sen21' proton O
'Sen21' pump O
'Sen21' inhibitors O
'Sen21' omeprazole O
'Sen21' , O
'Sen21' lansoprazole O
'Sen21' , O
'Sen21' or O
'Sen21' pantoprazole U-DRUG
'Sen21' for O
'Sen21' 7 O
'Sen21' - O
'Sen21' 15 O
'Sen21' days O
'Sen21' for O
'Sen21' peptic O
'Sen21' acid O
'Sen21' diseases O
'Sen21' in O
'Sen21' recommended O
'Sen21' standard U-DOSAGE
'Sen21' doses O
'Sen21' . O

'Sen22' We O
'Sen22' observed O
'Sen22' ventricular O
'Sen22' fibrillation O
'Sen22' in O
'Sen22' 2 O
'Sen22' patients O
'Sen22' who O
'Sen22' presented O
'Sen22' to O
'Sen22' the O
'Sen22' emergency O
'Sen22' department O
'Sen22' with O
'Sen22' pre O
'Sen22' - O
'Sen22' excited O
'Sen22' atrial O
'Sen22' fibrillation O
'Sen22' and O
'Sen22' were O
'Sen22' given O
'Sen22' 12 B-DOSAGE
'Sen22' mg L-DOSAGE
'Sen22' of O
'Sen22' adenosine U-DRUG
'Sen22' . O

'Sen23' After O
'Sen23' the O
'Sen23' dose O
'Sen23' of O
'Sen23' methylprednisolone U-DRUG
'Sen23' was O
'Sen23' reduced O
'Sen23' from O
'Sen23' 40 B-DOSAGE
'Sen23' mg L-DOSAGE
'Sen23' to O
'Sen23' 20 O
'Sen23' mg O
'Sen23' i.v O
'Sen23' . O
'Sen23' q6h O
'Sen23' and O
'Sen23' shifted O
'Sen23' to O
'Sen23' other O
'Sen23' anti O
'Sen23' - O
'Sen23' asthma O
'Sen23' treatment O
'Sen23' by O
'Sen23' procaterol O
'Sen23' metered O
'Sen23' dose O
'Sen23' inhaler O
'Sen23' via O
'Sen23' spacer O
'Sen23' , O
'Sen23' the O
'Sen23' psychotic O
'Sen23' reaction O
'Sen23' disappeared O
'Sen23' a O
'Sen23' few O
'Sen23' hours O
'Sen23' later O
'Sen23' . O

'Sen24' Continuous O
'Sen24' EEG O
'Sen24' monitoring O
'Sen24' is O
'Sen24' helpful O
'Sen24' in O
'Sen24' managing O
'Sen24' seizures O
'Sen24' that O
'Sen24' occur O
'Sen24' as O
'Sen24' a O
'Sen24' complication O
'Sen24' of O
'Sen24' CBZ U-DRUG
'Sen24' OD U-DOSAGE
'Sen24' , O
'Sen24' after O
'Sen24' the O
'Sen24' course O
'Sen24' of O
'Sen24' recovery O
'Sen24' or O
'Sen24' worsening O
'Sen24' , O
'Sen24' and O
'Sen24' in O
'Sen24' providing O
'Sen24' assistance O
'Sen24' with O
'Sen24' prognosis O
'Sen24' . O

'Sen25' Massive O
'Sen25' CBZ U-DRUG
'Sen25' OD U-DOSAGE
'Sen25' may O
'Sen25' produce O
'Sen25' a O
'Sen25' reversible O
'Sen25' encephalopathy O
'Sen25' that O
'Sen25' includes O
'Sen25' cortical O
'Sen25' hyperexcitability O
'Sen25' , O
'Sen25' a O
'Sen25' profound O
'Sen25' burst O
'Sen25' - O
'Sen25' suppression O
'Sen25' EEG O
'Sen25' pattern O
'Sen25' , O
'Sen25' and O
'Sen25' cranial O
'Sen25' nerve O
'Sen25' areflexia O
'Sen25' . O

'Sen26' We O
'Sen26' describe O
'Sen26' a O
'Sen26' case O
'Sen26' of O
'Sen26' advanced O
'Sen26' ovarian O
'Sen26' carcinoma O
'Sen26' who O
'Sen26' developed O
'Sen26' difficulty O
'Sen26' walking O
'Sen26' because O
'Sen26' of O
'Sen26' marked O
'Sen26' pain O
'Sen26' in O
'Sen26' the O
'Sen26' lower O
'Sen26' extremities O
'Sen26' and O
'Sen26' loss O
'Sen26' of O
'Sen26' proprioception O
'Sen26' 25 O
'Sen26' days O
'Sen26' after O
'Sen26' treatment O
'Sen26' with O
'Sen26' weekly O
'Sen26' taxol U-DRUG
'Sen26' ( O
'Sen26' 80 O
'Sen26' mg O
'Sen26' / O
'Sen26' m(2)x3 O
'Sen26' ) O
'Sen26' . O

'Sen27' Myasthenia O
'Sen27' gravis O
'Sen27' during O
'Sen27' low U-DOSAGE
'Sen27' - O
'Sen27' dose O
'Sen27' IFN B-DRUG
'Sen27' - I-DRUG
'Sen27' alpha L-DRUG
'Sen27' therapy O
'Sen27' for O
'Sen27' chronic O
'Sen27' hepatitis O
'Sen27' C. O

'Sen28' A O
'Sen28' patient O
'Sen28' with O
'Sen28' rheumatoid O
'Sen28' arthritis O
'Sen28' developed O
'Sen28' an O
'Sen28' acute O
'Sen28' intrahepatic O
'Sen28' cholestasis O
'Sen28' after O
'Sen28' 100 B-DOSAGE
'Sen28' mg L-DOSAGE
'Sen28' of O
'Sen28' sodium B-DRUG
'Sen28' aurothiomalate L-DRUG
'Sen28' . O

'Sen29' CONCLUSIONS O
'Sen29' : O
'Sen29' LTG U-DRUG
'Sen29' overdose U-DOSAGE
'Sen29' may O
'Sen29' result O
'Sen29' in O
'Sen29' a O
'Sen29' severe O
'Sen29' but O
'Sen29' reversible O
'Sen29' encephalopathy O
'Sen29' , O
'Sen29' a O
'Sen29' previously O
'Sen29' undescribed O
'Sen29' phenomenon O
'Sen29' . O

'Sen30' METHODS O
'Sen30' : O
'Sen30' A O
'Sen30' 55-year O
'Sen30' - O
'Sen30' old O
'Sen30' woman O
'Sen30' became O
'Sen30' stuporous O
'Sen30' after O
'Sen30' overdose U-DOSAGE
'Sen30' with O
'Sen30' lamotrigine U-DRUG
'Sen30' ( O
'Sen30' LTG O
'Sen30' ) O
'Sen30' and O
'Sen30' valproic O
'Sen30' acid O
'Sen30' ( O
'Sen30' VPA O
'Sen30' ) O
'Sen30' tablets O
'Sen30' . O

'Sen31' METHODS O
'Sen31' : O
'Sen31' A O
'Sen31' 55-year O
'Sen31' - O
'Sen31' old O
'Sen31' woman O
'Sen31' became O
'Sen31' stuporous O
'Sen31' after O
'Sen31' overdose U-DOSAGE
'Sen31' with O
'Sen31' lamotrigine O
'Sen31' ( O
'Sen31' LTG U-DRUG
'Sen31' ) O
'Sen31' and O
'Sen31' valproic O
'Sen31' acid O
'Sen31' ( O
'Sen31' VPA O
'Sen31' ) O
'Sen31' tablets O
'Sen31' . O

'Sen32' METHODS O
'Sen32' : O
'Sen32' A O
'Sen32' 55-year O
'Sen32' - O
'Sen32' old O
'Sen32' woman O
'Sen32' became O
'Sen32' stuporous O
'Sen32' after O
'Sen32' overdose U-DOSAGE
'Sen32' with O
'Sen32' lamotrigine O
'Sen32' ( O
'Sen32' LTG O
'Sen32' ) O
'Sen32' and O
'Sen32' valproic B-DRUG
'Sen32' acid L-DRUG
'Sen32' ( O
'Sen32' VPA O
'Sen32' ) O
'Sen32' tablets O
'Sen32' . O

'Sen33' METHODS O
'Sen33' : O
'Sen33' A O
'Sen33' 55-year O
'Sen33' - O
'Sen33' old O
'Sen33' woman O
'Sen33' became O
'Sen33' stuporous O
'Sen33' after O
'Sen33' overdose U-DOSAGE
'Sen33' with O
'Sen33' lamotrigine O
'Sen33' ( O
'Sen33' LTG O
'Sen33' ) O
'Sen33' and O
'Sen33' valproic O
'Sen33' acid O
'Sen33' ( O
'Sen33' VPA U-DRUG
'Sen33' ) O
'Sen33' tablets O
'Sen33' . O

'Sen34' A O
'Sen34' 53 O
'Sen34' year O
'Sen34' old O
'Sen34' Greenlandic O
'Sen34' male O
'Sen34' was O
'Sen34' admitted O
'Sen34' twice O
'Sen34' over O
'Sen34' a O
'Sen34' period O
'Sen34' of O
'Sen34' 4 O
'Sen34' years O
'Sen34' with O
'Sen34' a O
'Sen34' new O
'Sen34' complete O
'Sen34' right O
'Sen34' bundle O
'Sen34' branch O
'Sen34' block O
'Sen34' after O
'Sen34' ingestion O
'Sen34' of O
'Sen34' 10 B-DOSAGE
'Sen34' g L-DOSAGE
'Sen34' and O
'Sen34' 4 O
'Sen34' g O
'Sen34' of O
'Sen34' carbamazepine U-DRUG
'Sen34' respectively O
'Sen34' . O

'Sen35' A O
'Sen35' 53 O
'Sen35' year O
'Sen35' old O
'Sen35' Greenlandic O
'Sen35' male O
'Sen35' was O
'Sen35' admitted O
'Sen35' twice O
'Sen35' over O
'Sen35' a O
'Sen35' period O
'Sen35' of O
'Sen35' 4 O
'Sen35' years O
'Sen35' with O
'Sen35' a O
'Sen35' new O
'Sen35' complete O
'Sen35' right O
'Sen35' bundle O
'Sen35' branch O
'Sen35' block O
'Sen35' after O
'Sen35' ingestion O
'Sen35' of O
'Sen35' 10 O
'Sen35' g O
'Sen35' and O
'Sen35' 4 B-DOSAGE
'Sen35' g L-DOSAGE
'Sen35' of O
'Sen35' carbamazepine U-DRUG
'Sen35' respectively O
'Sen35' . O

'Sen36' We O
'Sen36' report O
'Sen36' a O
'Sen36' 31-year O
'Sen36' - O
'Sen36' old O
'Sen36' women O
'Sen36' with O
'Sen36' recurrent O
'Sen36' Hodgkin O
'Sen36' 's O
'Sen36' lymphoma O
'Sen36' and O
'Sen36' unrecognized O
'Sen36' HMSN-1 O
'Sen36' who O
'Sen36' developed O
'Sen36' severe O
'Sen36' motor O
'Sen36' neuropathy O
'Sen36' 3 O
'Sen36' weeks O
'Sen36' after O
'Sen36' the O
'Sen36' first O
'Sen36' cycle O
'Sen36' of O
'Sen36' treatment O
'Sen36' including O
'Sen36' 2 B-DOSAGE
'Sen36' mg L-DOSAGE
'Sen36' of O
'Sen36' vincristine U-DRUG
'Sen36' . O

'Sen37' A O
'Sen37' 33-year O
'Sen37' - O
'Sen37' old O
'Sen37' man O
'Sen37' with O
'Sen37' a O
'Sen37' history O
'Sen37' of O
'Sen37' recreational O
'Sen37' benztropine U-DRUG
'Sen37' abuse U-DOSAGE
'Sen37' presented O
'Sen37' to O
'Sen37' the O
'Sen37' emergency O
'Sen37' department O
'Sen37' with O
'Sen37' confusion O
'Sen37' , O
'Sen37' abdominal O
'Sen37' pain O
'Sen37' , O
'Sen37' and O
'Sen37' distention O
'Sen37' . O

'Sen38' CONCLUSIONS O
'Sen38' : O
'Sen38' Clinicians O
'Sen38' should O
'Sen38' be O
'Sen38' aware O
'Sen38' of O
'Sen38' a O
'Sen38' risk O
'Sen38' of O
'Sen38' serotonin O
'Sen38' syndrome O
'Sen38' with O
'Sen38' serious O
'Sen38' extrapyramidal O
'Sen38' reactions O
'Sen38' in O
'Sen38' patients O
'Sen38' receiving O
'Sen38' sertraline O
'Sen38' or O
'Sen38' venlafaxine O
'Sen38' when O
'Sen38' metoclopramide U-DRUG
'Sen38' is O
'Sen38' coadministered O
'Sen38' even O
'Sen38' in O
'Sen38' a O
'Sen38' single O
'Sen38' , O
'Sen38' conventional U-DOSAGE
'Sen38' dose O
'Sen38' . O

'Sen39' CONCLUSIONS O
'Sen39' : O
'Sen39' Clinicians O
'Sen39' should O
'Sen39' be O
'Sen39' aware O
'Sen39' of O
'Sen39' a O
'Sen39' risk O
'Sen39' of O
'Sen39' serotonin O
'Sen39' syndrome O
'Sen39' with O
'Sen39' serious O
'Sen39' extrapyramidal O
'Sen39' reactions O
'Sen39' in O
'Sen39' patients O
'Sen39' receiving O
'Sen39' sertraline U-DRUG
'Sen39' or O
'Sen39' venlafaxine O
'Sen39' when O
'Sen39' metoclopramide O
'Sen39' is O
'Sen39' coadministered O
'Sen39' even O
'Sen39' in O
'Sen39' a O
'Sen39' single O
'Sen39' , O
'Sen39' conventional U-DOSAGE
'Sen39' dose O
'Sen39' . O

'Sen40' CONCLUSIONS O
'Sen40' : O
'Sen40' Clinicians O
'Sen40' should O
'Sen40' be O
'Sen40' aware O
'Sen40' of O
'Sen40' a O
'Sen40' risk O
'Sen40' of O
'Sen40' serotonin O
'Sen40' syndrome O
'Sen40' with O
'Sen40' serious O
'Sen40' extrapyramidal O
'Sen40' reactions O
'Sen40' in O
'Sen40' patients O
'Sen40' receiving O
'Sen40' sertraline O
'Sen40' or O
'Sen40' venlafaxine U-DRUG
'Sen40' when O
'Sen40' metoclopramide O
'Sen40' is O
'Sen40' coadministered O
'Sen40' even O
'Sen40' in O
'Sen40' a O
'Sen40' single O
'Sen40' , O
'Sen40' conventional U-DOSAGE
'Sen40' dose O
'Sen40' . O

'Sen41' He O
'Sen41' was O
'Sen41' started O
'Sen41' on O
'Sen41' oral O
'Sen41' lansoprazole U-DRUG
'Sen41' 60 B-DOSAGE
'Sen41' mg I-DOSAGE
'Sen41' twice I-DOSAGE
'Sen41' daily L-DOSAGE
'Sen41' and O
'Sen41' , O
'Sen41' on O
'Sen41' hospital O
'Sen41' day O
'Sen41' 2 O
'Sen41' , O
'Sen41' his O
'Sen41' platelet O
'Sen41' count O
'Sen41' decreased O
'Sen41' to O
'Sen41' 102 O
'Sen41' x O
'Sen41' 10(3)/mm(3 O
'Sen41' ) O
'Sen41' ; O
'Sen41' on O
'Sen41' hospital O
'Sen41' day O
'Sen41' 3 O
'Sen41' , O
'Sen41' the O
'Sen41' platelet O
'Sen41' count O
'Sen41' was O
'Sen41' 36 O
'Sen41' x O
'Sen41' 10(3)/mm(3 O
'Sen41' ) O
'Sen41' . O

'Sen42' We O
'Sen42' describe O
'Sen42' a O
'Sen42' patient O
'Sen42' who O
'Sen42' developed O
'Sen42' HUS O
'Sen42' after O
'Sen42' treatment O
'Sen42' with O
'Sen42' mitomycin B-DRUG
'Sen42' C L-DRUG
'Sen42' ( O
'Sen42' total O
'Sen42' dose O
'Sen42' 144 B-DOSAGE
'Sen42' mg I-DOSAGE
'Sen42' / I-DOSAGE
'Sen42' m2 L-DOSAGE
'Sen42' ) O
'Sen42' due O
'Sen42' to O
'Sen42' a O
'Sen42' carcinoma O
'Sen42' of O
'Sen42' the O
'Sen42' ascending O
'Sen42' colon O
'Sen42' . O

'Sen43' A O
'Sen43' 53-year O
'Sen43' - O
'Sen43' old O
'Sen43' man O
'Sen43' developed O
'Sen43' lower O
'Sen43' leg O
'Sen43' edema O
'Sen43' 4 O
'Sen43' weeks O
'Sen43' after O
'Sen43' rosiglitazone U-DRUG
'Sen43' was O
'Sen43' increased O
'Sen43' from O
'Sen43' 4 O
'Sen43' mg O
'Sen43' once O
'Sen43' / O
'Sen43' day O
'Sen43' to O
'Sen43' 4 B-DOSAGE
'Sen43' mg I-DOSAGE
'Sen43' twice I-DOSAGE
'Sen43' / I-DOSAGE
'Sen43' day L-DOSAGE
'Sen43' . O

'Sen44' We O
'Sen44' present O
'Sen44' a O
'Sen44' neonate O
'Sen44' with O
'Sen44' a O
'Sen44' seizure O
'Sen44' disorder O
'Sen44' who O
'Sen44' acutely O
'Sen44' developed O
'Sen44' pupillary O
'Sen44' mydriasis O
'Sen44' secondary O
'Sen44' to O
'Sen44' lidocaine U-DRUG
'Sen44' overdose U-DOSAGE
'Sen44' . O

'Sen45' CONCLUSIONS O
'Sen45' : O
'Sen45' Peripheral O
'Sen45' administration O
'Sen45' of O
'Sen45' low U-DOSAGE
'Sen45' - O
'Sen45' dose O
'Sen45' vasopressin U-DRUG
'Sen45' for O
'Sen45' septic O
'Sen45' shock O
'Sen45' should O
'Sen45' be O
'Sen45' discouraged O
'Sen45' because O
'Sen45' of O
'Sen45' the O
'Sen45' risk O
'Sen45' of O
'Sen45' ischemic O
'Sen45' skin O
'Sen45' complications O
'Sen45' . O

'Sen46' The O
'Sen46' first O
'Sen46' case O
'Sen46' concerns O
'Sen46' a O
'Sen46' 70-year O
'Sen46' - O
'Sen46' old O
'Sen46' man O
'Sen46' who O
'Sen46' developed O
'Sen46' severe O
'Sen46' aplastic O
'Sen46' anemia O
'Sen46' 7 O
'Sen46' weeks O
'Sen46' after O
'Sen46' treatment O
'Sen46' with O
'Sen46' 500 B-DOSAGE
'Sen46' mg L-DOSAGE
'Sen46' of O
'Sen46' ticlopidine U-DRUG
'Sen46' daily O
'Sen46' . O

'Sen47' Mean O
'Sen47' time O
'Sen47' between O
'Sen47' initiation O
'Sen47' of O
'Sen47' gemcitabine O
'Sen47' therapy O
'Sen47' and O
'Sen47' onset O
'Sen47' of O
'Sen47' HUS O
'Sen47' was O
'Sen47' 7.4 O
'Sen47' + O
'Sen47' /- O
'Sen47' 3.5 O
'Sen47' months O
'Sen47' , O
'Sen47' or O
'Sen47' 21.9 O
'Sen47' + O
'Sen47' /- O
'Sen47' 10.9 O
'Sen47' doses O
'Sen47' of O
'Sen47' gemcitabine U-DRUG
'Sen47' . O

'Sen48' Mean O
'Sen48' time O
'Sen48' between O
'Sen48' initiation O
'Sen48' of O
'Sen48' gemcitabine O
'Sen48' therapy O
'Sen48' and O
'Sen48' onset O
'Sen48' of O
'Sen48' HUS O
'Sen48' was O
'Sen48' 7.4 O
'Sen48' + O
'Sen48' /- O
'Sen48' 3.5 O
'Sen48' months O
'Sen48' , O
'Sen48' or O
'Sen48' 21.9 O
'Sen48' + O
'Sen48' /- O
'Sen48' 10.9 O
'Sen48' doses O
'Sen48' of O
'Sen48' gemcitabine U-DRUG
'Sen48' . O

'Sen49' CASE O
'Sen49' REPORT O
'Sen49' : O
'Sen49' Soon O
'Sen49' after O
'Sen49' initiation O
'Sen49' of O
'Sen49' amiodarone B-DRUG
'Sen49' HCl L-DRUG
'Sen49' ( O
'Sen49' 200 B-DOSAGE
'Sen49' mg I-DOSAGE
'Sen49' / I-DOSAGE
'Sen49' day L-DOSAGE
'Sen49' ) O
'Sen49' , O
'Sen49' a O
'Sen49' 76-year O
'Sen49' - O
'Sen49' old O
'Sen49' man O
'Sen49' came O
'Sen49' to O
'Sen49' us O
'Sen49' with O
'Sen49' symptoms O
'Sen49' of O
'Sen49' visual O
'Sen49' " O
'Sen49' shining O
'Sen49' , O
'Sen49' " O
'Sen49' glare O
'Sen49' , O
'Sen49' color O
'Sen49' vision O
'Sen49' anomalies O
'Sen49' , O
'Sen49' and O
'Sen49' gradually O
'Sen49' decreased O
'Sen49' vision O
'Sen49' . O

'Sen50' Successful O
'Sen50' desensitization O
'Sen50' to O
'Sen50' high U-DOSAGE
'Sen50' - O
'Sen50' dose O
'Sen50' methotrexate U-DRUG
'Sen50' after O
'Sen50' systemic O
'Sen50' anaphylaxis O
'Sen50' . O

'Sen51' While O
'Sen51' 40 B-DOSAGE
'Sen51' mg I-DOSAGE
'Sen51' / I-DOSAGE
'Sen51' day L-DOSAGE
'Sen51' of O
'Sen51' prednisolone U-DRUG
'Sen51' improved O
'Sen51' hepatic O
'Sen51' dysfunction O
'Sen51' dramatically O
'Sen51' , O
'Sen51' her O
'Sen51' diabetic O
'Sen51' milieu O
'Sen51' deteriorated O
'Sen51' seriously O
'Sen51' . O

'Sen52' This O
'Sen52' report O
'Sen52' describes O
'Sen52' an O
'Sen52' individual O
'Sen52' with O
'Sen52' mental O
'Sen52' retardation O
'Sen52' who O
'Sen52' experienced O
'Sen52' behavioral O
'Sen52' exacerbation O
'Sen52' associated O
'Sen52' with O
'Sen52' clonazepam U-DRUG
'Sen52' prescribed O
'Sen52' at O
'Sen52' 2 O
'Sen52' mg O
'Sen52' / O
'Sen52' day O
'Sen52' ( O
'Sen52' 0.02 B-DOSAGE
'Sen52' mg I-DOSAGE
'Sen52' / I-DOSAGE
'Sen52' kg I-DOSAGE
'Sen52' / I-DOSAGE
'Sen52' day L-DOSAGE
'Sen52' ) O
'Sen52' to O
'Sen52' treat O
'Sen52' aggression O
'Sen52' , O
'Sen52' self O
'Sen52' - O
'Sen52' injurious O
'Sen52' behavior O
'Sen52' , O
'Sen52' property O
'Sen52' destruction O
'Sen52' , O
'Sen52' and O
'Sen52' screaming O
'Sen52' , O
'Sen52' which O
'Sen52' was O
'Sen52' measured O
'Sen52' with O
'Sen52' a O
'Sen52' 15-minute O
'Sen52' partial O
'Sen52' interval O
'Sen52' recording O
'Sen52' measurement O
'Sen52' method O
'Sen52' . O

'Sen53' This O
'Sen53' entity O
'Sen53' is O
'Sen53' probably O
'Sen53' related O
'Sen53' to O
'Sen53' a O
'Sen53' combination O
'Sen53' of O
'Sen53' high B-DOSAGE
'Sen53' doses L-DOSAGE
'Sen53' of O
'Sen53' corticosteroids O
'Sen53' , O
'Sen53' vecuronium U-DRUG
'Sen53' administration O
'Sen53' and O
'Sen53' metabolic O
'Sen53' abnormalities O
'Sen53' associated O
'Sen53' with O
'Sen53' respiratory O
'Sen53' failure O
'Sen53' . O

'Sen54' We O
'Sen54' describe O
'Sen54' the O
'Sen54' development O
'Sen54' of O
'Sen54' cutaneous O
'Sen54' scleroderma O
'Sen54' in O
'Sen54' 3 O
'Sen54' patients O
'Sen54' coincident O
'Sen54' with O
'Sen54' the O
'Sen54' use O
'Sen54' of O
'Sen54' bleomycin U-DRUG
'Sen54' in O
'Sen54' low O
'Sen54' cumulative O
'Sen54' doses O
'Sen54' of O
'Sen54' less O
'Sen54' than O
'Sen54' 100 -
'Sen54' U. -

'Sen55' We O
'Sen55' consider O
'Sen55' asterixis O
'Sen55' to O
'Sen55' be O
'Sen55' an O
'Sen55' easily O
'Sen55' overlooked O
'Sen55' sign O
'Sen55' of O
'Sen55' neurotoxicity O
'Sen55' , O
'Sen55' which O
'Sen55' may O
'Sen55' occur O
'Sen55' even O
'Sen55' at O
'Sen55' low B-DOSAGE
'Sen55' or I-DOSAGE
'Sen55' moderate I-DOSAGE
'Sen55' dosage L-DOSAGE
'Sen55' levels O
'Sen55' , O
'Sen55' if O
'Sen55' certain O
'Sen55' drugs O
'Sen55' as O
'Sen55' lithium O
'Sen55' or O
'Sen55' clozapine O
'Sen55' are O
'Sen55' used O
'Sen55' in O
'Sen55' combination O
'Sen55' with O
'Sen55' CBZ U-DRUG
'Sen55' . O

'Sen56' We O
'Sen56' consider O
'Sen56' asterixis O
'Sen56' to O
'Sen56' be O
'Sen56' an O
'Sen56' easily O
'Sen56' overlooked O
'Sen56' sign O
'Sen56' of O
'Sen56' neurotoxicity O
'Sen56' , O
'Sen56' which O
'Sen56' may O
'Sen56' occur O
'Sen56' even O
'Sen56' at O
'Sen56' low B-DOSAGE
'Sen56' or I-DOSAGE
'Sen56' moderate I-DOSAGE
'Sen56' dosage L-DOSAGE
'Sen56' levels O
'Sen56' , O
'Sen56' if O
'Sen56' certain O
'Sen56' drugs O
'Sen56' as O
'Sen56' lithium O
'Sen56' or O
'Sen56' clozapine U-DRUG
'Sen56' are O
'Sen56' used O
'Sen56' in O
'Sen56' combination O
'Sen56' with O
'Sen56' CBZ O
'Sen56' . O

'Sen57' We O
'Sen57' consider O
'Sen57' asterixis O
'Sen57' to O
'Sen57' be O
'Sen57' an O
'Sen57' easily O
'Sen57' overlooked O
'Sen57' sign O
'Sen57' of O
'Sen57' neurotoxicity O
'Sen57' , O
'Sen57' which O
'Sen57' may O
'Sen57' occur O
'Sen57' even O
'Sen57' at O
'Sen57' low B-DOSAGE
'Sen57' or I-DOSAGE
'Sen57' moderate I-DOSAGE
'Sen57' dosage L-DOSAGE
'Sen57' levels O
'Sen57' , O
'Sen57' if O
'Sen57' certain O
'Sen57' drugs O
'Sen57' as O
'Sen57' lithium U-DRUG
'Sen57' or O
'Sen57' clozapine O
'Sen57' are O
'Sen57' used O
'Sen57' in O
'Sen57' combination O
'Sen57' with O
'Sen57' CBZ O
'Sen57' . O

'Sen58' A O
'Sen58' 74-year O
'Sen58' - O
'Sen58' old O
'Sen58' patient O
'Sen58' with O
'Sen58' idiopathic O
'Sen58' Parkinson O
'Sen58' 's O
'Sen58' disease O
'Sen58' was O
'Sen58' evaluated O
'Sen58' for O
'Sen58' unintended O
'Sen58' sleep O
'Sen58' episodes O
'Sen58' that O
'Sen58' occurred O
'Sen58' after O
'Sen58' long O
'Sen58' - O
'Sen58' term O
'Sen58' treatment O
'Sen58' with O
'Sen58' 400 B-DOSAGE
'Sen58' mg I-DOSAGE
'Sen58' / I-DOSAGE
'Sen58' day L-DOSAGE
'Sen58' of O
'Sen58' L B-DRUG
'Sen58' - I-DRUG
'Sen58' dopa L-DRUG
'Sen58' . O

'Sen59' We O
'Sen59' present O
'Sen59' a O
'Sen59' case O
'Sen59' of O
'Sen59' a O
'Sen59' 20-year O
'Sen59' - O
'Sen59' old O
'Sen59' woman O
'Sen59' who O
'Sen59' ingested O
'Sen59' 900 B-DOSAGE
'Sen59' mg L-DOSAGE
'Sen59' of O
'Sen59' glyburide U-DRUG
'Sen59' causing O
'Sen59' refractory O
'Sen59' hypoglycemia O
'Sen59' resistant O
'Sen59' to O
'Sen59' treatment O
'Sen59' with O
'Sen59' intravenous O
'Sen59' dextrose O
'Sen59' , O
'Sen59' glucagon O
'Sen59' , O
'Sen59' and O
'Sen59' diazoxide O
'Sen59' . O

'Sen60' We O
'Sen60' describe O
'Sen60' the O
'Sen60' infectious O
'Sen60' toxicities O
'Sen60' experienced O
'Sen60' by O
'Sen60' the O
'Sen60' first O
'Sen60' two O
'Sen60' patients O
'Sen60' in O
'Sen60' our O
'Sen60' institution O
'Sen60' treated O
'Sen60' with O
'Sen60' dexamethasone O
'Sen60' ( O
'Sen60' 10 O
'Sen60' mg O
'Sen60' / O
'Sen60' m(2)/day O
'Sen60' for O
'Sen60' 4 O
'Sen60' weeks O
'Sen60' with O
'Sen60' gradual O
'Sen60' tapering O
'Sen60' ) O
'Sen60' during O
'Sen60' induction O
'Sen60' according O
'Sen60' to O
'Sen60' the O
'Sen60' dexamethasone O
'Sen60' arm O
'Sen60' of O
'Sen60' BFM O
'Sen60' 2000 O
'Sen60' and O
'Sen60' review O
'Sen60' the O
'Sen60' relevant O
'Sen60' literature O
'Sen60' that O
'Sen60' suggests O
'Sen60' an O
'Sen60' increased O
'Sen60' risk O
'Sen60' of O
'Sen60' infectious O
'Sen60' complications O
'Sen60' with O
'Sen60' dexamethasone U-DRUG
'Sen60' . O

'Sen61' We O
'Sen61' describe O
'Sen61' the O
'Sen61' infectious O
'Sen61' toxicities O
'Sen61' experienced O
'Sen61' by O
'Sen61' the O
'Sen61' first O
'Sen61' two O
'Sen61' patients O
'Sen61' in O
'Sen61' our O
'Sen61' institution O
'Sen61' treated O
'Sen61' with O
'Sen61' dexamethasone O
'Sen61' ( O
'Sen61' 10 O
'Sen61' mg O
'Sen61' / O
'Sen61' m(2)/day O
'Sen61' for O
'Sen61' 4 O
'Sen61' weeks O
'Sen61' with O
'Sen61' gradual O
'Sen61' tapering O
'Sen61' ) O
'Sen61' during O
'Sen61' induction O
'Sen61' according O
'Sen61' to O
'Sen61' the O
'Sen61' dexamethasone O
'Sen61' arm O
'Sen61' of O
'Sen61' BFM O
'Sen61' 2000 O
'Sen61' and O
'Sen61' review O
'Sen61' the O
'Sen61' relevant O
'Sen61' literature O
'Sen61' that O
'Sen61' suggests O
'Sen61' an O
'Sen61' increased O
'Sen61' risk O
'Sen61' of O
'Sen61' infectious O
'Sen61' complications O
'Sen61' with O
'Sen61' dexamethasone U-DRUG
'Sen61' . O

'Sen62' After O
'Sen62' initiation O
'Sen62' of O
'Sen62' topical O
'Sen62' vitamin B-DRUG
'Sen62' D3 L-DRUG
'Sen62' ointment O
'Sen62' ( O
'Sen62' 20 B-DOSAGE
'Sen62' micro I-DOSAGE
'Sen62' g I-DOSAGE
'Sen62' / I-DOSAGE
'Sen62' g L-DOSAGE
'Sen62' of O
'Sen62' tacalcitol O
'Sen62' ) O
'Sen62' 10 O
'Sen62' g O
'Sen62' / O
'Sen62' day O
'Sen62' for O
'Sen62' the O
'Sen62' skin O
'Sen62' lesions O
'Sen62' , O
'Sen62' both O
'Sen62' the O
'Sen62' serum O
'Sen62' level O
'Sen62' of O
'Sen62' calcium O
'Sen62' and O
'Sen62' urinary O
'Sen62' excretion O
'Sen62' of O
'Sen62' calcium O
'Sen62' increased O
'Sen62' gradually O
'Sen62' . O

'Sen63' DATA O
'Sen63' SYNTHESIS O
'Sen63' : O
'Sen63' A O
'Sen63' 49-year O
'Sen63' - O
'Sen63' old O
'Sen63' man O
'Sen63' developed O
'Sen63' symptoms O
'Sen63' of O
'Sen63' severe O
'Sen63' psychosis O
'Sen63' concomitant O
'Sen63' with O
'Sen63' ciprofloxacin U-DRUG
'Sen63' ( O
'Sen63' 250 B-DOSAGE
'Sen63' mg I-DOSAGE
'Sen63' bid L-DOSAGE
'Sen63' ) O
'Sen63' treatment O
'Sen63' . O

'Sen64' However O
'Sen64' here O
'Sen64' we O
'Sen64' reported O
'Sen64' two O
'Sen64' patients O
'Sen64' , O
'Sen64' presenting O
'Sen64' with O
'Sen64' PD O
'Sen64' during O
'Sen64' high U-DOSAGE
'Sen64' dose O
'Sen64' colchicine U-DRUG
'Sen64' treatment O
'Sen64' for O
'Sen64' familiar O
'Sen64' mediterranean O
'Sen64' fever O
'Sen64' ( O
'Sen64' FMF O
'Sen64' ) O
'Sen64' . O

'Sen65' We O
'Sen65' report O
'Sen65' a O
'Sen65' case O
'Sen65' of O
'Sen65' unintentional O
'Sen65' overdose U-DOSAGE
'Sen65' of O
'Sen65' oral O
'Sen65' pilocarpine U-DRUG
'Sen65' tablets O
'Sen65' that O
'Sen65' resulted O
'Sen65' in O
'Sen65' bradycardia O
'Sen65' , O
'Sen65' mild O
'Sen65' hypotension O
'Sen65' , O
'Sen65' and O
'Sen65' muscarinic O
'Sen65' symptoms O
'Sen65' in O
'Sen65' a O
'Sen65' patient O
'Sen65' with O
'Sen65' Sjogren O
'Sen65' 's O
'Sen65' syndrome O
'Sen65' . O

'Sen66' We O
'Sen66' report O
'Sen66' here O
'Sen66' a O
'Sen66' 26-year O
'Sen66' - O
'Sen66' old O
'Sen66' female O
'Sen66' with O
'Sen66' diffuse O
'Sen66' large O
'Sen66' B O
'Sen66' - O
'Sen66' cell O
'Sen66' lymphoma O
'Sen66' who O
'Sen66' died O
'Sen66' of O
'Sen66' severe O
'Sen66' pulmonary O
'Sen66' fibrosis O
'Sen66' 81 O
'Sen66' days O
'Sen66' after O
'Sen66' the O
'Sen66' administration O
'Sen66' of O
'Sen66' high O
'Sen66' - O
'Sen66' dose O
'Sen66' BCNU U-DRUG
'Sen66' ( O
'Sen66' 600 B-DOSAGE
'Sen66' mg I-DOSAGE
'Sen66' / I-DOSAGE
'Sen66' m2 L-DOSAGE
'Sen66' ) O
'Sen66' . O

'Sen67' We O
'Sen67' report O
'Sen67' here O
'Sen67' a O
'Sen67' 26-year O
'Sen67' - O
'Sen67' old O
'Sen67' female O
'Sen67' with O
'Sen67' diffuse O
'Sen67' large O
'Sen67' B O
'Sen67' - O
'Sen67' cell O
'Sen67' lymphoma O
'Sen67' who O
'Sen67' died O
'Sen67' of O
'Sen67' severe O
'Sen67' pulmonary O
'Sen67' fibrosis O
'Sen67' 81 O
'Sen67' days O
'Sen67' after O
'Sen67' the O
'Sen67' administration O
'Sen67' of O
'Sen67' high B-DOSAGE
'Sen67' - I-DOSAGE
'Sen67' dose L-DOSAGE
'Sen67' BCNU U-DRUG
'Sen67' ( O
'Sen67' 600 O
'Sen67' mg O
'Sen67' / O
'Sen67' m2 O
'Sen67' ) O
'Sen67' . O

'Sen68' In O
'Sen68' this O
'Sen68' paper O
'Sen68' we O
'Sen68' report O
'Sen68' a O
'Sen68' case O
'Sen68' of O
'Sen68' nimodipine U-DRUG
'Sen68' overdosage U-DOSAGE
'Sen68' resulting O
'Sen68' in O
'Sen68' prolonged O
'Sen68' hypotension O
'Sen68' and O
'Sen68' hypoxemia O
'Sen68' , O
'Sen68' which O
'Sen68' was O
'Sen68' successfully O
'Sen68' treated O
'Sen68' with O
'Sen68' calcium O
'Sen68' gluconate O
'Sen68' . O

'Sen69' Tiagabine U-DRUG
'Sen69' overdose U-DOSAGE
'Sen69' causes O
'Sen69' an O
'Sen69' unusual O
'Sen69' array O
'Sen69' of O
'Sen69' neurological O
'Sen69' symptoms O
'Sen69' , O
'Sen69' many O
'Sen69' similar O
'Sen69' to O
'Sen69' reported O
'Sen69' adverse O
'Sen69' effects O
'Sen69' during O
'Sen69' therapeutic O
'Sen69' use O
'Sen69' . O

'Sen70' Neurologic O
'Sen70' symptoms O
'Sen70' resolved O
'Sen70' after O
'Sen70' stopping O
'Sen70' CAP O
'Sen70' for O
'Sen70' 4 O
'Sen70' weeks O
'Sen70' in O
'Sen70' Patient O
'Sen70' A O
'Sen70' , O
'Sen70' with O
'Sen70' no O
'Sen70' recurrence O
'Sen70' after O
'Sen70' reinitiating O
'Sen70' CAP U-DRUG
'Sen70' alone O
'Sen70' at O
'Sen70' 2000 B-DOSAGE
'Sen70' mg I-DOSAGE
'Sen70' / I-DOSAGE
'Sen70' m2 L-DOSAGE
'Sen70' . O

'Sen71' Neurologic O
'Sen71' symptoms O
'Sen71' resolved O
'Sen71' after O
'Sen71' stopping O
'Sen71' CAP O
'Sen71' for O
'Sen71' 4 O
'Sen71' weeks O
'Sen71' in O
'Sen71' Patient O
'Sen71' A O
'Sen71' , O
'Sen71' with O
'Sen71' no O
'Sen71' recurrence O
'Sen71' after O
'Sen71' reinitiating O
'Sen71' CAP U-DRUG
'Sen71' alone O
'Sen71' at O
'Sen71' 2000 B-DOSAGE
'Sen71' mg I-DOSAGE
'Sen71' / I-DOSAGE
'Sen71' m2 L-DOSAGE
'Sen71' . O

'Sen72' Patient O
'Sen72' A O
'Sen72' reported O
'Sen72' right O
'Sen72' leg O
'Sen72' weakness O
'Sen72' ( O
'Sen72' foot O
'Sen72' drop O
'Sen72' ) O
'Sen72' during O
'Sen72' week O
'Sen72' 4 O
'Sen72' of O
'Sen72' CAP B-DRUG
'Sen72' - I-DRUG
'Sen72' XRT L-DRUG
'Sen72' ( O
'Sen72' 1600 B-DOSAGE
'Sen72' mg I-DOSAGE
'Sen72' / I-DOSAGE
'Sen72' m2 L-DOSAGE
'Sen72' ) O
'Sen72' . O

'Sen73' Patient O
'Sen73' B O
'Sen73' developed O
'Sen73' perioral O
'Sen73' and O
'Sen73' upper O
'Sen73' extremity O
'Sen73' paresthesias O
'Sen73' during O
'Sen73' the O
'Sen73' fourth O
'Sen73' cycle O
'Sen73' of O
'Sen73' CAP U-DRUG
'Sen73' alone O
'Sen73' ( O
'Sen73' 2500 B-DOSAGE
'Sen73' mg I-DOSAGE
'Sen73' / I-DOSAGE
'Sen73' m2 L-DOSAGE
'Sen73' ) O
'Sen73' . O

'Sen74' In O
'Sen74' all O
'Sen74' cases O
'Sen74' , O
'Sen74' drugs O
'Sen74' in O
'Sen74' addition O
'Sen74' to O
'Sen74' quetiapine O
'Sen74' were O
'Sen74' detected O
'Sen74' , O
'Sen74' but O
'Sen74' in O
'Sen74' cases O
'Sen74' # O
'Sen74' 1 O
'Sen74' and O
'Sen74' # O
'Sen74' 2 O
'Sen74' , O
'Sen74' the O
'Sen74' cause O
'Sen74' of O
'Sen74' death O
'Sen74' was O
'Sen74' considered O
'Sen74' to O
'Sen74' be O
'Sen74' a O
'Sen74' quetiapine U-DRUG
'Sen74' overdose U-DOSAGE
'Sen74' and O
'Sen74' the O
'Sen74' other O
'Sen74' drugs O
'Sen74' were O
'Sen74' not O
'Sen74' considered O
'Sen74' to O
'Sen74' be O
'Sen74' contributory O
'Sen74' . O

'Sen75' We O
'Sen75' present O
'Sen75' three O
'Sen75' cases O
'Sen75' from O
'Sen75' the O
'Sen75' Provincial O
'Sen75' Toxicology O
'Sen75' Center O
'Sen75' of O
'Sen75' British O
'Sen75' Columbia O
'Sen75' , O
'Sen75' Canada O
'Sen75' in O
'Sen75' which O
'Sen75' suicidal O
'Sen75' overdose U-DOSAGE
'Sen75' deaths O
'Sen75' were O
'Sen75' associated O
'Sen75' with O
'Sen75' quetiapine U-DRUG
'Sen75' . O

'Sen76' Paradoxical O
'Sen76' cerebral O
'Sen76' cortical O
'Sen76' hyperexcitability O
'Sen76' following O
'Sen76' flupirtine U-DRUG
'Sen76' overdose U-DOSAGE
'Sen76' . O

'Sen77' The O
'Sen77' patient O
'Sen77' was O
'Sen77' found O
'Sen77' to O
'Sen77' have O
'Sen77' no O
'Sen77' motile O
'Sen77' sperm O
'Sen77' with O
'Sen77' a O
'Sen77' normal O
'Sen77' sperm O
'Sen77' count O
'Sen77' , O
'Sen77' while O
'Sen77' taking O
'Sen77' a O
'Sen77' dose O
'Sen77' of O
'Sen77' 400 B-DOSAGE
'Sen77' mg I-DOSAGE
'Sen77' / I-DOSAGE
'Sen77' day L-DOSAGE
'Sen77' of O
'Sen77' carbamazepine U-DRUG
'Sen77' . O

'Sen78' A O
'Sen78' 64-year O
'Sen78' - O
'Sen78' old O
'Sen78' man O
'Sen78' with O
'Sen78' schizophrenia O
'Sen78' developed O
'Sen78' myoclonic O
'Sen78' jerks O
'Sen78' when O
'Sen78' given O
'Sen78' higher B-DOSAGE
'Sen78' doses L-DOSAGE
'Sen78' of O
'Sen78' quetiapine U-DRUG
'Sen78' . O

'Sen79' A O
'Sen79' 74-year O
'Sen79' - O
'Sen79' old O
'Sen79' hypercholestrerolaemic O
'Sen79' woman O
'Sen79' taking O
'Sen79' cerivastatin U-DRUG
'Sen79' ( O
'Sen79' 0.15 B-DOSAGE
'Sen79' mg I-DOSAGE
'Sen79' / I-DOSAGE
'Sen79' day L-DOSAGE
'Sen79' ) O
'Sen79' for O
'Sen79' 22 O
'Sen79' days O
'Sen79' complained O
'Sen79' of O
'Sen79' general O
'Sen79' muscle O
'Sen79' weakness O
'Sen79' and O
'Sen79' muscle O
'Sen79' pain O
'Sen79' . O

'Sen80' Carboplatin U-DRUG
'Sen80' hypersensitivity O
'Sen80' induced O
'Sen80' by O
'Sen80' low B-DOSAGE
'Sen80' - I-DOSAGE
'Sen80' dose L-DOSAGE
'Sen80' paclitaxel O
'Sen80' / O
'Sen80' carboplatin O
'Sen80' in O
'Sen80' multiple O
'Sen80' platinum O
'Sen80' - O
'Sen80' treated O
'Sen80' patients O
'Sen80' with O
'Sen80' recurrent O
'Sen80' ovarian O
'Sen80' cancer O
'Sen80' . O

'Sen81' Carboplatin O
'Sen81' hypersensitivity O
'Sen81' induced O
'Sen81' by O
'Sen81' low B-DOSAGE
'Sen81' - I-DOSAGE
'Sen81' dose L-DOSAGE
'Sen81' paclitaxel O
'Sen81' / O
'Sen81' carboplatin U-DRUG
'Sen81' in O
'Sen81' multiple O
'Sen81' platinum O
'Sen81' - O
'Sen81' treated O
'Sen81' patients O
'Sen81' with O
'Sen81' recurrent O
'Sen81' ovarian O
'Sen81' cancer O
'Sen81' . O

'Sen82' Carboplatin O
'Sen82' hypersensitivity O
'Sen82' induced O
'Sen82' by O
'Sen82' low B-DOSAGE
'Sen82' - I-DOSAGE
'Sen82' dose L-DOSAGE
'Sen82' paclitaxel U-DRUG
'Sen82' / O
'Sen82' carboplatin O
'Sen82' in O
'Sen82' multiple O
'Sen82' platinum O
'Sen82' - O
'Sen82' treated O
'Sen82' patients O
'Sen82' with O
'Sen82' recurrent O
'Sen82' ovarian O
'Sen82' cancer O
'Sen82' . O

'Sen83' Our O
'Sen83' report O
'Sen83' suggested O
'Sen83' that O
'Sen83' CBDCA O
'Sen83' hypersensitivity O
'Sen83' was O
'Sen83' correlated O
'Sen83' with O
'Sen83' the O
'Sen83' total O
'Sen83' dose O
'Sen83' of O
'Sen83' previously O
'Sen83' administered O
'Sen83' platinum O
'Sen83' agents O
'Sen83' and O
'Sen83' that O
'Sen83' CBDCA O
'Sen83' should O
'Sen83' be O
'Sen83' excluded O
'Sen83' in O
'Sen83' patients O
'Sen83' who O
'Sen83' have O
'Sen83' received O
'Sen83' multiple O
'Sen83' platinum O
'Sen83' - O
'Sen83' based O
'Sen83' chemotherapy O
'Sen83' , O
'Sen83' even O
'Sen83' in O
'Sen83' platinum O
'Sen83' - O
'Sen83' sensitive O
'Sen83' cases O
'Sen83' , O
'Sen83' because O
'Sen83' CBDCA O
'Sen83' hypersensitivity O
'Sen83' can O
'Sen83' occur O
'Sen83' even O
'Sen83' with O
'Sen83' low B-DOSAGE
'Sen83' - I-DOSAGE
'Sen83' dose L-DOSAGE
'Sen83' CBDCA U-DRUG
'Sen83' administration O
'Sen83' . O

'Sen84' Our O
'Sen84' report O
'Sen84' suggested O
'Sen84' that O
'Sen84' CBDCA O
'Sen84' hypersensitivity O
'Sen84' was O
'Sen84' correlated O
'Sen84' with O
'Sen84' the O
'Sen84' total O
'Sen84' dose O
'Sen84' of O
'Sen84' previously O
'Sen84' administered O
'Sen84' platinum O
'Sen84' agents O
'Sen84' and O
'Sen84' that O
'Sen84' CBDCA O
'Sen84' should O
'Sen84' be O
'Sen84' excluded O
'Sen84' in O
'Sen84' patients O
'Sen84' who O
'Sen84' have O
'Sen84' received O
'Sen84' multiple O
'Sen84' platinum O
'Sen84' - O
'Sen84' based O
'Sen84' chemotherapy O
'Sen84' , O
'Sen84' even O
'Sen84' in O
'Sen84' platinum O
'Sen84' - O
'Sen84' sensitive O
'Sen84' cases O
'Sen84' , O
'Sen84' because O
'Sen84' CBDCA O
'Sen84' hypersensitivity O
'Sen84' can O
'Sen84' occur O
'Sen84' even O
'Sen84' with O
'Sen84' low B-DOSAGE
'Sen84' - I-DOSAGE
'Sen84' dose L-DOSAGE
'Sen84' CBDCA U-DRUG
'Sen84' administration O
'Sen84' . O

'Sen85' Our O
'Sen85' report O
'Sen85' suggested O
'Sen85' that O
'Sen85' CBDCA O
'Sen85' hypersensitivity O
'Sen85' was O
'Sen85' correlated O
'Sen85' with O
'Sen85' the O
'Sen85' total O
'Sen85' dose O
'Sen85' of O
'Sen85' previously O
'Sen85' administered O
'Sen85' platinum O
'Sen85' agents O
'Sen85' and O
'Sen85' that O
'Sen85' CBDCA O
'Sen85' should O
'Sen85' be O
'Sen85' excluded O
'Sen85' in O
'Sen85' patients O
'Sen85' who O
'Sen85' have O
'Sen85' received O
'Sen85' multiple O
'Sen85' platinum O
'Sen85' - O
'Sen85' based O
'Sen85' chemotherapy O
'Sen85' , O
'Sen85' even O
'Sen85' in O
'Sen85' platinum O
'Sen85' - O
'Sen85' sensitive O
'Sen85' cases O
'Sen85' , O
'Sen85' because O
'Sen85' CBDCA O
'Sen85' hypersensitivity O
'Sen85' can O
'Sen85' occur O
'Sen85' even O
'Sen85' with O
'Sen85' low B-DOSAGE
'Sen85' - I-DOSAGE
'Sen85' dose L-DOSAGE
'Sen85' CBDCA U-DRUG
'Sen85' administration O
'Sen85' . O

'Sen86' We O
'Sen86' report O
'Sen86' five O
'Sen86' cases O
'Sen86' of O
'Sen86' carboplatin U-DRUG
'Sen86' ( O
'Sen86' CBDCA O
'Sen86' ) O
'Sen86' hypersensitivity O
'Sen86' after O
'Sen86' weekly O
'Sen86' low O
'Sen86' - O
'Sen86' dose O
'Sen86' paclitaxel O
'Sen86' ( O
'Sen86' 60 -
'Sen86' mg -
'Sen86' / -
'Sen86' m2)/CBDCA -
'Sen86' ( O
'Sen86' area O
'Sen86' under O
'Sen86' the O
'Sen86' concentration O
'Sen86' curve O
'Sen86' = O
'Sen86' 2 O
'Sen86' ) O
'Sen86' therapy O
'Sen86' in O
'Sen86' patients O
'Sen86' with O
'Sen86' recurrent O
'Sen86' ovarian O
'Sen86' cancer O
'Sen86' receiving O
'Sen86' multiple O
'Sen86' platinum O
'Sen86' - O
'Sen86' based O
'Sen86' chemotherapy O
'Sen86' . O

'Sen87' We O
'Sen87' report O
'Sen87' five O
'Sen87' cases O
'Sen87' of O
'Sen87' carboplatin O
'Sen87' ( O
'Sen87' CBDCA O
'Sen87' ) O
'Sen87' hypersensitivity O
'Sen87' after O
'Sen87' weekly O
'Sen87' low O
'Sen87' - O
'Sen87' dose O
'Sen87' paclitaxel O
'Sen87' ( O
'Sen87' 60 -
'Sen87' mg -
'Sen87' / -
'Sen87' m2)/CBDCA -
'Sen87' ( O
'Sen87' area O
'Sen87' under O
'Sen87' the O
'Sen87' concentration O
'Sen87' curve O
'Sen87' = O
'Sen87' 2 O
'Sen87' ) O
'Sen87' therapy O
'Sen87' in O
'Sen87' patients O
'Sen87' with O
'Sen87' recurrent O
'Sen87' ovarian O
'Sen87' cancer O
'Sen87' receiving O
'Sen87' multiple O
'Sen87' platinum O
'Sen87' - O
'Sen87' based O
'Sen87' chemotherapy O
'Sen87' . O

'Sen88' We O
'Sen88' report O
'Sen88' five O
'Sen88' cases O
'Sen88' of O
'Sen88' carboplatin O
'Sen88' ( O
'Sen88' CBDCA O
'Sen88' ) O
'Sen88' hypersensitivity O
'Sen88' after O
'Sen88' weekly O
'Sen88' low O
'Sen88' - O
'Sen88' dose O
'Sen88' paclitaxel U-DRUG
'Sen88' ( O
'Sen88' 60 -
'Sen88' mg -
'Sen88' / -
'Sen88' m2)/CBDCA -
'Sen88' ( O
'Sen88' area O
'Sen88' under O
'Sen88' the O
'Sen88' concentration O
'Sen88' curve O
'Sen88' = O
'Sen88' 2 O
'Sen88' ) O
'Sen88' therapy O
'Sen88' in O
'Sen88' patients O
'Sen88' with O
'Sen88' recurrent O
'Sen88' ovarian O
'Sen88' cancer O
'Sen88' receiving O
'Sen88' multiple O
'Sen88' platinum O
'Sen88' - O
'Sen88' based O
'Sen88' chemotherapy O
'Sen88' . O

'Sen89' We O
'Sen89' report O
'Sen89' five O
'Sen89' cases O
'Sen89' of O
'Sen89' carboplatin U-DRUG
'Sen89' ( O
'Sen89' CBDCA O
'Sen89' ) O
'Sen89' hypersensitivity O
'Sen89' after O
'Sen89' weekly O
'Sen89' low B-DOSAGE
'Sen89' - I-DOSAGE
'Sen89' dose L-DOSAGE
'Sen89' paclitaxel O
'Sen89' ( O
'Sen89' 60 O
'Sen89' mg O
'Sen89' / O
'Sen89' m2)/CBDCA O
'Sen89' ( O
'Sen89' area O
'Sen89' under O
'Sen89' the O
'Sen89' concentration O
'Sen89' curve O
'Sen89' = O
'Sen89' 2 O
'Sen89' ) O
'Sen89' therapy O
'Sen89' in O
'Sen89' patients O
'Sen89' with O
'Sen89' recurrent O
'Sen89' ovarian O
'Sen89' cancer O
'Sen89' receiving O
'Sen89' multiple O
'Sen89' platinum O
'Sen89' - O
'Sen89' based O
'Sen89' chemotherapy O
'Sen89' . O

'Sen90' We O
'Sen90' report O
'Sen90' five O
'Sen90' cases O
'Sen90' of O
'Sen90' carboplatin O
'Sen90' ( O
'Sen90' CBDCA O
'Sen90' ) O
'Sen90' hypersensitivity O
'Sen90' after O
'Sen90' weekly O
'Sen90' low B-DOSAGE
'Sen90' - I-DOSAGE
'Sen90' dose L-DOSAGE
'Sen90' paclitaxel O
'Sen90' ( O
'Sen90' 60 O
'Sen90' mg O
'Sen90' / O
'Sen90' m2)/CBDCA -
'Sen90' ( O
'Sen90' area O
'Sen90' under O
'Sen90' the O
'Sen90' concentration O
'Sen90' curve O
'Sen90' = O
'Sen90' 2 O
'Sen90' ) O
'Sen90' therapy O
'Sen90' in O
'Sen90' patients O
'Sen90' with O
'Sen90' recurrent O
'Sen90' ovarian O
'Sen90' cancer O
'Sen90' receiving O
'Sen90' multiple O
'Sen90' platinum O
'Sen90' - O
'Sen90' based O
'Sen90' chemotherapy O
'Sen90' . O

'Sen91' We O
'Sen91' report O
'Sen91' five O
'Sen91' cases O
'Sen91' of O
'Sen91' carboplatin O
'Sen91' ( O
'Sen91' CBDCA O
'Sen91' ) O
'Sen91' hypersensitivity O
'Sen91' after O
'Sen91' weekly O
'Sen91' low B-DOSAGE
'Sen91' - I-DOSAGE
'Sen91' dose L-DOSAGE
'Sen91' paclitaxel U-DRUG
'Sen91' ( O
'Sen91' 60 O
'Sen91' mg O
'Sen91' / O
'Sen91' m2)/CBDCA O
'Sen91' ( O
'Sen91' area O
'Sen91' under O
'Sen91' the O
'Sen91' concentration O
'Sen91' curve O
'Sen91' = O
'Sen91' 2 O
'Sen91' ) O
'Sen91' therapy O
'Sen91' in O
'Sen91' patients O
'Sen91' with O
'Sen91' recurrent O
'Sen91' ovarian O
'Sen91' cancer O
'Sen91' receiving O
'Sen91' multiple O
'Sen91' platinum O
'Sen91' - O
'Sen91' based O
'Sen91' chemotherapy O
'Sen91' . O

'Sen92' We O
'Sen92' report O
'Sen92' an O
'Sen92' unusual O
'Sen92' case O
'Sen92' of O
'Sen92' massive U-DOSAGE
'Sen92' fluoxetine U-DRUG
'Sen92' ingestion O
'Sen92' resulting O
'Sen92' in O
'Sen92' neurological O
'Sen92' and O
'Sen92' cardiovascular O
'Sen92' toxicity O
'Sen92' resulting O
'Sen92' in O
'Sen92' death O
'Sen92' . O

'Sen93' The O
'Sen93' case O
'Sen93' reported O
'Sen93' here O
'Sen93' is O
'Sen93' of O
'Sen93' a O
'Sen93' child O
'Sen93' given O
'Sen93' a O
'Sen93' large O
'Sen93' dose O
'Sen93' of O
'Sen93' intravenous O
'Sen93' iron B-DRUG
'Sen93' sucrose L-DRUG
'Sen93' ( O
'Sen93' 16 B-DOSAGE
'Sen93' mg I-DOSAGE
'Sen93' / I-DOSAGE
'Sen93' kg L-DOSAGE
'Sen93' ) O
'Sen93' over O
'Sen93' 3 O
'Sen93' hours O
'Sen93' , O
'Sen93' who O
'Sen93' subsequently O
'Sen93' developed O
'Sen93' features O
'Sen93' of O
'Sen93' systemic O
'Sen93' iron O
'Sen93' toxicity O
'Sen93' . O

'Sen94' Fatal O
'Sen94' radiation O
'Sen94' myelopathy O
'Sen94' after O
'Sen94' high B-DOSAGE
'Sen94' - I-DOSAGE
'Sen94' dose L-DOSAGE
'Sen94' busulfan U-DRUG
'Sen94' and O
'Sen94' melphalan O
'Sen94' chemotherapy O
'Sen94' and O
'Sen94' radiotherapy O
'Sen94' for O
'Sen94' Ewing O
'Sen94' 's O
'Sen94' sarcoma O
'Sen94' : O
'Sen94' a O
'Sen94' review O
'Sen94' of O
'Sen94' the O
'Sen94' literature O
'Sen94' and O
'Sen94' implications O
'Sen94' for O
'Sen94' practice O
'Sen94' . O

'Sen95' Fatal O
'Sen95' radiation O
'Sen95' myelopathy O
'Sen95' after O
'Sen95' high B-DOSAGE
'Sen95' - I-DOSAGE
'Sen95' dose L-DOSAGE
'Sen95' busulfan O
'Sen95' and O
'Sen95' melphalan U-DRUG
'Sen95' chemotherapy O
'Sen95' and O
'Sen95' radiotherapy O
'Sen95' for O
'Sen95' Ewing O
'Sen95' 's O
'Sen95' sarcoma O
'Sen95' : O
'Sen95' a O
'Sen95' review O
'Sen95' of O
'Sen95' the O
'Sen95' literature O
'Sen95' and O
'Sen95' implications O
'Sen95' for O
'Sen95' practice O
'Sen95' . O

'Sen96' Inadvertent O
'Sen96' and O
'Sen96' accidental O
'Sen96' epinephrine U-DRUG
'Sen96' overdose U-DOSAGE
'Sen96' might O
'Sen96' result O
'Sen96' in O
'Sen96' potentially O
'Sen96' lethal O
'Sen96' complications O
'Sen96' . O

'Sen97' Prominent O
'Sen97' positive O
'Sen97' U O
'Sen97' waves O
'Sen97' appearing O
'Sen97' with O
'Sen97' high B-DOSAGE
'Sen97' - I-DOSAGE
'Sen97' dose L-DOSAGE
'Sen97' intravenous O
'Sen97' phenylephrine U-DRUG
'Sen97' . O

'Sen98' A O
'Sen98' 56-year O
'Sen98' - O
'Sen98' old O
'Sen98' white O
'Sen98' woman O
'Sen98' with O
'Sen98' a O
'Sen98' diagnosis O
'Sen98' of O
'Sen98' reactive O
'Sen98' depression O
'Sen98' developed O
'Sen98' severe O
'Sen98' UI O
'Sen98' after O
'Sen98' a O
'Sen98' 30 O
'Sen98' days O
'Sen98' ' O
'Sen98' treatment O
'Sen98' with O
'Sen98' venlafaxine U-DRUG
'Sen98' 75 B-DOSAGE
'Sen98' mg I-DOSAGE
'Sen98' / I-DOSAGE
'Sen98' day L-DOSAGE
'Sen98' . O

'Sen99' A O
'Sen99' 17-year O
'Sen99' - O
'Sen99' old O
'Sen99' boy O
'Sen99' with O
'Sen99' acute O
'Sen99' lymphoblastic O
'Sen99' leukemia O
'Sen99' developed O
'Sen99' acute O
'Sen99' renal O
'Sen99' failure O
'Sen99' within O
'Sen99' 48 O
'Sen99' h O
'Sen99' of O
'Sen99' an O
'Sen99' intravenous O
'Sen99' high O
'Sen99' - O
'Sen99' dose O
'Sen99' methotrexate U-DRUG
'Sen99' ( O
'Sen99' 5 B-DOSAGE
'Sen99' g I-DOSAGE
'Sen99' / I-DOSAGE
'Sen99' m2 L-DOSAGE
'Sen99' ) O
'Sen99' infusion O
'Sen99' . O

'Sen100' A O
'Sen100' 17-year O
'Sen100' - O
'Sen100' old O
'Sen100' boy O
'Sen100' with O
'Sen100' acute O
'Sen100' lymphoblastic O
'Sen100' leukemia O
'Sen100' developed O
'Sen100' acute O
'Sen100' renal O
'Sen100' failure O
'Sen100' within O
'Sen100' 48 O
'Sen100' h O
'Sen100' of O
'Sen100' an O
'Sen100' intravenous O
'Sen100' high B-DOSAGE
'Sen100' - I-DOSAGE
'Sen100' dose L-DOSAGE
'Sen100' methotrexate U-DRUG
'Sen100' ( O
'Sen100' 5 O
'Sen100' g O
'Sen100' / O
'Sen100' m2 O
'Sen100' ) O
'Sen100' infusion O
'Sen100' . O

'Sen101' High B-DOSAGE
'Sen101' - I-DOSAGE
'Sen101' dose L-DOSAGE
'Sen101' methotrexate U-DRUG
'Sen101' - O
'Sen101' associated O
'Sen101' acute O
'Sen101' renal O
'Sen101' failure O
'Sen101' may O
'Sen101' be O
'Sen101' an O
'Sen101' avoidable O
'Sen101' complication O
'Sen101' . O

'Sen102' A O
'Sen102' 55-year O
'Sen102' - O
'Sen102' old O
'Sen102' woman O
'Sen102' presented O
'Sen102' an O
'Sen102' episode O
'Sen102' of O
'Sen102' acute O
'Sen102' urticaria O
'Sen102' and O
'Sen102' labial O
'Sen102' angioedema O
'Sen102' 60 O
'Sen102' minutes O
'Sen102' after O
'Sen102' ingesting O
'Sen102' 500 B-DOSAGE
'Sen102' mg L-DOSAGE
'Sen102' of O
'Sen102' cloxacillin U-DRUG
'Sen102' for O
'Sen102' a O
'Sen102' skin O
'Sen102' abscess O
'Sen102' . O

'Sen103' Myocardial O
'Sen103' ischemia O
'Sen103' associated O
'Sen103' with O
'Sen103' high B-DOSAGE
'Sen103' - I-DOSAGE
'Sen103' dose L-DOSAGE
'Sen103' carmustine U-DRUG
'Sen103' infusion O
'Sen103' . O

'Sen104' Acute O
'Sen104' myocardial O
'Sen104' infarction O
'Sen104' during O
'Sen104' high B-DOSAGE
'Sen104' - I-DOSAGE
'Sen104' dose L-DOSAGE
'Sen104' methylprednisolone U-DRUG
'Sen104' therapy O
'Sen104' for O
'Sen104' Graves O
'Sen104' ' O
'Sen104' ophthalmopathy O
'Sen104' . O

'Sen105' We O
'Sen105' conclude O
'Sen105' that O
'Sen105' myocardial O
'Sen105' infarction O
'Sen105' may O
'Sen105' develop O
'Sen105' in O
'Sen105' patients O
'Sen105' treated O
'Sen105' with O
'Sen105' high B-DOSAGE
'Sen105' - I-DOSAGE
'Sen105' dose L-DOSAGE
'Sen105' glucocorticoids U-DRUG
'Sen105' for O
'Sen105' Graves O
'Sen105' ' O
'Sen105' ophthalmopathy O
'Sen105' , O
'Sen105' and O
'Sen105' increased O
'Sen105' blood O
'Sen105' pressure O
'Sen105' may O
'Sen105' herald O
'Sen105' this O
'Sen105' complication O
'Sen105' . O

'Sen106' We O
'Sen106' present O
'Sen106' the O
'Sen106' case O
'Sen106' of O
'Sen106' a O
'Sen106' 58-year O
'Sen106' - O
'Sen106' old O
'Sen106' woman O
'Sen106' who O
'Sen106' ingested O
'Sen106' more O
'Sen106' than O
'Sen106' 35 B-DOSAGE
'Sen106' g L-DOSAGE
'Sen106' of O
'Sen106' caffeine U-DRUG
'Sen106' in O
'Sen106' a O
'Sen106' suicide O
'Sen106' attempt O
'Sen106' . O

'Sen107' Flecainide U-DRUG
'Sen107' overdose U-DOSAGE
'Sen107' can O
'Sen107' rapidly O
'Sen107' result O
'Sen107' in O
'Sen107' profound O
'Sen107' cardiovascular O
'Sen107' collapse O
'Sen107' , O
'Sen107' and O
'Sen107' is O
'Sen107' associated O
'Sen107' with O
'Sen107' a O
'Sen107' relatively O
'Sen107' high O
'Sen107' mortality O
'Sen107' . O

'Sen108' Managing O
'Sen108' cardiovascular O
'Sen108' collapse O
'Sen108' in O
'Sen108' severe O
'Sen108' flecainide U-DRUG
'Sen108' overdose U-DOSAGE
'Sen108' without O
'Sen108' recourse O
'Sen108' to O
'Sen108' extracorporeal O
'Sen108' therapy O
'Sen108' . O

'Sen109' Two O
'Sen109' patients O
'Sen109' are O
'Sen109' described O
'Sen109' who O
'Sen109' developed O
'Sen109' sensory O
'Sen109' neuropathy O
'Sen109' after O
'Sen109' the O
'Sen109' ingestion O
'Sen109' of O
'Sen109' 30.6 O
'Sen109' and O
'Sen109' 114 B-DOSAGE
'Sen109' g L-DOSAGE
'Sen109' metronidazole U-DRUG
'Sen109' respectively O
'Sen109' . O

'Sen110' Two O
'Sen110' patients O
'Sen110' are O
'Sen110' described O
'Sen110' who O
'Sen110' developed O
'Sen110' sensory O
'Sen110' neuropathy O
'Sen110' after O
'Sen110' the O
'Sen110' ingestion O
'Sen110' of O
'Sen110' 30.6 U-DOSAGE
'Sen110' and O
'Sen110' 114 O
'Sen110' g O
'Sen110' metronidazole U-DRUG
'Sen110' respectively O
'Sen110' . O

'Sen111' We O
'Sen111' report O
'Sen111' a O
'Sen111' case O
'Sen111' of O
'Sen111' a O
'Sen111' patient O
'Sen111' with O
'Sen111' rheumatoid O
'Sen111' arthritis O
'Sen111' treated O
'Sen111' with O
'Sen111' low O
'Sen111' - O
'Sen111' dose O
'Sen111' methotrexate U-DRUG
'Sen111' ( O
'Sen111' 15 B-DOSAGE
'Sen111' mg I-DOSAGE
'Sen111' / I-DOSAGE
'Sen111' week L-DOSAGE
'Sen111' ) O
'Sen111' who O
'Sen111' developed O
'Sen111' infection O
'Sen111' with O
'Sen111' both O
'Sen111' M. O
'Sen111' tuberculosis O
'Sen111' and O
'Sen111' M. O
'Sen111' chelonae O
'Sen111' after O
'Sen111' the O
'Sen111' revision O
'Sen111' of O
'Sen111' a O
'Sen111' prosthetic O
'Sen111' hip O
'Sen111' . O

'Sen112' We O
'Sen112' report O
'Sen112' a O
'Sen112' case O
'Sen112' of O
'Sen112' a O
'Sen112' patient O
'Sen112' with O
'Sen112' rheumatoid O
'Sen112' arthritis O
'Sen112' treated O
'Sen112' with O
'Sen112' low B-DOSAGE
'Sen112' - I-DOSAGE
'Sen112' dose L-DOSAGE
'Sen112' methotrexate U-DRUG
'Sen112' ( O
'Sen112' 15 O
'Sen112' mg O
'Sen112' / O
'Sen112' week O
'Sen112' ) O
'Sen112' who O
'Sen112' developed O
'Sen112' infection O
'Sen112' with O
'Sen112' both O
'Sen112' M. O
'Sen112' tuberculosis O
'Sen112' and O
'Sen112' M. O
'Sen112' chelonae O
'Sen112' after O
'Sen112' the O
'Sen112' revision O
'Sen112' of O
'Sen112' a O
'Sen112' prosthetic O
'Sen112' hip O
'Sen112' . O

'Sen113' The O
'Sen113' authors O
'Sen113' describe O
'Sen113' pericardial O
'Sen113' hemorrhage O
'Sen113' , O
'Sen113' which O
'Sen113' is O
'Sen113' related O
'Sen113' to O
'Sen113' the O
'Sen113' use O
'Sen113' of O
'Sen113' low B-DOSAGE
'Sen113' - I-DOSAGE
'Sen113' dose L-DOSAGE
'Sen113' acetylsalicylic B-DRUG
'Sen113' acid L-DRUG
'Sen113' in O
'Sen113' a O
'Sen113' patient O
'Sen113' with O
'Sen113' essential O
'Sen113' thrombocythemia O
'Sen113' . O

'Sen114' Hyponatraemia O
'Sen114' during O
'Sen114' low B-DOSAGE
'Sen114' - I-DOSAGE
'Sen114' dose L-DOSAGE
'Sen114' carbamazepine U-DRUG
'Sen114' therapy O
'Sen114' . O

'Sen115' We O
'Sen115' report O
'Sen115' on O
'Sen115' 7 O
'Sen115' patients O
'Sen115' ( O
'Sen115' 2 O
'Sen115' women O
'Sen115' , O
'Sen115' 5 O
'Sen115' men O
'Sen115' ) O
'Sen115' with O
'Sen115' chronic O
'Sen115' renal O
'Sen115' failure O
'Sen115' , O
'Sen115' who O
'Sen115' developed O
'Sen115' under O
'Sen115' a O
'Sen115' high O
'Sen115' dosage O
'Sen115' of O
'Sen115' the O
'Sen115' new O
'Sen115' diuretic O
'Sen115' muzolimine U-DRUG
'Sen115' ( O
'Sen115' range O
'Sen115' 240 B-DOSAGE
'Sen115' to I-DOSAGE
'Sen115' 1440 I-DOSAGE
'Sen115' mg I-DOSAGE
'Sen115' per I-DOSAGE
'Sen115' day L-DOSAGE
'Sen115' ) O
'Sen115' fatal O
'Sen115' neuromyeloencephalopathy O
'Sen115' . O

'Sen116' We O
'Sen116' report O
'Sen116' on O
'Sen116' 7 O
'Sen116' patients O
'Sen116' ( O
'Sen116' 2 O
'Sen116' women O
'Sen116' , O
'Sen116' 5 O
'Sen116' men O
'Sen116' ) O
'Sen116' with O
'Sen116' chronic O
'Sen116' renal O
'Sen116' failure O
'Sen116' , O
'Sen116' who O
'Sen116' developed O
'Sen116' under O
'Sen116' a O
'Sen116' high B-DOSAGE
'Sen116' dosage L-DOSAGE
'Sen116' of O
'Sen116' the O
'Sen116' new O
'Sen116' diuretic O
'Sen116' muzolimine U-DRUG
'Sen116' ( O
'Sen116' range O
'Sen116' 240 O
'Sen116' to O
'Sen116' 1440 O
'Sen116' mg O
'Sen116' per O
'Sen116' day O
'Sen116' ) O
'Sen116' fatal O
'Sen116' neuromyeloencephalopathy O
'Sen116' . O

'Sen117' The O
'Sen117' fourth O
'Sen117' patient O
'Sen117' showed O
'Sen117' RLS O
'Sen117' symptoms O
'Sen117' that O
'Sen117' were O
'Sen117' initially O
'Sen117' caused O
'Sen117' by O
'Sen117' a O
'Sen117' 20-mg B-DOSAGE
'Sen117' daily L-DOSAGE
'Sen117' olanzapine O
'Sen117' dosage O
'Sen117' and O
'Sen117' were O
'Sen117' later O
'Sen117' mitigated O
'Sen117' when O
'Sen117' olanzapine U-DRUG
'Sen117' was O
'Sen117' reduced O
'Sen117' and O
'Sen117' ropinirole O
'Sen117' was O
'Sen117' administered O
'Sen117' . O

'Sen118' She O
'Sen118' had O
'Sen118' been O
'Sen118' on O
'Sen118' Copaxone U-DRUG
'Sen118' 20 B-DOSAGE
'Sen118' mg I-DOSAGE
'Sen118' / I-DOSAGE
'Sen118' day L-DOSAGE
'Sen118' treatment O
'Sen118' for O
'Sen118' 2 O
'Sen118' years O
'Sen118' when O
'Sen118' she O
'Sen118' first O
'Sen118' exhibited O
'Sen118' gastrointestinal O
'Sen118' symptoms O
'Sen118' . O

'Sen119' Multiple O
'Sen119' seizures O
'Sen119' after O
'Sen119' bupropion U-DRUG
'Sen119' overdose U-DOSAGE
'Sen119' in O
'Sen119' a O
'Sen119' small O
'Sen119' child O
'Sen119' . O

'Sen120' The O
'Sen120' patient O
'Sen120' experienced O
'Sen120' hallucinations O
'Sen120' , O
'Sen120' agitation O
'Sen120' , O
'Sen120' vomiting O
'Sen120' , O
'Sen120' tachycardia O
'Sen120' and O
'Sen120' seizures O
'Sen120' after O
'Sen120' ingestion O
'Sen120' of O
'Sen120' 1050 O
'Sen120' ( O
'Sen120' 48 B-DOSAGE
'Sen120' mg I-DOSAGE
'Sen120' / I-DOSAGE
'Sen120' kg L-DOSAGE
'Sen120' ) O
'Sen120' of O
'Sen120' extended O
'Sen120' - O
'Sen120' release O
'Sen120' bupropion U-DRUG
'Sen120' . O

'Sen121' CASE O
'Sen121' SUMMARY O
'Sen121' : O
'Sen121' An O
'Sen121' 80-year O
'Sen121' - O
'Sen121' old O
'Sen121' white O
'Sen121' female O
'Sen121' , O
'Sen121' followed O
'Sen121' up O
'Sen121' at O
'Sen121' the O
'Sen121' Memory O
'Sen121' Clinic O
'Sen121' for O
'Sen121' mild O
'Sen121' cognitive O
'Sen121' impairment O
'Sen121' , O
'Sen121' had O
'Sen121' been O
'Sen121' taking O
'Sen121' propafenone U-DRUG
'Sen121' 900 B-DOSAGE
'Sen121' mg I-DOSAGE
'Sen121' / I-DOSAGE
'Sen121' d L-DOSAGE
'Sen121' for O
'Sen121' > O
'Sen121' 10 O
'Sen121' years O
'Sen121' for O
'Sen121' paroxysmal O
'Sen121' atrial O
'Sen121' fibrillation O
'Sen121' without O
'Sen121' adverse O
'Sen121' effects O
'Sen121' . O

'Sen122' Hemorrhage O
'Sen122' from O
'Sen122' a O
'Sen122' falx O
'Sen122' meningioma O
'Sen122' after O
'Sen122' internal O
'Sen122' use O
'Sen122' of O
'Sen122' low B-DOSAGE
'Sen122' - I-DOSAGE
'Sen122' dose L-DOSAGE
'Sen122' aspirin U-DRUG
'Sen122' . O

'Sen123' We O
'Sen123' report O
'Sen123' a O
'Sen123' case O
'Sen123' in O
'Sen123' which O
'Sen123' hemorrhage O
'Sen123' occurred O
'Sen123' in O
'Sen123' an O
'Sen123' asymptomatic O
'Sen123' falx O
'Sen123' meningioma O
'Sen123' known O
'Sen123' beforehand O
'Sen123' , O
'Sen123' after O
'Sen123' the O
'Sen123' internal O
'Sen123' use O
'Sen123' of O
'Sen123' low B-DOSAGE
'Sen123' - I-DOSAGE
'Sen123' dose L-DOSAGE
'Sen123' aspirin U-DRUG
'Sen123' for O
'Sen123' 16 O
'Sen123' months O
'Sen123' . O

'Sen124' CONCLUSIONS O
'Sen124' : O
'Sen124' Life O
'Sen124' - O
'Sen124' threatening O
'Sen124' adrenal O
'Sen124' suppression O
'Sen124' , O
'Sen124' requiring O
'Sen124' hydrocortisone O
'Sen124' supplementation O
'Sen124' and O
'Sen124' intensive O
'Sen124' therapy O
'Sen124' , O
'Sen124' was O
'Sen124' observed O
'Sen124' and O
'Sen124' successfully O
'Sen124' treated O
'Sen124' in O
'Sen124' a O
'Sen124' newborn O
'Sen124' , O
'Sen124' whose O
'Sen124' mother O
'Sen124' had O
'Sen124' received O
'Sen124' high B-DOSAGE
'Sen124' - I-DOSAGE
'Sen124' dose L-DOSAGE
'Sen124' methylprednisolone U-DRUG
'Sen124' in O
'Sen124' late O
'Sen124' pregnancy O
'Sen124' . O

'Sen125' High B-DOSAGE
'Sen125' - I-DOSAGE
'Sen125' dose L-DOSAGE
'Sen125' methylprednisolone U-DRUG
'Sen125' in O
'Sen125' a O
'Sen125' pregnant O
'Sen125' woman O
'Sen125' with O
'Sen125' Crohn O
'Sen125' 's O
'Sen125' disease O
'Sen125' and O
'Sen125' adrenal O
'Sen125' suppression O
'Sen125' in O
'Sen125' her O
'Sen125' newborn O
'Sen125' . O

'Sen126' A O
'Sen126' 10-year O
'Sen126' - O
'Sen126' old O
'Sen126' boy O
'Sen126' with O
'Sen126' osteosarcoma O
'Sen126' and O
'Sen126' normal O
'Sen126' renal O
'Sen126' function O
'Sen126' manifested O
'Sen126' laboratory O
'Sen126' evidence O
'Sen126' of O
'Sen126' impending O
'Sen126' renal O
'Sen126' toxicity O
'Sen126' and O
'Sen126' extreme O
'Sen126' elevation O
'Sen126' of O
'Sen126' aspartate O
'Sen126' aminotrasferase O
'Sen126' and O
'Sen126' alanine O
'Sen126' aminotransferase O
'Sen126' within O
'Sen126' 2 O
'Sen126' hours O
'Sen126' after O
'Sen126' the O
'Sen126' completion O
'Sen126' of O
'Sen126' a O
'Sen126' 4-hour O
'Sen126' infusion O
'Sen126' of O
'Sen126' high O
'Sen126' - O
'Sen126' dose O
'Sen126' methotrexate U-DRUG
'Sen126' ( O
'Sen126' MTX O
'Sen126' ) O
'Sen126' ( O
'Sen126' 12 B-DOSAGE
'Sen126' g I-DOSAGE
'Sen126' / I-DOSAGE
'Sen126' m2 L-DOSAGE
'Sen126' ) O
'Sen126' , O
'Sen126' and O
'Sen126' went O
'Sen126' on O
'Sen126' to O
'Sen126' develop O
'Sen126' acute O
'Sen126' renal O
'Sen126' failure O
'Sen126' with O
'Sen126' life O
'Sen126' - O
'Sen126' threatening O
'Sen126' hyperkalemia O
'Sen126' 29 O
'Sen126' hours O
'Sen126' later O
'Sen126' . O

'Sen127' A O
'Sen127' 10-year O
'Sen127' - O
'Sen127' old O
'Sen127' boy O
'Sen127' with O
'Sen127' osteosarcoma O
'Sen127' and O
'Sen127' normal O
'Sen127' renal O
'Sen127' function O
'Sen127' manifested O
'Sen127' laboratory O
'Sen127' evidence O
'Sen127' of O
'Sen127' impending O
'Sen127' renal O
'Sen127' toxicity O
'Sen127' and O
'Sen127' extreme O
'Sen127' elevation O
'Sen127' of O
'Sen127' aspartate O
'Sen127' aminotrasferase O
'Sen127' and O
'Sen127' alanine O
'Sen127' aminotransferase O
'Sen127' within O
'Sen127' 2 O
'Sen127' hours O
'Sen127' after O
'Sen127' the O
'Sen127' completion O
'Sen127' of O
'Sen127' a O
'Sen127' 4-hour O
'Sen127' infusion O
'Sen127' of O
'Sen127' high O
'Sen127' - O
'Sen127' dose O
'Sen127' methotrexate O
'Sen127' ( O
'Sen127' MTX U-DRUG
'Sen127' ) O
'Sen127' ( O
'Sen127' 12 B-DOSAGE
'Sen127' g I-DOSAGE
'Sen127' / I-DOSAGE
'Sen127' m2 L-DOSAGE
'Sen127' ) O
'Sen127' , O
'Sen127' and O
'Sen127' went O
'Sen127' on O
'Sen127' to O
'Sen127' develop O
'Sen127' acute O
'Sen127' renal O
'Sen127' failure O
'Sen127' with O
'Sen127' life O
'Sen127' - O
'Sen127' threatening O
'Sen127' hyperkalemia O
'Sen127' 29 O
'Sen127' hours O
'Sen127' later O
'Sen127' . O

'Sen128' A O
'Sen128' 10-year O
'Sen128' - O
'Sen128' old O
'Sen128' boy O
'Sen128' with O
'Sen128' osteosarcoma O
'Sen128' and O
'Sen128' normal O
'Sen128' renal O
'Sen128' function O
'Sen128' manifested O
'Sen128' laboratory O
'Sen128' evidence O
'Sen128' of O
'Sen128' impending O
'Sen128' renal O
'Sen128' toxicity O
'Sen128' and O
'Sen128' extreme O
'Sen128' elevation O
'Sen128' of O
'Sen128' aspartate O
'Sen128' aminotrasferase O
'Sen128' and O
'Sen128' alanine O
'Sen128' aminotransferase O
'Sen128' within O
'Sen128' 2 O
'Sen128' hours O
'Sen128' after O
'Sen128' the O
'Sen128' completion O
'Sen128' of O
'Sen128' a O
'Sen128' 4-hour O
'Sen128' infusion O
'Sen128' of O
'Sen128' high B-DOSAGE
'Sen128' - I-DOSAGE
'Sen128' dose L-DOSAGE
'Sen128' methotrexate U-DRUG
'Sen128' ( O
'Sen128' MTX O
'Sen128' ) O
'Sen128' ( O
'Sen128' 12 O
'Sen128' g O
'Sen128' / O
'Sen128' m2 O
'Sen128' ) O
'Sen128' , O
'Sen128' and O
'Sen128' went O
'Sen128' on O
'Sen128' to O
'Sen128' develop O
'Sen128' acute O
'Sen128' renal O
'Sen128' failure O
'Sen128' with O
'Sen128' life O
'Sen128' - O
'Sen128' threatening O
'Sen128' hyperkalemia O
'Sen128' 29 O
'Sen128' hours O
'Sen128' later O
'Sen128' . O

'Sen129' A O
'Sen129' 10-year O
'Sen129' - O
'Sen129' old O
'Sen129' boy O
'Sen129' with O
'Sen129' osteosarcoma O
'Sen129' and O
'Sen129' normal O
'Sen129' renal O
'Sen129' function O
'Sen129' manifested O
'Sen129' laboratory O
'Sen129' evidence O
'Sen129' of O
'Sen129' impending O
'Sen129' renal O
'Sen129' toxicity O
'Sen129' and O
'Sen129' extreme O
'Sen129' elevation O
'Sen129' of O
'Sen129' aspartate O
'Sen129' aminotrasferase O
'Sen129' and O
'Sen129' alanine O
'Sen129' aminotransferase O
'Sen129' within O
'Sen129' 2 O
'Sen129' hours O
'Sen129' after O
'Sen129' the O
'Sen129' completion O
'Sen129' of O
'Sen129' a O
'Sen129' 4-hour O
'Sen129' infusion O
'Sen129' of O
'Sen129' high B-DOSAGE
'Sen129' - I-DOSAGE
'Sen129' dose L-DOSAGE
'Sen129' methotrexate O
'Sen129' ( O
'Sen129' MTX U-DRUG
'Sen129' ) O
'Sen129' ( O
'Sen129' 12 O
'Sen129' g O
'Sen129' / O
'Sen129' m2 O
'Sen129' ) O
'Sen129' , O
'Sen129' and O
'Sen129' went O
'Sen129' on O
'Sen129' to O
'Sen129' develop O
'Sen129' acute O
'Sen129' renal O
'Sen129' failure O
'Sen129' with O
'Sen129' life O
'Sen129' - O
'Sen129' threatening O
'Sen129' hyperkalemia O
'Sen129' 29 O
'Sen129' hours O
'Sen129' later O
'Sen129' . O

'Sen130' Early O
'Sen130' recognition O
'Sen130' of O
'Sen130' renal O
'Sen130' toxicity O
'Sen130' of O
'Sen130' high B-DOSAGE
'Sen130' - I-DOSAGE
'Sen130' dose L-DOSAGE
'Sen130' methotrexate U-DRUG
'Sen130' therapy O
'Sen130' : O
'Sen130' a O
'Sen130' case O
'Sen130' report O
'Sen130' . O

'Sen131' We O
'Sen131' report O
'Sen131' on O
'Sen131' three O
'Sen131' cases O
'Sen131' wherein O
'Sen131' treatment O
'Sen131' of O
'Sen131' dexmedetomidine U-DRUG
'Sen131' - O
'Sen131' induced O
'Sen131' bradycardia O
'Sen131' with O
'Sen131' i.v O
'Sen131' . O
'Sen131' glycopyrrolate O
'Sen131' ( O
'Sen131' 5.0 B-DOSAGE
'Sen131' microg I-DOSAGE
'Sen131' / I-DOSAGE
'Sen131' kg L-DOSAGE
'Sen131' ) O
'Sen131' not O
'Sen131' only O
'Sen131' resulting O
'Sen131' in O
'Sen131' resolution O
'Sen131' of O
'Sen131' bradycardia O
'Sen131' but O
'Sen131' also O
'Sen131' resulting O
'Sen131' in O
'Sen131' an O
'Sen131' exaggerated O
'Sen131' increase O
'Sen131' of O
'Sen131' arterial O
'Sen131' blood O
'Sen131' pressure O
'Sen131' . O

'Sen132' We O
'Sen132' report O
'Sen132' on O
'Sen132' three O
'Sen132' cases O
'Sen132' wherein O
'Sen132' treatment O
'Sen132' of O
'Sen132' dexmedetomidine O
'Sen132' - O
'Sen132' induced O
'Sen132' bradycardia O
'Sen132' with O
'Sen132' i.v O
'Sen132' . O
'Sen132' glycopyrrolate U-DRUG
'Sen132' ( O
'Sen132' 5.0 B-DOSAGE
'Sen132' microg I-DOSAGE
'Sen132' / I-DOSAGE
'Sen132' kg L-DOSAGE
'Sen132' ) O
'Sen132' not O
'Sen132' only O
'Sen132' resulting O
'Sen132' in O
'Sen132' resolution O
'Sen132' of O
'Sen132' bradycardia O
'Sen132' but O
'Sen132' also O
'Sen132' resulting O
'Sen132' in O
'Sen132' an O
'Sen132' exaggerated O
'Sen132' increase O
'Sen132' of O
'Sen132' arterial O
'Sen132' blood O
'Sen132' pressure O
'Sen132' . O

'Sen133' Three O
'Sen133' days O
'Sen133' after O
'Sen133' receiving O
'Sen133' intravitreal O
'Sen133' injection O
'Sen133' of O
'Sen133' bevacizumab U-DRUG
'Sen133' ( O
'Sen133' 1.25 B-DOSAGE
'Sen133' mg I-DOSAGE
'Sen133' in I-DOSAGE
'Sen133' 0.1 I-DOSAGE
'Sen133' ml L-DOSAGE
'Sen133' ) O
'Sen133' , O
'Sen133' he O
'Sen133' developed O
'Sen133' acute O
'Sen133' vision O
'Sen133' loss O
'Sen133' and O
'Sen133' change O
'Sen133' of O
'Sen133' consciousness O
'Sen133' . O

'Sen134' One O
'Sen134' week O
'Sen134' after O
'Sen134' the O
'Sen134' initial O
'Sen134' - O
'Sen134' dose O
'Sen134' of O
'Sen134' adalimumab U-DRUG
'Sen134' ( O
'Sen134' 160 B-DOSAGE
'Sen134' mg L-DOSAGE
'Sen134' ) O
'Sen134' , O
'Sen134' which O
'Sen134' was O
'Sen134' initiated O
'Sen134' due O
'Sen134' to O
'Sen134' an O
'Sen134' acute O
'Sen134' exacerbation O
'Sen134' of O
'Sen134' Crohn O
'Sen134' 's O
'Sen134' disease O
'Sen134' , O
'Sen134' the O
'Sen134' patient O
'Sen134' developed O
'Sen134' a O
'Sen134' fulminant O
'Sen134' cardiomyopathy O
'Sen134' . O

'Sen135' Hepatotoxicity O
'Sen135' after O
'Sen135' high B-DOSAGE
'Sen135' - I-DOSAGE
'Sen135' dose L-DOSAGE
'Sen135' methylprednisolone U-DRUG
'Sen135' for O
'Sen135' demyelinating O
'Sen135' disease O
'Sen135' . O

'Sen136' We O
'Sen136' observed O
'Sen136' 2 O
'Sen136' cases O
'Sen136' of O
'Sen136' hepatotoxicity O
'Sen136' after O
'Sen136' a O
'Sen136' high B-DOSAGE
'Sen136' - I-DOSAGE
'Sen136' dose L-DOSAGE
'Sen136' methylprednisolone U-DRUG
'Sen136' treatment O
'Sen136' of O
'Sen136' a O
'Sen136' demyelinating O
'Sen136' disease O
'Sen136' and O
'Sen136' evaluated O
'Sen136' the O
'Sen136' potential O
'Sen136' relationship O
'Sen136' in O
'Sen136' the O
'Sen136' light O
'Sen136' of O
'Sen136' available O
'Sen136' evidence O
'Sen136' . O

'Sen137' CONCLUSIONS O
'Sen137' : O
'Sen137' We O
'Sen137' present O
'Sen137' a O
'Sen137' case O
'Sen137' of O
'Sen137' a O
'Sen137' patient O
'Sen137' with O
'Sen137' CML O
'Sen137' who O
'Sen137' developed O
'Sen137' KS O
'Sen137' 12 O
'Sen137' months O
'Sen137' after O
'Sen137' starting O
'Sen137' treatment O
'Sen137' with O
'Sen137' imatinib U-DRUG
'Sen137' 400 B-DOSAGE
'Sen137' mg I-DOSAGE
'Sen137' / I-DOSAGE
'Sen137' d L-DOSAGE
'Sen137' . O

'Sen138' Bulbar O
'Sen138' and O
'Sen138' pseudobulbar O
'Sen138' palsy O
'Sen138' complicating O
'Sen138' therapy O
'Sen138' with O
'Sen138' high B-DOSAGE
'Sen138' - I-DOSAGE
'Sen138' dose L-DOSAGE
'Sen138' cytosine B-DRUG
'Sen138' arabinoside L-DRUG
'Sen138' in O
'Sen138' children O
'Sen138' with O
'Sen138' leukemia O
'Sen138' . O

'Sen139' Common O
'Sen139' adverse O
'Sen139' events O
'Sen139' ( O
'Sen139' frequency O
'Sen139' 10 O
'Sen139' % O
'Sen139' ) O
'Sen139' of O
'Sen139' lacosamide U-DRUG
'Sen139' doses O
'Sen139' up O
'Sen139' to O
'Sen139' 600 B-DOSAGE
'Sen139' mg I-DOSAGE
'Sen139' / I-DOSAGE
'Sen139' day L-DOSAGE
'Sen139' include O
'Sen139' nonspecific O
'Sen139' central O
'Sen139' nervous O
'Sen139' system O
'Sen139' effects O
'Sen139' ( O
'Sen139' e.g. O
'Sen139' , O
'Sen139' dizziness O
'Sen139' , O
'Sen139' ataxia O
'Sen139' , O
'Sen139' diplopia O
'Sen139' , O
'Sen139' and O
'Sen139' somnolence O
'Sen139' ) O
'Sen139' . O

'Sen140' An O
'Sen140' episode O
'Sen140' of O
'Sen140' leukoencephalopathy O
'Sen140' is O
'Sen140' reported O
'Sen140' in O
'Sen140' a O
'Sen140' 13-year O
'Sen140' - O
'Sen140' old O
'Sen140' girl O
'Sen140' who O
'Sen140' , O
'Sen140' after O
'Sen140' standard O
'Sen140' radiotherapy O
'Sen140' for O
'Sen140' a O
'Sen140' posterior O
'Sen140' fossa O
'Sen140' medulloblastoma O
'Sen140' , O
'Sen140' received O
'Sen140' 8 O
'Sen140' treatments O
'Sen140' with O
'Sen140' a O
'Sen140' protocol O
'Sen140' containing O
'Sen140' a O
'Sen140' 4-hour O
'Sen140' infusion O
'Sen140' of O
'Sen140' 500 O
'Sen140' mg O
'Sen140' / O
'Sen140' m2 O
'Sen140' methotrexate O
'Sen140' and O
'Sen140' 12 B-DOSAGE
'Sen140' mg L-DOSAGE
'Sen140' intrathecal O
'Sen140' methotrexate U-DRUG
'Sen140' . O

'Sen141' An O
'Sen141' episode O
'Sen141' of O
'Sen141' leukoencephalopathy O
'Sen141' is O
'Sen141' reported O
'Sen141' in O
'Sen141' a O
'Sen141' 13-year O
'Sen141' - O
'Sen141' old O
'Sen141' girl O
'Sen141' who O
'Sen141' , O
'Sen141' after O
'Sen141' standard O
'Sen141' radiotherapy O
'Sen141' for O
'Sen141' a O
'Sen141' posterior O
'Sen141' fossa O
'Sen141' medulloblastoma O
'Sen141' , O
'Sen141' received O
'Sen141' 8 O
'Sen141' treatments O
'Sen141' with O
'Sen141' a O
'Sen141' protocol O
'Sen141' containing O
'Sen141' a O
'Sen141' 4-hour O
'Sen141' infusion O
'Sen141' of O
'Sen141' 500 B-DOSAGE
'Sen141' mg I-DOSAGE
'Sen141' / I-DOSAGE
'Sen141' m2 L-DOSAGE
'Sen141' methotrexate O
'Sen141' and O
'Sen141' 12 O
'Sen141' mg O
'Sen141' intrathecal O
'Sen141' methotrexate U-DRUG
'Sen141' . O

'Sen142' An O
'Sen142' 83-year O
'Sen142' - O
'Sen142' old O
'Sen142' man O
'Sen142' receiving O
'Sen142' glipizide U-DRUG
'Sen142' 10 B-DOSAGE
'Sen142' mg L-DOSAGE
'Sen142' bid O
'Sen142' developed O
'Sen142' symptomatic O
'Sen142' hypoglycemia O
'Sen142' within O
'Sen142' three O
'Sen142' days O
'Sen142' of O
'Sen142' adding O
'Sen142' trimethoprim O
'Sen142' / O
'Sen142' sulfamethoxazole O
'Sen142' ( O
'Sen142' TMP O
'Sen142' / O
'Sen142' SMX O
'Sen142' ) O
'Sen142' to O
'Sen142' his O
'Sen142' regimen O
'Sen142' . O

'Sen143' An O
'Sen143' 83-year O
'Sen143' - O
'Sen143' old O
'Sen143' man O
'Sen143' receiving O
'Sen143' glipizide O
'Sen143' 10 B-DOSAGE
'Sen143' mg L-DOSAGE
'Sen143' bid O
'Sen143' developed O
'Sen143' symptomatic O
'Sen143' hypoglycemia O
'Sen143' within O
'Sen143' three O
'Sen143' days O
'Sen143' of O
'Sen143' adding O
'Sen143' trimethoprim O
'Sen143' / O
'Sen143' sulfamethoxazole O
'Sen143' ( O
'Sen143' TMP O
'Sen143' / O
'Sen143' SMX U-DRUG
'Sen143' ) O
'Sen143' to O
'Sen143' his O
'Sen143' regimen O
'Sen143' . O

'Sen144' An O
'Sen144' 83-year O
'Sen144' - O
'Sen144' old O
'Sen144' man O
'Sen144' receiving O
'Sen144' glipizide O
'Sen144' 10 B-DOSAGE
'Sen144' mg L-DOSAGE
'Sen144' bid O
'Sen144' developed O
'Sen144' symptomatic O
'Sen144' hypoglycemia O
'Sen144' within O
'Sen144' three O
'Sen144' days O
'Sen144' of O
'Sen144' adding O
'Sen144' trimethoprim O
'Sen144' / O
'Sen144' sulfamethoxazole U-DRUG
'Sen144' ( O
'Sen144' TMP O
'Sen144' / O
'Sen144' SMX O
'Sen144' ) O
'Sen144' to O
'Sen144' his O
'Sen144' regimen O
'Sen144' . O

'Sen145' An O
'Sen145' 83-year O
'Sen145' - O
'Sen145' old O
'Sen145' man O
'Sen145' receiving O
'Sen145' glipizide O
'Sen145' 10 B-DOSAGE
'Sen145' mg L-DOSAGE
'Sen145' bid O
'Sen145' developed O
'Sen145' symptomatic O
'Sen145' hypoglycemia O
'Sen145' within O
'Sen145' three O
'Sen145' days O
'Sen145' of O
'Sen145' adding O
'Sen145' trimethoprim O
'Sen145' / O
'Sen145' sulfamethoxazole O
'Sen145' ( O
'Sen145' TMP U-DRUG
'Sen145' / O
'Sen145' SMX O
'Sen145' ) O
'Sen145' to O
'Sen145' his O
'Sen145' regimen O
'Sen145' . O

'Sen146' An O
'Sen146' 83-year O
'Sen146' - O
'Sen146' old O
'Sen146' man O
'Sen146' receiving O
'Sen146' glipizide O
'Sen146' 10 B-DOSAGE
'Sen146' mg L-DOSAGE
'Sen146' bid O
'Sen146' developed O
'Sen146' symptomatic O
'Sen146' hypoglycemia O
'Sen146' within O
'Sen146' three O
'Sen146' days O
'Sen146' of O
'Sen146' adding O
'Sen146' trimethoprim U-DRUG
'Sen146' / O
'Sen146' sulfamethoxazole O
'Sen146' ( O
'Sen146' TMP O
'Sen146' / O
'Sen146' SMX O
'Sen146' ) O
'Sen146' to O
'Sen146' his O
'Sen146' regimen O
'Sen146' . O

'Sen147' A O
'Sen147' sixty O
'Sen147' - O
'Sen147' year O
'Sen147' - O
'Sen147' old O
'Sen147' woman O
'Sen147' with O
'Sen147' advanced O
'Sen147' breast O
'Sen147' cancer O
'Sen147' , O
'Sen147' previously O
'Sen147' treated O
'Sen147' with O
'Sen147' cisplatin O
'Sen147' , O
'Sen147' developed O
'Sen147' an O
'Sen147' irreversible O
'Sen147' lethal O
'Sen147' renal O
'Sen147' failure O
'Sen147' with O
'Sen147' anuria O
'Sen147' , O
'Sen147' the O
'Sen147' day O
'Sen147' after O
'Sen147' 5 B-DOSAGE
'Sen147' g I-DOSAGE
'Sen147' / I-DOSAGE
'Sen147' m2 L-DOSAGE
'Sen147' bolus O
'Sen147' ifosfamide U-DRUG
'Sen147' . O

'Sen148' Lethal O
'Sen148' anuria O
'Sen148' complicating O
'Sen148' high B-DOSAGE
'Sen148' dose L-DOSAGE
'Sen148' ifosfamide U-DRUG
'Sen148' chemotherapy O
'Sen148' in O
'Sen148' a O
'Sen148' breast O
'Sen148' cancer O
'Sen148' patient O
'Sen148' with O
'Sen148' an O
'Sen148' impaired O
'Sen148' renal O
'Sen148' function O
'Sen148' . O

'Sen149' Horner O
'Sen149' 's O
'Sen149' syndrome O
'Sen149' and O
'Sen149' demyelinating O
'Sen149' peripheral O
'Sen149' neuropathy O
'Sen149' caused O
'Sen149' by O
'Sen149' high B-DOSAGE
'Sen149' - I-DOSAGE
'Sen149' dose L-DOSAGE
'Sen149' cytosine B-DRUG
'Sen149' arabinoside L-DRUG
'Sen149' . O

'Sen150' Peripheral O
'Sen150' nerve O
'Sen150' dysfunction O
'Sen150' is O
'Sen150' a O
'Sen150' potentially O
'Sen150' serious O
'Sen150' complication O
'Sen150' of O
'Sen150' high B-DOSAGE
'Sen150' - I-DOSAGE
'Sen150' dose L-DOSAGE
'Sen150' cytosine B-DRUG
'Sen150' arabinoside L-DRUG
'Sen150' . O

'Sen151' We O
'Sen151' describe O
'Sen151' a O
'Sen151' patient O
'Sen151' with O
'Sen151' acute O
'Sen151' leukemia O
'Sen151' who O
'Sen151' developed O
'Sen151' Horner O
'Sen151' 's O
'Sen151' syndrome O
'Sen151' and O
'Sen151' a O
'Sen151' severe O
'Sen151' demyelinating O
'Sen151' peripheral O
'Sen151' neuropathy O
'Sen151' leading O
'Sen151' to O
'Sen151' death O
'Sen151' after O
'Sen151' receiving O
'Sen151' high B-DOSAGE
'Sen151' - I-DOSAGE
'Sen151' dose L-DOSAGE
'Sen151' cytosine B-DRUG
'Sen151' arabinoside L-DRUG
'Sen151' . O

'Sen152' Life O
'Sen152' - O
'Sen152' threatening O
'Sen152' acute O
'Sen152' hyponatraemia O
'Sen152' induced O
'Sen152' by O
'Sen152' low B-DOSAGE
'Sen152' dose L-DOSAGE
'Sen152' cyclophosphamide U-DRUG
'Sen152' and O
'Sen152' indomethacin O
'Sen152' . O

'Sen153' Life O
'Sen153' - O
'Sen153' threatening O
'Sen153' acute O
'Sen153' hyponatraemia O
'Sen153' induced O
'Sen153' by O
'Sen153' low B-DOSAGE
'Sen153' dose L-DOSAGE
'Sen153' cyclophosphamide O
'Sen153' and O
'Sen153' indomethacin U-DRUG
'Sen153' . O

'Sen154' We O
'Sen154' report O
'Sen154' the O
'Sen154' case O
'Sen154' of O
'Sen154' a O
'Sen154' patient O
'Sen154' with O
'Sen154' multiple O
'Sen154' myeloma O
'Sen154' who O
'Sen154' developed O
'Sen154' acute O
'Sen154' life O
'Sen154' - O
'Sen154' threatening O
'Sen154' water O
'Sen154' intoxication O
'Sen154' following O
'Sen154' treatment O
'Sen154' with O
'Sen154' oral O
'Sen154' indomethacin O
'Sen154' and O
'Sen154' low B-DOSAGE
'Sen154' dose L-DOSAGE
'Sen154' intravenous O
'Sen154' cyclophosphamide U-DRUG
'Sen154' . O

'Sen155' We O
'Sen155' report O
'Sen155' the O
'Sen155' case O
'Sen155' of O
'Sen155' a O
'Sen155' patient O
'Sen155' with O
'Sen155' multiple O
'Sen155' myeloma O
'Sen155' who O
'Sen155' developed O
'Sen155' acute O
'Sen155' life O
'Sen155' - O
'Sen155' threatening O
'Sen155' water O
'Sen155' intoxication O
'Sen155' following O
'Sen155' treatment O
'Sen155' with O
'Sen155' oral O
'Sen155' indomethacin U-DRUG
'Sen155' and O
'Sen155' low B-DOSAGE
'Sen155' dose L-DOSAGE
'Sen155' intravenous O
'Sen155' cyclophosphamide O
'Sen155' . O

'Sen156' Two O
'Sen156' cases O
'Sen156' of O
'Sen156' lepromatous O
'Sen156' leprosy O
'Sen156' with O
'Sen156' erythema O
'Sen156' nodosum O
'Sen156' leprosum O
'Sen156' who O
'Sen156' were O
'Sen156' on O
'Sen156' high B-DOSAGE
'Sen156' doses L-DOSAGE
'Sen156' of O
'Sen156' clofazimine U-DRUG
'Sen156' , O
'Sen156' showed O
'Sen156' discoloration O
'Sen156' of O
'Sen156' nail O
'Sen156' plate O
'Sen156' , O
'Sen156' subungual O
'Sen156' hyperkeratosis O
'Sen156' and O
'Sen156' onycholysis O
'Sen156' . O

'Sen157' Paraplegia O
'Sen157' following O
'Sen157' prophylactic O
'Sen157' intrathecal O
'Sen157' cytosine O
'Sen157' arabinoside O
'Sen157' ( O
'Sen157' Ara B-DRUG
'Sen157' - I-DRUG
'Sen157' C L-DRUG
'Sen157' ) O
'Sen157' is O
'Sen157' described O
'Sen157' in O
'Sen157' a O
'Sen157' patient O
'Sen157' with O
'Sen157' acute O
'Sen157' myelogenous O
'Sen157' leukemia O
'Sen157' in O
'Sen157' remission O
'Sen157' who O
'Sen157' received O
'Sen157' doses O
'Sen157' of O
'Sen157' 100 B-DOSAGE
'Sen157' mg I-DOSAGE
'Sen157' / I-DOSAGE
'Sen157' m2 I-DOSAGE
'Sen157' / I-DOSAGE
'Sen157' d L-DOSAGE
'Sen157' for O
'Sen157' 5 O
'Sen157' consecutive O
'Sen157' days O
'Sen157' . O

'Sen158' Paraplegia O
'Sen158' following O
'Sen158' prophylactic O
'Sen158' intrathecal O
'Sen158' cytosine B-DRUG
'Sen158' arabinoside L-DRUG
'Sen158' ( O
'Sen158' Ara O
'Sen158' - O
'Sen158' C O
'Sen158' ) O
'Sen158' is O
'Sen158' described O
'Sen158' in O
'Sen158' a O
'Sen158' patient O
'Sen158' with O
'Sen158' acute O
'Sen158' myelogenous O
'Sen158' leukemia O
'Sen158' in O
'Sen158' remission O
'Sen158' who O
'Sen158' received O
'Sen158' doses O
'Sen158' of O
'Sen158' 100 B-DOSAGE
'Sen158' mg I-DOSAGE
'Sen158' / I-DOSAGE
'Sen158' m2 I-DOSAGE
'Sen158' / I-DOSAGE
'Sen158' d L-DOSAGE
'Sen158' for O
'Sen158' 5 O
'Sen158' consecutive O
'Sen158' days O
'Sen158' . O

'Sen159' Three O
'Sen159' of O
'Sen159' 50 O
'Sen159' patients O
'Sen159' treated O
'Sen159' with O
'Sen159' isotretinoin U-DRUG
'Sen159' ( O
'Sen159' 1 B-DOSAGE
'Sen159' mg I-DOSAGE
'Sen159' / I-DOSAGE
'Sen159' kg I-DOSAGE
'Sen159' / I-DOSAGE
'Sen159' day L-DOSAGE
'Sen159' ) O
'Sen159' for O
'Sen159' cystic O
'Sen159' acne O
'Sen159' complained O
'Sen159' of O
'Sen159' poor O
'Sen159' night O
'Sen159' vision O
'Sen159' and/or O
'Sen159' excessive O
'Sen159' glare O
'Sen159' sensitivity O
'Sen159' . O

'Sen160' The O
'Sen160' pharmacology O
'Sen160' and O
'Sen160' toxicology O
'Sen160' of O
'Sen160' chloral B-DRUG
'Sen160' hydrate L-DRUG
'Sen160' are O
'Sen160' discussed O
'Sen160' with O
'Sen160' particular O
'Sen160' reference O
'Sen160' to O
'Sen160' the O
'Sen160' cardiac O
'Sen160' arrhythmias O
'Sen160' that O
'Sen160' are O
'Sen160' seen O
'Sen160' with O
'Sen160' overdosage U-DOSAGE
'Sen160' . O

'Sen161' A O
'Sen161' case O
'Sen161' of O
'Sen161' severe O
'Sen161' visual O
'Sen161' loss O
'Sen161' following O
'Sen161' a O
'Sen161' single B-DOSAGE
'Sen161' dose L-DOSAGE
'Sen161' of O
'Sen161' vincristine U-DRUG
'Sen161' is O
'Sen161' described O
'Sen161' . O

'Sen162' Severe O
'Sen162' visual O
'Sen162' loss O
'Sen162' after O
'Sen162' a O
'Sen162' single B-DOSAGE
'Sen162' dose L-DOSAGE
'Sen162' of O
'Sen162' vincristine U-DRUG
'Sen162' in O
'Sen162' a O
'Sen162' patient O
'Sen162' with O
'Sen162' spinal O
'Sen162' cord O
'Sen162' astrocytoma O
'Sen162' . O

'Sen163' Visual O
'Sen163' loss O
'Sen163' after O
'Sen163' a O
'Sen163' single B-DOSAGE
'Sen163' small I-DOSAGE
'Sen163' dose L-DOSAGE
'Sen163' of O
'Sen163' vincristine U-DRUG
'Sen163' has O
'Sen163' never O
'Sen163' been O
'Sen163' reported O
'Sen163' . O

'Sen164' Renal O
'Sen164' hypophosphatemia O
'Sen164' in O
'Sen164' this O
'Sen164' patient O
'Sen164' was O
'Sen164' caused O
'Sen164' by O
'Sen164' the O
'Sen164' erroneous O
'Sen164' intake O
'Sen164' of O
'Sen164' 1 B-DOSAGE
'Sen164' g L-DOSAGE
'Sen164' doxycycline U-DRUG
'Sen164' . O

'Sen165' After O
'Sen165' a O
'Sen165' six O
'Sen165' - O
'Sen165' week O
'Sen165' course O
'Sen165' of O
'Sen165' low B-DOSAGE
'Sen165' - I-DOSAGE
'Sen165' dose L-DOSAGE
'Sen165' cyclosporine O
'Sen165' A O
'Sen165' , O
'Sen165' she O
'Sen165' developed O
'Sen165' a O
'Sen165' severe O
'Sen165' but O
'Sen165' reversible O
'Sen165' loss O
'Sen165' of O
'Sen165' glomerular O
'Sen165' filtration O
'Sen165' rate O
'Sen165' and O
'Sen165' effective O
'Sen165' renal O
'Sen165' plasma O
'Sen165' flow O
'Sen165' despite O
'Sen165' of O
'Sen165' low O
'Sen165' cyclosporine B-DRUG
'Sen165' A L-DRUG
'Sen165' plasma O
'Sen165' levels O
'Sen165' . O

'Sen166' A O
'Sen166' patient O
'Sen166' is O
'Sen166' presented O
'Sen166' with O
'Sen166' typical O
'Sen166' hyperthyroidism O
'Sen166' , O
'Sen166' who O
'Sen166' developed O
'Sen166' a O
'Sen166' severe O
'Sen166' proximal O
'Sen166' muscle O
'Sen166' weakness O
'Sen166' and O
'Sen166' a O
'Sen166' raised O
'Sen166' creatine O
'Sen166' phosphokinase O
'Sen166' after O
'Sen166' treatment O
'Sen166' for O
'Sen166' hyperthyroidism O
'Sen166' with O
'Sen166' propylthiouracil U-DRUG
'Sen166' ( O
'Sen166' 100 B-DOSAGE
'Sen166' mg I-DOSAGE
'Sen166' orally I-DOSAGE
'Sen166' , I-DOSAGE
'Sen166' three I-DOSAGE
'Sen166' times I-DOSAGE
'Sen166' a I-DOSAGE
'Sen166' day L-DOSAGE
'Sen166' ) O
'Sen166' . O

'Sen167' A O
'Sen167' 56-year O
'Sen167' - O
'Sen167' old O
'Sen167' woman O
'Sen167' with O
'Sen167' scleroderma O
'Sen167' developed O
'Sen167' rapidly O
'Sen167' progressive O
'Sen167' glomerulonephritis O
'Sen167' with O
'Sen167' epithelial O
'Sen167' crescents O
'Sen167' associated O
'Sen167' with O
'Sen167' hemoptysis O
'Sen167' after O
'Sen167' 27 O
'Sen167' months O
'Sen167' of O
'Sen167' D B-DRUG
'Sen167' - I-DRUG
'Sen167' penicillamine L-DRUG
'Sen167' therapy O
'Sen167' and O
'Sen167' a O
'Sen167' cumulative O
'Sen167' dose O
'Sen167' of O
'Sen167' 1,200 -
'Sen167' g. -

'Sen168' We O
'Sen168' report O
'Sen168' a O
'Sen168' case O
'Sen168' of O
'Sen168' torsade O
'Sen168' de O
'Sen168' pointes O
'Sen168' following O
'Sen168' a O
'Sen168' single O
'Sen168' oral O
'Sen168' dose O
'Sen168' of O
'Sen168' amiodarone U-DRUG
'Sen168' ( O
'Sen168' 1400 B-DOSAGE
'Sen168' mg L-DOSAGE
'Sen168' or O
'Sen168' 30 O
'Sen168' mg O
'Sen168' kg-1 O
'Sen168' ) O
'Sen168' administered O
'Sen168' after O
'Sen168' short O
'Sen168' intravenous O
'Sen168' loading O
'Sen168' for O
'Sen168' prevention O
'Sen168' of O
'Sen168' paroxysmal O
'Sen168' atrial O
'Sen168' flutter O
'Sen168' . O

'Sen169' We O
'Sen169' report O
'Sen169' a O
'Sen169' case O
'Sen169' of O
'Sen169' torsade O
'Sen169' de O
'Sen169' pointes O
'Sen169' following O
'Sen169' a O
'Sen169' single O
'Sen169' oral O
'Sen169' dose O
'Sen169' of O
'Sen169' amiodarone U-DRUG
'Sen169' ( O
'Sen169' 1400 O
'Sen169' mg O
'Sen169' or O
'Sen169' 30 B-DOSAGE
'Sen169' mg I-DOSAGE
'Sen169' kg-1 L-DOSAGE
'Sen169' ) O
'Sen169' administered O
'Sen169' after O
'Sen169' short O
'Sen169' intravenous O
'Sen169' loading O
'Sen169' for O
'Sen169' prevention O
'Sen169' of O
'Sen169' paroxysmal O
'Sen169' atrial O
'Sen169' flutter O
'Sen169' . O

'Sen170' A O
'Sen170' small O
'Sen170' initial O
'Sen170' dose O
'Sen170' of O
'Sen170' prazosin O
'Sen170' ranging O
'Sen170' from O
'Sen170' 0.5 B-DOSAGE
'Sen170' to I-DOSAGE
'Sen170' 1 I-DOSAGE
'Sen170' mg L-DOSAGE
'Sen170' has O
'Sen170' been O
'Sen170' recommended O
'Sen170' to O
'Sen170' avoid O
'Sen170' the O
'Sen170' first O
'Sen170' - O
'Sen170' dose O
'Sen170' phenomenon O
'Sen170' characterized O
'Sen170' by O
'Sen170' a O
'Sen170' sudden O
'Sen170' and O
'Sen170' severe O
'Sen170' drop O
'Sen170' in O
'Sen170' blood O
'Sen170' pressure O
'Sen170' after O
'Sen170' the O
'Sen170' administration O
'Sen170' of O
'Sen170' the O
'Sen170' first O
'Sen170' dose O
'Sen170' of O
'Sen170' prazosin U-DRUG
'Sen170' . O

'Sen171' A O
'Sen171' small O
'Sen171' initial O
'Sen171' dose O
'Sen171' of O
'Sen171' prazosin O
'Sen171' ranging O
'Sen171' from O
'Sen171' 0.5 B-DOSAGE
'Sen171' to I-DOSAGE
'Sen171' 1 I-DOSAGE
'Sen171' mg L-DOSAGE
'Sen171' has O
'Sen171' been O
'Sen171' recommended O
'Sen171' to O
'Sen171' avoid O
'Sen171' the O
'Sen171' first O
'Sen171' - O
'Sen171' dose O
'Sen171' phenomenon O
'Sen171' characterized O
'Sen171' by O
'Sen171' a O
'Sen171' sudden O
'Sen171' and O
'Sen171' severe O
'Sen171' drop O
'Sen171' in O
'Sen171' blood O
'Sen171' pressure O
'Sen171' after O
'Sen171' the O
'Sen171' administration O
'Sen171' of O
'Sen171' the O
'Sen171' first O
'Sen171' dose O
'Sen171' of O
'Sen171' prazosin U-DRUG
'Sen171' . O

'Sen172' Phenytoin O
'Sen172' was O
'Sen172' discontinued O
'Sen172' after O
'Sen172' admission O
'Sen172' ; O
'Sen172' however O
'Sen172' , O
'Sen172' phenytoin U-DRUG
'Sen172' 1 B-DOSAGE
'Sen172' g L-DOSAGE
'Sen172' i.v O
'Sen172' . O
'Sen172' was O
'Sen172' given O
'Sen172' for O
'Sen172' a O
'Sen172' tonic O
'Sen172' - O
'Sen172' clonic O
'Sen172' seizure O
'Sen172' two O
'Sen172' days O
'Sen172' after O
'Sen172' admission O
'Sen172' , O
'Sen172' after O
'Sen172' which O
'Sen172' swelling O
'Sen172' of O
'Sen172' the O
'Sen172' face O
'Sen172' and O
'Sen172' legs O
'Sen172' and O
'Sen172' pruritus O
'Sen172' developed O
'Sen172' . O

'Sen173' She O
'Sen173' was O
'Sen173' receiving O
'Sen173' phenytoin O
'Sen173' sodium O
'Sen173' 300 O
'Sen173' mg O
'Sen173' / O
'Sen173' day O
'Sen173' ; O
'Sen173' carbamazepine U-DRUG
'Sen173' 200 B-DOSAGE
'Sen173' mg L-DOSAGE
'Sen173' four O
'Sen173' times O
'Sen173' daily O
'Sen173' had O
'Sen173' been O
'Sen173' discontinued O
'Sen173' four O
'Sen173' days O
'Sen173' before O
'Sen173' admission O
'Sen173' because O
'Sen173' of O
'Sen173' leukopenia O
'Sen173' . O

'Sen174' She O
'Sen174' was O
'Sen174' receiving O
'Sen174' phenytoin B-DRUG
'Sen174' sodium L-DRUG
'Sen174' 300 B-DOSAGE
'Sen174' mg I-DOSAGE
'Sen174' / I-DOSAGE
'Sen174' day L-DOSAGE
'Sen174' ; O
'Sen174' carbamazepine O
'Sen174' 200 O
'Sen174' mg O
'Sen174' four O
'Sen174' times O
'Sen174' daily O
'Sen174' had O
'Sen174' been O
'Sen174' discontinued O
'Sen174' four O
'Sen174' days O
'Sen174' before O
'Sen174' admission O
'Sen174' because O
'Sen174' of O
'Sen174' leukopenia O
'Sen174' . O

'Sen175' After O
'Sen175' therapy O
'Sen175' with O
'Sen175' parenteral O
'Sen175' amiodarone U-DRUG
'Sen175' ( O
'Sen175' 2300 B-DOSAGE
'Sen175' mg I-DOSAGE
'Sen175' in I-DOSAGE
'Sen175' 3 I-DOSAGE
'Sen175' days L-DOSAGE
'Sen175' ) O
'Sen175' and O
'Sen175' other O
'Sen175' measures O
'Sen175' , O
'Sen175' signs O
'Sen175' of O
'Sen175' congestive O
'Sen175' heart O
'Sen175' failure O
'Sen175' disappeared O
'Sen175' ; O
'Sen175' subsequently O
'Sen175' the O
'Sen175' patient O
'Sen175' developed O
'Sen175' jaundice O
'Sen175' , O
'Sen175' marked O
'Sen175' increase O
'Sen175' in O
'Sen175' serum O
'Sen175' transaminase O
'Sen175' levels O
'Sen175' and O
'Sen175' fall O
'Sen175' in O
'Sen175' prothrombin O
'Sen175' time O
'Sen175' , O
'Sen175' and O
'Sen175' histologic O
'Sen175' changes O
'Sen175' of O
'Sen175' severe O
'Sen175' centrilobular O
'Sen175' necrosis O
'Sen175' were O
'Sen175' observed O
'Sen175' in O
'Sen175' hepatic O
'Sen175' biopsy O
'Sen175' . O

'Sen176' The O
'Sen176' main O
'Sen176' clinical O
'Sen176' features O
'Sen176' of O
'Sen176' this O
'Sen176' 58-year O
'Sen176' - O
'Sen176' old O
'Sen176' female O
'Sen176' patient O
'Sen176' were O
'Sen176' laboratory O
'Sen176' evidence O
'Sen176' of O
'Sen176' leucopenia O
'Sen176' and O
'Sen176' cholestasis O
'Sen176' , O
'Sen176' and O
'Sen176' biopsy O
'Sen176' features O
'Sen176' of O
'Sen176' fatty O
'Sen176' liver O
'Sen176' parenchyma O
'Sen176' degeneration O
'Sen176' with O
'Sen176' granulocytic O
'Sen176' portal O
'Sen176' infiltration O
'Sen176' and O
'Sen176' bile O
'Sen176' stasis O
'Sen176' , O
'Sen176' demonstrated O
'Sen176' 20 O
'Sen176' days O
'Sen176' after O
'Sen176' the O
'Sen176' initiation O
'Sen176' of O
'Sen176' antithyroid O
'Sen176' therapy O
'Sen176' with O
'Sen176' 20 B-DOSAGE
'Sen176' mg L-DOSAGE
'Sen176' methimazole U-DRUG
'Sen176' daily O
'Sen176' . O

'Sen177' A O
'Sen177' case O
'Sen177' of O
'Sen177' propranolol U-DRUG
'Sen177' overdose U-DOSAGE
'Sen177' complicated O
'Sen177' by O
'Sen177' esophageal O
'Sen177' spasm O
'Sen177' preventing O
'Sen177' extrication O
'Sen177' of O
'Sen177' an O
'Sen177' orogastric O
'Sen177' lavage O
'Sen177' tube O
'Sen177' and O
'Sen177' relieved O
'Sen177' by O
'Sen177' intravenous O
'Sen177' glucagon O
'Sen177' is O
'Sen177' presented O
'Sen177' . O

'Sen178' Esophageal O
'Sen178' spasm O
'Sen178' following O
'Sen178' propranolol U-DRUG
'Sen178' overdose U-DOSAGE
'Sen178' relieved O
'Sen178' by O
'Sen178' glucagon O
'Sen178' . O

'Sen179' Our O
'Sen179' findings O
'Sen179' suggest O
'Sen179' that O
'Sen179' hyperkalemia O
'Sen179' can O
'Sen179' develop O
'Sen179' with O
'Sen179' the O
'Sen179' use O
'Sen179' of O
'Sen179' low B-DOSAGE
'Sen179' - I-DOSAGE
'Sen179' dose L-DOSAGE
'Sen179' heparin O
'Sen179' , O
'Sen179' within O
'Sen179' seven O
'Sen179' days O
'Sen179' of O
'Sen179' initiating O
'Sen179' heparin U-DRUG
'Sen179' therapy O
'Sen179' , O
'Sen179' and O
'Sen179' that O
'Sen179' patients O
'Sen179' with O
'Sen179' diabetes O
'Sen179' mellitus O
'Sen179' or O
'Sen179' chronic O
'Sen179' renal O
'Sen179' insufficiency O
'Sen179' are O
'Sen179' especially O
'Sen179' predisposed O
'Sen179' to O
'Sen179' this O
'Sen179' complication O
'Sen179' . O

'Sen180' Our O
'Sen180' findings O
'Sen180' suggest O
'Sen180' that O
'Sen180' hyperkalemia O
'Sen180' can O
'Sen180' develop O
'Sen180' with O
'Sen180' the O
'Sen180' use O
'Sen180' of O
'Sen180' low B-DOSAGE
'Sen180' - I-DOSAGE
'Sen180' dose L-DOSAGE
'Sen180' heparin O
'Sen180' , O
'Sen180' within O
'Sen180' seven O
'Sen180' days O
'Sen180' of O
'Sen180' initiating O
'Sen180' heparin U-DRUG
'Sen180' therapy O
'Sen180' , O
'Sen180' and O
'Sen180' that O
'Sen180' patients O
'Sen180' with O
'Sen180' diabetes O
'Sen180' mellitus O
'Sen180' or O
'Sen180' chronic O
'Sen180' renal O
'Sen180' insufficiency O
'Sen180' are O
'Sen180' especially O
'Sen180' predisposed O
'Sen180' to O
'Sen180' this O
'Sen180' complication O
'Sen180' . O

'Sen181' A O
'Sen181' 65-year O
'Sen181' - O
'Sen181' old O
'Sen181' woman O
'Sen181' with O
'Sen181' bipolar O
'Sen181' disorder O
'Sen181' and O
'Sen181' complicated O
'Sen181' cardiovascular O
'Sen181' disease O
'Sen181' who O
'Sen181' was O
'Sen181' on O
'Sen181' maintenance O
'Sen181' lithium U-DRUG
'Sen181' therapy O
'Sen181' developed O
'Sen181' a O
'Sen181' movement O
'Sen181' disorder O
'Sen181' following O
'Sen181' high B-DOSAGE
'Sen181' doses L-DOSAGE
'Sen181' of O
'Sen181' trazodone O
'Sen181' for O
'Sen181' treatment O
'Sen181' of O
'Sen181' an O
'Sen181' acute O
'Sen181' depression O
'Sen181' . O

'Sen182' A O
'Sen182' 65-year O
'Sen182' - O
'Sen182' old O
'Sen182' woman O
'Sen182' with O
'Sen182' bipolar O
'Sen182' disorder O
'Sen182' and O
'Sen182' complicated O
'Sen182' cardiovascular O
'Sen182' disease O
'Sen182' who O
'Sen182' was O
'Sen182' on O
'Sen182' maintenance O
'Sen182' lithium O
'Sen182' therapy O
'Sen182' developed O
'Sen182' a O
'Sen182' movement O
'Sen182' disorder O
'Sen182' following O
'Sen182' high B-DOSAGE
'Sen182' doses L-DOSAGE
'Sen182' of O
'Sen182' trazodone U-DRUG
'Sen182' for O
'Sen182' treatment O
'Sen182' of O
'Sen182' an O
'Sen182' acute O
'Sen182' depression O
'Sen182' . O

'Sen183' Two O
'Sen183' other O
'Sen183' patients O
'Sen183' who O
'Sen183' did O
'Sen183' not O
'Sen183' receive O
'Sen183' prochlorperazine O
'Sen183' , O
'Sen183' developed O
'Sen183' retinal O
'Sen183' problems O
'Sen183' which O
'Sen183' later O
'Sen183' improved O
'Sen183' , O
'Sen183' one O
'Sen183' after O
'Sen183' only O
'Sen183' 15 B-DOSAGE
'Sen183' g L-DOSAGE
'Sen183' of O
'Sen183' desferrioxamine U-DRUG
'Sen183' . O

'Sen184' Four O
'Sen184' cases O
'Sen184' of O
'Sen184' fat O
'Sen184' embolism O
'Sen184' are O
'Sen184' described O
'Sen184' in O
'Sen184' infants O
'Sen184' receiving O
'Sen184' prolonged O
'Sen184' intravenous O
'Sen184' infusion O
'Sen184' of O
'Sen184' fat O
'Sen184' ( O
'Sen184' Intralipid U-DRUG
'Sen184' 20 B-DOSAGE
'Sen184' % L-DOSAGE
'Sen184' ) O
'Sen184' . O

'Sen185' Three O
'Sen185' patients O
'Sen185' received O
'Sen185' respectively O
'Sen185' 190 O
'Sen185' mg O
'Sen185' , O
'Sen185' 175 B-DOSAGE
'Sen185' mg L-DOSAGE
'Sen185' , O
'Sen185' and O
'Sen185' 196 O
'Sen185' mg O
'Sen185' of O
'Sen185' methotrexate U-DRUG
'Sen185' and O
'Sen185' developed O
'Sen185' bilateral O
'Sen185' pulmonary O
'Sen185' infiltrates O
'Sen185' without O
'Sen185' evidence O
'Sen185' of O
'Sen185' peripheral O
'Sen185' blood O
'Sen185' eosinophilia O
'Sen185' . O

'Sen186' Three O
'Sen186' patients O
'Sen186' received O
'Sen186' respectively O
'Sen186' 190 B-DOSAGE
'Sen186' mg L-DOSAGE
'Sen186' , O
'Sen186' 175 O
'Sen186' mg O
'Sen186' , O
'Sen186' and O
'Sen186' 196 O
'Sen186' mg O
'Sen186' of O
'Sen186' methotrexate U-DRUG
'Sen186' and O
'Sen186' developed O
'Sen186' bilateral O
'Sen186' pulmonary O
'Sen186' infiltrates O
'Sen186' without O
'Sen186' evidence O
'Sen186' of O
'Sen186' peripheral O
'Sen186' blood O
'Sen186' eosinophilia O
'Sen186' . O

'Sen187' Three O
'Sen187' patients O
'Sen187' received O
'Sen187' respectively O
'Sen187' 190 O
'Sen187' mg O
'Sen187' , O
'Sen187' 175 O
'Sen187' mg O
'Sen187' , O
'Sen187' and O
'Sen187' 196 B-DOSAGE
'Sen187' mg L-DOSAGE
'Sen187' of O
'Sen187' methotrexate U-DRUG
'Sen187' and O
'Sen187' developed O
'Sen187' bilateral O
'Sen187' pulmonary O
'Sen187' infiltrates O
'Sen187' without O
'Sen187' evidence O
'Sen187' of O
'Sen187' peripheral O
'Sen187' blood O
'Sen187' eosinophilia O
'Sen187' . O

'Sen188' Two O
'Sen188' children O
'Sen188' with O
'Sen188' rheumatic O
'Sen188' fever O
'Sen188' developed O
'Sen188' anicteric O
'Sen188' hepatitis O
'Sen188' while O
'Sen188' on O
'Sen188' high B-DOSAGE
'Sen188' - I-DOSAGE
'Sen188' dose L-DOSAGE
'Sen188' aspirin U-DRUG
'Sen188' therapy O
'Sen188' . O

'Sen189' In O
'Sen189' three O
'Sen189' of O
'Sen189' these O
'Sen189' patients O
'Sen189' the O
'Sen189' infection O
'Sen189' was O
'Sen189' clinically O
'Sen189' unsuspected O
'Sen189' ; O
'Sen189' in O
'Sen189' the O
'Sen189' fourth O
'Sen189' , O
'Sen189' cutaneous O
'Sen189' herpes O
'Sen189' zoster O
'Sen189' developed O
'Sen189' after O
'Sen189' administration O
'Sen189' of O
'Sen189' 300 B-DOSAGE
'Sen189' mg L-DOSAGE
'Sen189' of O
'Sen189' cytarabine U-DRUG
'Sen189' daily O
'Sen189' for O
'Sen189' the O
'Sen189' preceding O
'Sen189' five O
'Sen189' days O
'Sen189' . O

'Sen190' Four O
'Sen190' patients O
'Sen190' receiving O
'Sen190' high B-DOSAGE
'Sen190' - I-DOSAGE
'Sen190' dose L-DOSAGE
'Sen190' tamoxifen U-DRUG
'Sen190' for O
'Sen190' greater O
'Sen190' than O
'Sen190' 1 O
'Sen190' year O
'Sen190' have O
'Sen190' demonstrated O
'Sen190' similar O
'Sen190' retinal O
'Sen190' changes O
'Sen190' . O

'Sen191' In O
'Sen191' eight O
'Sen191' patients O
'Sen191' , O
'Sen191' a O
'Sen191' mean O
'Sen191' decrease O
'Sen191' in O
'Sen191' serum O
'Sen191' Na+ O
'Sen191' of O
'Sen191' 8.25 O
'Sen191' + O
'Sen191' /- O
'Sen191' 3.2 O
'Sen191' mEq O
'Sen191' / O
'Sen191' L O
'Sen191' was O
'Sen191' observed O
'Sen191' after O
'Sen191' a O
'Sen191' single O
'Sen191' 200 B-DOSAGE
'Sen191' mg L-DOSAGE
'Sen191' intravenous O
'Sen191' dose O
'Sen191' of O
'Sen191' lorcainide U-DRUG
'Sen191' . O

'Sen192' In O
'Sen192' a O
'Sen192' 61-year O
'Sen192' - O
'Sen192' old O
'Sen192' man O
'Sen192' receiving O
'Sen192' chronic O
'Sen192' low B-DOSAGE
'Sen192' - I-DOSAGE
'Sen192' dosage L-DOSAGE
'Sen192' amiodarone U-DRUG
'Sen192' an O
'Sen192' interstitial O
'Sen192' pneumopathy O
'Sen192' was O
'Sen192' observed O
'Sen192' . O

'Sen193' Interstitial O
'Sen193' pneumopathy O
'Sen193' and O
'Sen193' low B-DOSAGE
'Sen193' - I-DOSAGE
'Sen193' dosage L-DOSAGE
'Sen193' amiodarone U-DRUG
'Sen193' . O

'Sen194' Alternating O
'Sen194' sinus O
'Sen194' rhythm O
'Sen194' and O
'Sen194' intermittent O
'Sen194' sinoatrial O
'Sen194' ( O
'Sen194' S O
'Sen194' - O
'Sen194' A O
'Sen194' ) O
'Sen194' block O
'Sen194' was O
'Sen194' observed O
'Sen194' in O
'Sen194' a O
'Sen194' 57-year O
'Sen194' - O
'Sen194' old O
'Sen194' woman O
'Sen194' , O
'Sen194' under O
'Sen194' treatment O
'Sen194' for O
'Sen194' angina O
'Sen194' with O
'Sen194' 80 B-DOSAGE
'Sen194' mg L-DOSAGE
'Sen194' propranolol U-DRUG
'Sen194' daily O
'Sen194' . O

'Sen195' Pulmonary O
'Sen195' fibrosis O
'Sen195' subsequent O
'Sen195' to O
'Sen195' high B-DOSAGE
'Sen195' doses L-DOSAGE
'Sen195' of O
'Sen195' CCNU U-DRUG
'Sen195' for O
'Sen195' chronic O
'Sen195' myeloid O
'Sen195' leukemia O
'Sen195' . O

'Sen196' Two O
'Sen196' patients O
'Sen196' treated O
'Sen196' for O
'Sen196' chronic O
'Sen196' myeloid O
'Sen196' leukemia O
'Sen196' with O
'Sen196' high O
'Sen196' doses O
'Sen196' of O
'Sen196' CCNU U-DRUG
'Sen196' ( O
'Sen196' 1100 B-DOSAGE
'Sen196' mg I-DOSAGE
'Sen196' / I-DOSAGE
'Sen196' m2 L-DOSAGE
'Sen196' and O
'Sen196' 1240 O
'Sen196' mg O
'Sen196' / O
'Sen196' m2 O
'Sen196' , O
'Sen196' respectively O
'Sen196' ) O
'Sen196' developed O
'Sen196' a O
'Sen196' fatal O
'Sen196' pulmonary O
'Sen196' fibrosis O
'Sen196' . O

'Sen197' Two O
'Sen197' patients O
'Sen197' treated O
'Sen197' for O
'Sen197' chronic O
'Sen197' myeloid O
'Sen197' leukemia O
'Sen197' with O
'Sen197' high O
'Sen197' doses O
'Sen197' of O
'Sen197' CCNU U-DRUG
'Sen197' ( O
'Sen197' 1100 O
'Sen197' mg O
'Sen197' / O
'Sen197' m2 O
'Sen197' and O
'Sen197' 1240 B-DOSAGE
'Sen197' mg I-DOSAGE
'Sen197' / I-DOSAGE
'Sen197' m2 L-DOSAGE
'Sen197' , O
'Sen197' respectively O
'Sen197' ) O
'Sen197' developed O
'Sen197' a O
'Sen197' fatal O
'Sen197' pulmonary O
'Sen197' fibrosis O
'Sen197' . O

'Sen198' Two O
'Sen198' patients O
'Sen198' treated O
'Sen198' for O
'Sen198' chronic O
'Sen198' myeloid O
'Sen198' leukemia O
'Sen198' with O
'Sen198' high B-DOSAGE
'Sen198' doses L-DOSAGE
'Sen198' of O
'Sen198' CCNU U-DRUG
'Sen198' ( O
'Sen198' 1100 O
'Sen198' mg O
'Sen198' / O
'Sen198' m2 O
'Sen198' and O
'Sen198' 1240 O
'Sen198' mg O
'Sen198' / O
'Sen198' m2 O
'Sen198' , O
'Sen198' respectively O
'Sen198' ) O
'Sen198' developed O
'Sen198' a O
'Sen198' fatal O
'Sen198' pulmonary O
'Sen198' fibrosis O
'Sen198' . O

'Sen199' Gynecomastia O
'Sen199' developed O
'Sen199' in O
'Sen199' two O
'Sen199' epileptic O
'Sen199' patients O
'Sen199' some O
'Sen199' months O
'Sen199' after O
'Sen199' the O
'Sen199' addition O
'Sen199' of O
'Sen199' oral O
'Sen199' fluoresone U-DRUG
'Sen199' 750 B-DOSAGE
'Sen199' mg L-DOSAGE
'Sen199' daily O
'Sen199' to O
'Sen199' the O
'Sen199' phenobarbital O
'Sen199' and O
'Sen199' phenytoin O
'Sen199' already O
'Sen199' being O
'Sen199' administered O
'Sen199' . O

'Sen200' Gynecomastia O
'Sen200' developed O
'Sen200' in O
'Sen200' two O
'Sen200' epileptic O
'Sen200' patients O
'Sen200' some O
'Sen200' months O
'Sen200' after O
'Sen200' the O
'Sen200' addition O
'Sen200' of O
'Sen200' oral O
'Sen200' fluoresone O
'Sen200' 750 B-DOSAGE
'Sen200' mg L-DOSAGE
'Sen200' daily O
'Sen200' to O
'Sen200' the O
'Sen200' phenobarbital U-DRUG
'Sen200' and O
'Sen200' phenytoin O
'Sen200' already O
'Sen200' being O
'Sen200' administered O
'Sen200' . O

'Sen201' Gynecomastia O
'Sen201' developed O
'Sen201' in O
'Sen201' two O
'Sen201' epileptic O
'Sen201' patients O
'Sen201' some O
'Sen201' months O
'Sen201' after O
'Sen201' the O
'Sen201' addition O
'Sen201' of O
'Sen201' oral O
'Sen201' fluoresone O
'Sen201' 750 B-DOSAGE
'Sen201' mg L-DOSAGE
'Sen201' daily O
'Sen201' to O
'Sen201' the O
'Sen201' phenobarbital O
'Sen201' and O
'Sen201' phenytoin U-DRUG
'Sen201' already O
'Sen201' being O
'Sen201' administered O
'Sen201' . O

'Sen202' Drug O
'Sen202' - O
'Sen202' induced O
'Sen202' psychosis O
'Sen202' resulted O
'Sen202' from O
'Sen202' the O
'Sen202' administration O
'Sen202' of O
'Sen202' quinacrine B-DRUG
'Sen202' hydrochloride L-DRUG
'Sen202' at O
'Sen202' a O
'Sen202' dosage O
'Sen202' of O
'Sen202' 100 B-DOSAGE
'Sen202' mg L-DOSAGE
'Sen202' twice O
'Sen202' daily O
'Sen202' for O
'Sen202' the O
'Sen202' treatment O
'Sen202' of O
'Sen202' discoid O
'Sen202' lupus O
'Sen202' . O

'Sen203' In O
'Sen203' four O
'Sen203' patients O
'Sen203' , O
'Sen203' spasm O
'Sen203' occurred O
'Sen203' spontaneous O
'Sen203' and O
'Sen203' in O
'Sen203' one O
'Sen203' patient O
'Sen203' after O
'Sen203' 0.05 B-DOSAGE
'Sen203' mg L-DOSAGE
'Sen203' of O
'Sen203' ergonovine U-DRUG
'Sen203' . O

'Sen204' Two O
'Sen204' years O
'Sen204' later O
'Sen204' , O
'Sen204' 24 O
'Sen204' hours O
'Sen204' following O
'Sen204' an O
'Sen204' increase O
'Sen204' in O
'Sen204' the O
'Sen204' dose O
'Sen204' of O
'Sen204' disopyramide U-DRUG
'Sen204' from O
'Sen204' 300 B-DOSAGE
'Sen204' to I-DOSAGE
'Sen204' 600 I-DOSAGE
'Sen204' mg I-DOSAGE
'Sen204' / I-DOSAGE
'Sen204' day L-DOSAGE
'Sen204' , O
'Sen204' AVT O
'Sen204' with O
'Sen204' syncope O
'Sen204' occurred O
'Sen204' ; O
'Sen204' isoproterenol O
'Sen204' abolished O
'Sen204' the O
'Sen204' arrhythmia O
'Sen204' instantly O
'Sen204' . O

'Sen205' He O
'Sen205' was O
'Sen205' started O
'Sen205' on O
'Sen205' digoxin U-DRUG
'Sen205' , O
'Sen205' 0.25 B-DOSAGE
'Sen205' mg L-DOSAGE
'Sen205' daily O
'Sen205' , O
'Sen205' because O
'Sen205' of O
'Sen205' echocardiographically O
'Sen205' demonstrated O
'Sen205' left O
'Sen205' ventricular O
'Sen205' dilatation O
'Sen205' and O
'Sen205' functional O
'Sen205' impairment O
'Sen205' ; O
'Sen205' he O
'Sen205' died O
'Sen205' of O
'Sen205' ventricular O
'Sen205' fibrillation O
'Sen205' 15 O
'Sen205' days O
'Sen205' later O
'Sen205' . O

'Sen206' Inappropriate O
'Sen206' antidiuretic O
'Sen206' hormone O
'Sen206' secretion O
'Sen206' after O
'Sen206' high B-DOSAGE
'Sen206' dose L-DOSAGE
'Sen206' vinblastine U-DRUG
'Sen206' . O

'Sen207' We O
'Sen207' report O
'Sen207' on O
'Sen207' a O
'Sen207' patient O
'Sen207' with O
'Sen207' an O
'Sen207' embryonal O
'Sen207' teratocarcinoma O
'Sen207' of O
'Sen207' the O
'Sen207' testicle O
'Sen207' who O
'Sen207' had O
'Sen207' the O
'Sen207' syndrome O
'Sen207' of O
'Sen207' inappropriate O
'Sen207' secretion O
'Sen207' of O
'Sen207' antidiuretic O
'Sen207' hormone O
'Sen207' after O
'Sen207' receiving O
'Sen207' a O
'Sen207' high B-DOSAGE
'Sen207' dose L-DOSAGE
'Sen207' of O
'Sen207' vinblastine U-DRUG
'Sen207' . O

'Sen208' Fatal O
'Sen208' interstitial O
'Sen208' pneumonitis O
'Sen208' following O
'Sen208' high B-DOSAGE
'Sen208' - I-DOSAGE
'Sen208' dose L-DOSAGE
'Sen208' intermittent O
'Sen208' chlorambucil U-DRUG
'Sen208' therapy O
'Sen208' for O
'Sen208' chronic O
'Sen208' lymphocyte O
'Sen208' leukemia O
'Sen208' . O

'Sen209' A O
'Sen209' 71-year O
'Sen209' - O
'Sen209' old O
'Sen209' man O
'Sen209' with O
'Sen209' paroxysmal O
'Sen209' atrial O
'Sen209' fibrillation O
'Sen209' who O
'Sen209' had O
'Sen209' a O
'Sen209' previous O
'Sen209' anterior O
'Sen209' myocardial O
'Sen209' infarction O
'Sen209' exhibited O
'Sen209' granulocytopenia O
'Sen209' 8 O
'Sen209' days O
'Sen209' following O
'Sen209' the O
'Sen209' administration O
'Sen209' of O
'Sen209' oral O
'Sen209' sustained O
'Sen209' - O
'Sen209' release O
'Sen209' procainamide U-DRUG
'Sen209' ( O
'Sen209' 750 B-DOSAGE
'Sen209' mg I-DOSAGE
'Sen209' / I-DOSAGE
'Sen209' day L-DOSAGE
'Sen209' ) O
'Sen209' . O

'Sen210' A O
'Sen210' 64 O
'Sen210' year O
'Sen210' old O
'Sen210' man O
'Sen210' with O
'Sen210' recurrent O
'Sen210' metastatic O
'Sen210' squamous O
'Sen210' cell O
'Sen210' carcinoma O
'Sen210' of O
'Sen210' the O
'Sen210' head O
'Sen210' and O
'Sen210' neck O
'Sen210' developed O
'Sen210' severe O
'Sen210' skin O
'Sen210' rash O
'Sen210' and O
'Sen210' bone O
'Sen210' marrow O
'Sen210' aplasia O
'Sen210' 4 O
'Sen210' and O
'Sen210' 7 O
'Sen210' days O
'Sen210' , O
'Sen210' respectively O
'Sen210' , O
'Sen210' following O
'Sen210' a O
'Sen210' single O
'Sen210' dose O
'Sen210' of O
'Sen210' 40 B-DOSAGE
'Sen210' mg I-DOSAGE
'Sen210' / I-DOSAGE
'Sen210' m2 L-DOSAGE
'Sen210' methotrexate U-DRUG
'Sen210' ( O
'Sen210' MTX O
'Sen210' ) O
'Sen210' . O

'Sen211' A O
'Sen211' 64 O
'Sen211' year O
'Sen211' old O
'Sen211' man O
'Sen211' with O
'Sen211' recurrent O
'Sen211' metastatic O
'Sen211' squamous O
'Sen211' cell O
'Sen211' carcinoma O
'Sen211' of O
'Sen211' the O
'Sen211' head O
'Sen211' and O
'Sen211' neck O
'Sen211' developed O
'Sen211' severe O
'Sen211' skin O
'Sen211' rash O
'Sen211' and O
'Sen211' bone O
'Sen211' marrow O
'Sen211' aplasia O
'Sen211' 4 O
'Sen211' and O
'Sen211' 7 O
'Sen211' days O
'Sen211' , O
'Sen211' respectively O
'Sen211' , O
'Sen211' following O
'Sen211' a O
'Sen211' single O
'Sen211' dose O
'Sen211' of O
'Sen211' 40 B-DOSAGE
'Sen211' mg I-DOSAGE
'Sen211' / I-DOSAGE
'Sen211' m2 L-DOSAGE
'Sen211' methotrexate O
'Sen211' ( O
'Sen211' MTX U-DRUG
'Sen211' ) O
'Sen211' . O

'Sen212' Bone O
'Sen212' marrow O
'Sen212' aplasia O
'Sen212' and O
'Sen212' severe O
'Sen212' skin O
'Sen212' rash O
'Sen212' after O
'Sen212' a O
'Sen212' single O
'Sen212' low B-DOSAGE
'Sen212' dose L-DOSAGE
'Sen212' of O
'Sen212' methotrexate U-DRUG
'Sen212' . O

'Sen213' We O
'Sen213' report O
'Sen213' the O
'Sen213' case O
'Sen213' of O
'Sen213' a O
'Sen213' 20-year O
'Sen213' - O
'Sen213' old O
'Sen213' female O
'Sen213' with O
'Sen213' polyarteritis O
'Sen213' nodosa O
'Sen213' ( O
'Sen213' PAN O
'Sen213' ) O
'Sen213' who O
'Sen213' developed O
'Sen213' bilateral O
'Sen213' sensorineural O
'Sen213' hearing O
'Sen213' loss O
'Sen213' 25 O
'Sen213' minutes O
'Sen213' after O
'Sen213' receiving O
'Sen213' 30 B-DOSAGE
'Sen213' mg L-DOSAGE
'Sen213' of O
'Sen213' intravenous O
'Sen213' ketoralac U-DRUG
'Sen213' . O

'Sen214' A O
'Sen214' 9-year O
'Sen214' - O
'Sen214' old O
'Sen214' boy O
'Sen214' developed O
'Sen214' acute O
'Sen214' renal O
'Sen214' failure O
'Sen214' following O
'Sen214' intravenous O
'Sen214' acyclovir U-DRUG
'Sen214' ( O
'Sen214' 30 B-DOSAGE
'Sen214' mg I-DOSAGE
'Sen214' / I-DOSAGE
'Sen214' kg I-DOSAGE
'Sen214' per I-DOSAGE
'Sen214' day L-DOSAGE
'Sen214' ) O
'Sen214' administered O
'Sen214' for O
'Sen214' 6 O
'Sen214' days O
'Sen214' to O
'Sen214' treat O
'Sen214' herpetic O
'Sen214' encephalitis O
'Sen214' . O

'Sen215' We O
'Sen215' report O
'Sen215' a O
'Sen215' case O
'Sen215' of O
'Sen215' hypoglycaemia O
'Sen215' after O
'Sen215' mefloquine U-DRUG
'Sen215' therapy O
'Sen215' ( O
'Sen215' 1,500 B-DOSAGE
'Sen215' mg I-DOSAGE
'Sen215' over I-DOSAGE
'Sen215' two I-DOSAGE
'Sen215' days L-DOSAGE
'Sen215' ) O
'Sen215' for O
'Sen215' severe O
'Sen215' gastrointestinal O
'Sen215' cryptosporidiasis O
'Sen215' in O
'Sen215' a O
'Sen215' cachectic O
'Sen215' AIDS O
'Sen215' patient O
'Sen215' with O
'Sen215' protracted O
'Sen215' diarrhoea O
'Sen215' . O

'Sen216' Aggressive O
'Sen216' management O
'Sen216' of O
'Sen216' doxorubicin O
'Sen216' - O
'Sen216' induced O
'Sen216' cardiomyopathy O
'Sen216' associated O
'Sen216' with O
'Sen216' ' B-DOSAGE
'Sen216' low I-DOSAGE
'Sen216' ' I-DOSAGE
'Sen216' doses L-DOSAGE
'Sen216' of O
'Sen216' doxorubicin U-DRUG
'Sen216' . O

'Sen217' Aggressive O
'Sen217' management O
'Sen217' of O
'Sen217' doxorubicin O
'Sen217' - O
'Sen217' induced O
'Sen217' cardiomyopathy O
'Sen217' associated O
'Sen217' with O
'Sen217' ' B-DOSAGE
'Sen217' low I-DOSAGE
'Sen217' ' I-DOSAGE
'Sen217' doses L-DOSAGE
'Sen217' of O
'Sen217' doxorubicin U-DRUG
'Sen217' . O

'Sen218' High B-DOSAGE
'Sen218' - I-DOSAGE
'Sen218' dose L-DOSAGE
'Sen218' intravenous O
'Sen218' mannitol U-DRUG
'Sen218' infusion O
'Sen218' in O
'Sen218' various O
'Sen218' clinical O
'Sen218' settings O
'Sen218' may O
'Sen218' result O
'Sen218' in O
'Sen218' acute O
'Sen218' renal O
'Sen218' failure O
'Sen218' ( O
'Sen218' ARF O
'Sen218' ) O
'Sen218' . O

'Sen219' This O
'Sen219' is O
'Sen219' a O
'Sen219' report O
'Sen219' of O
'Sen219' a O
'Sen219' case O
'Sen219' of O
'Sen219' anuric O
'Sen219' ARF O
'Sen219' after O
'Sen219' high B-DOSAGE
'Sen219' - I-DOSAGE
'Sen219' dose L-DOSAGE
'Sen219' mannitol U-DRUG
'Sen219' infusion O
'Sen219' for O
'Sen219' treatment O
'Sen219' of O
'Sen219' narrow O
'Sen219' - O
'Sen219' angle O
'Sen219' glaucoma O
'Sen219' that O
'Sen219' readily O
'Sen219' responded O
'Sen219' to O
'Sen219' acute O
'Sen219' hemodialysis O
'Sen219' . O

'Sen220' Temporary O
'Sen220' neurologic O
'Sen220' abnormalities O
'Sen220' were O
'Sen220' observed O
'Sen220' in O
'Sen220' one O
'Sen220' out O
'Sen220' of O
'Sen220' 23 O
'Sen220' patients O
'Sen220' undergoing O
'Sen220' chemotherapy O
'Sen220' with O
'Sen220' high B-DOSAGE
'Sen220' - I-DOSAGE
'Sen220' dose L-DOSAGE
'Sen220' methotrexate U-DRUG
'Sen220' ( O
'Sen220' HD O
'Sen220' - O
'Sen220' MTX O
'Sen220' ) O
'Sen220' for O
'Sen220' osteogenic O
'Sen220' sarcoma O
'Sen220' . O

'Sen221' This O
'Sen221' patient O
'Sen221' developed O
'Sen221' sequential O
'Sen221' symptoms O
'Sen221' including O
'Sen221' alternative O
'Sen221' hemiparesis O
'Sen221' , O
'Sen221' dysarthria O
'Sen221' and O
'Sen221' altered O
'Sen221' consciousness O
'Sen221' 5 O
'Sen221' days O
'Sen221' after O
'Sen221' the O
'Sen221' second O
'Sen221' course O
'Sen221' of O
'Sen221' HD B-DRUG
'Sen221' - I-DRUG
'Sen221' MTX L-DRUG
'Sen221' ( O
'Sen221' 8 B-DOSAGE
'Sen221' gm I-DOSAGE
'Sen221' / I-DOSAGE
'Sen221' m2 I-DOSAGE
'Sen221' by I-DOSAGE
'Sen221' 6 I-DOSAGE
'Sen221' h I-DOSAGE
'Sen221' continuous I-DOSAGE
'Sen221' infusion L-DOSAGE
'Sen221' ) O
'Sen221' with O
'Sen221' leucovorin O
'Sen221' rescue O
'Sen221' . O

'Sen222' Transient O
'Sen222' neurological O
'Sen222' disturbances O
'Sen222' induced O
'Sen222' by O
'Sen222' the O
'Sen222' chemotherapy O
'Sen222' of O
'Sen222' high B-DOSAGE
'Sen222' - I-DOSAGE
'Sen222' dose L-DOSAGE
'Sen222' methotrexate U-DRUG
'Sen222' for O
'Sen222' osteogenic O
'Sen222' sarcoma O
'Sen222' . O

'Sen223' We O
'Sen223' describe O
'Sen223' a O
'Sen223' patient O
'Sen223' with O
'Sen223' a O
'Sen223' liver O
'Sen223' abscess O
'Sen223' due O
'Sen223' to O
'Sen223' Entamoeba O
'Sen223' histolytica O
'Sen223' , O
'Sen223' in O
'Sen223' whom O
'Sen223' metronidazole U-DRUG
'Sen223' therapy O
'Sen223' ( O
'Sen223' total O
'Sen223' dose O
'Sen223' , O
'Sen223' 21 B-DOSAGE
'Sen223' g I-DOSAGE
'Sen223' over I-DOSAGE
'Sen223' 14 I-DOSAGE
'Sen223' days L-DOSAGE
'Sen223' ) O
'Sen223' was O
'Sen223' complicated O
'Sen223' by O
'Sen223' reversible O
'Sen223' deafness O
'Sen223' , O
'Sen223' tinnitus O
'Sen223' , O
'Sen223' and O
'Sen223' ataxia O
'Sen223' and O
'Sen223' who O
'Sen223' relapsed O
'Sen223' 5 O
'Sen223' months O
'Sen223' later O
'Sen223' with O
'Sen223' a O
'Sen223' splenic O
'Sen223' abscess O
'Sen223' . O

'Sen224' Reversible O
'Sen224' leukopenia O
'Sen224' was O
'Sen224' documented O
'Sen224' in O
'Sen224' an O
'Sen224' 81-year O
'Sen224' - O
'Sen224' old O
'Sen224' woman O
'Sen224' treated O
'Sen224' with O
'Sen224' adjunctive O
'Sen224' ibopamine U-DRUG
'Sen224' 100 B-DOSAGE
'Sen224' mg L-DOSAGE
'Sen224' t.i.d O
'Sen224' . O
'Sen224' for O
'Sen224' chronic O
'Sen224' congestive O
'Sen224' heart O
'Sen224' failure O
'Sen224' . O

'Sen225' A O
'Sen225' 53-year O
'Sen225' - O
'Sen225' old O
'Sen225' male O
'Sen225' , O
'Sen225' without O
'Sen225' any O
'Sen225' prior O
'Sen225' history O
'Sen225' of O
'Sen225' psychosis O
'Sen225' , O
'Sen225' developed O
'Sen225' schizophrenia O
'Sen225' 4 O
'Sen225' days O
'Sen225' after O
'Sen225' starting O
'Sen225' low B-DOSAGE
'Sen225' - I-DOSAGE
'Sen225' dose L-DOSAGE
'Sen225' bromocriptine U-DRUG
'Sen225' therapy O
'Sen225' for O
'Sen225' a O
'Sen225' macroprolactinoma O
'Sen225' . O

'Sen226' Concurrent O
'Sen226' acute O
'Sen226' megaloblastic O
'Sen226' anaemia O
'Sen226' and O
'Sen226' pneumonitis O
'Sen226' : O
'Sen226' a O
'Sen226' severe O
'Sen226' side O
'Sen226' - O
'Sen226' effect O
'Sen226' of O
'Sen226' low B-DOSAGE
'Sen226' - I-DOSAGE
'Sen226' dose L-DOSAGE
'Sen226' methotrexate U-DRUG
'Sen226' therapy O
'Sen226' during O
'Sen226' rheumatoid O
'Sen226' arthritis O
'Sen226' . O

'Sen227' In O
'Sen227' a O
'Sen227' patient O
'Sen227' suffering O
'Sen227' from O
'Sen227' rheumatoid O
'Sen227' arthritis O
'Sen227' , O
'Sen227' we O
'Sen227' report O
'Sen227' the O
'Sen227' first O
'Sen227' simultaneous O
'Sen227' occurrence O
'Sen227' of O
'Sen227' two O
'Sen227' side O
'Sen227' effects O
'Sen227' of O
'Sen227' low B-DOSAGE
'Sen227' - I-DOSAGE
'Sen227' dose L-DOSAGE
'Sen227' methotrexate U-DRUG
'Sen227' : O
'Sen227' an O
'Sen227' acute O
'Sen227' megaloblastic O
'Sen227' anaemia O
'Sen227' and O
'Sen227' a O
'Sen227' pneumonitis O
'Sen227' . O

'Sen228' An O
'Sen228' 11-year O
'Sen228' - O
'Sen228' old O
'Sen228' boy O
'Sen228' who O
'Sen228' was O
'Sen228' treated O
'Sen228' with O
'Sen228' a O
'Sen228' relatively O
'Sen228' high B-DOSAGE
'Sen228' dose L-DOSAGE
'Sen228' of O
'Sen228' methotrimeprazine O
'Sen228' meleate O
'Sen228' ( O
'Sen228' Levemepromazine U-DRUG
'Sen228' ) O
'Sen228' a O
'Sen228' phenothiazine O
'Sen228' antipsychotic O
'Sen228' drug O
'Sen228' , O
'Sen228' was O
'Sen228' admitted O
'Sen228' to O
'Sen228' the O
'Sen228' pediatric O
'Sen228' intensive O
'Sen228' care O
'Sen228' unit O
'Sen228' suffering O
'Sen228' from O
'Sen228' respiratory O
'Sen228' distress O
'Sen228' syndrome O
'Sen228' . O

'Sen229' An O
'Sen229' 11-year O
'Sen229' - O
'Sen229' old O
'Sen229' boy O
'Sen229' who O
'Sen229' was O
'Sen229' treated O
'Sen229' with O
'Sen229' a O
'Sen229' relatively O
'Sen229' high B-DOSAGE
'Sen229' dose L-DOSAGE
'Sen229' of O
'Sen229' methotrimeprazine B-DRUG
'Sen229' meleate L-DRUG
'Sen229' ( O
'Sen229' Levemepromazine O
'Sen229' ) O
'Sen229' a O
'Sen229' phenothiazine O
'Sen229' antipsychotic O
'Sen229' drug O
'Sen229' , O
'Sen229' was O
'Sen229' admitted O
'Sen229' to O
'Sen229' the O
'Sen229' pediatric O
'Sen229' intensive O
'Sen229' care O
'Sen229' unit O
'Sen229' suffering O
'Sen229' from O
'Sen229' respiratory O
'Sen229' distress O
'Sen229' syndrome O
'Sen229' . O

'Sen230' The O
'Sen230' association O
'Sen230' of O
'Sen230' phenothiazine U-DRUG
'Sen230' overdose U-DOSAGE
'Sen230' and O
'Sen230' respiratory O
'Sen230' distress O
'Sen230' syndrome O
'Sen230' merits O
'Sen230' consideration O
'Sen230' . O

'Sen231' She O
'Sen231' received O
'Sen231' an O
'Sen231' accidental O
'Sen231' 450-mg U-DOSAGE
'Sen231' bolus O
'Sen231' injection O
'Sen231' of O
'Sen231' morphine U-DRUG
'Sen231' intrathecally O
'Sen231' and O
'Sen231' developed O
'Sen231' hypertension O
'Sen231' , O
'Sen231' status O
'Sen231' epilepticus O
'Sen231' , O
'Sen231' intracerebral O
'Sen231' hemorrhage O
'Sen231' , O
'Sen231' and O
'Sen231' respiratory O
'Sen231' failure O
'Sen231' . O

'Sen232' A O
'Sen232' high U-DOSAGE
'Sen232' dose O
'Sen232' of O
'Sen232' cotrimoxazole U-DRUG
'Sen232' induced O
'Sen232' hyperkalaemia O
'Sen232' with O
'Sen232' the O
'Sen232' elevation O
'Sen232' of O
'Sen232' serum O
'Sen232' creatinine O
'Sen232' and O
'Sen232' blood O
'Sen232' urea O
'Sen232' , O
'Sen232' and O
'Sen232' increased O
'Sen232' urinary O
'Sen232' N O
'Sen232' - O
'Sen232' acetyl O
'Sen232' glucosaminase O
'Sen232' after O
'Sen232' several O
'Sen232' days O
'Sen232' of O
'Sen232' the O
'Sen232' drug O
'Sen232' administration O
'Sen232' in O
'Sen232' these O
'Sen232' patients O
'Sen232' ; O
'Sen232' one O
'Sen232' patient O
'Sen232' became O
'Sen232' unconscious O
'Sen232' . O

'Sen233' Severe O
'Sen233' abdominal O
'Sen233' pain O
'Sen233' in O
'Sen233' low U-DOSAGE
'Sen233' dosage O
'Sen233' clofazimine U-DRUG
'Sen233' . O

'Sen234' Amphotericin B-DRUG
'Sen234' B L-DRUG
'Sen234' overdose U-DOSAGE
'Sen234' in O
'Sen234' pediatric O
'Sen234' patients O
'Sen234' with O
'Sen234' associated O
'Sen234' cardiac O
'Sen234' arrest O
'Sen234' . O

'Sen235' CONCLUSIONS O
'Sen235' : O
'Sen235' Amphotericin B-DRUG
'Sen235' B L-DRUG
'Sen235' overdose U-DOSAGE
'Sen235' can O
'Sen235' be O
'Sen235' fatal O
'Sen235' in O
'Sen235' children O
'Sen235' and O
'Sen235' infants O
'Sen235' . O

'Sen236' Hydrocortisone O
'Sen236' may O
'Sen236' decrease O
'Sen236' the O
'Sen236' incidence O
'Sen236' of O
'Sen236' mortality O
'Sen236' associated O
'Sen236' with O
'Sen236' cardiac O
'Sen236' arrhythmias O
'Sen236' in O
'Sen236' children O
'Sen236' receiving O
'Sen236' amphotericin B-DRUG
'Sen236' B L-DRUG
'Sen236' overdoses U-DOSAGE
'Sen236' . O

'Sen237' INTERVENTIONS O
'Sen237' AND O
'Sen237' RESULTS O
'Sen237' : O
'Sen237' Cardiac O
'Sen237' complications O
'Sen237' were O
'Sen237' observed O
'Sen237' in O
'Sen237' five O
'Sen237' pediatric O
'Sen237' patients O
'Sen237' who O
'Sen237' received O
'Sen237' between B-DOSAGE
'Sen237' 4.6 I-DOSAGE
'Sen237' and I-DOSAGE
'Sen237' 40.8 I-DOSAGE
'Sen237' mg I-DOSAGE
'Sen237' / I-DOSAGE
'Sen237' kg I-DOSAGE
'Sen237' / I-DOSAGE
'Sen237' d L-DOSAGE
'Sen237' of O
'Sen237' amphotericin -
'Sen237' B. -

'Sen238' OBJECTIVE O
'Sen238' : O
'Sen238' To O
'Sen238' report O
'Sen238' the O
'Sen238' first O
'Sen238' five O
'Sen238' cases O
'Sen238' of O
'Sen238' amphotericin B-DRUG
'Sen238' B L-DRUG
'Sen238' overdose U-DOSAGE
'Sen238' with O
'Sen238' secondary O
'Sen238' cardiac O
'Sen238' complications O
'Sen238' in O
'Sen238' a O
'Sen238' pediatric O
'Sen238' population O
'Sen238' . O

'Sen239' METHODS O
'Sen239' : O
'Sen239' Repeated O
'Sen239' blood O
'Sen239' samples O
'Sen239' were O
'Sen239' drawn O
'Sen239' in O
'Sen239' a O
'Sen239' patient O
'Sen239' with O
'Sen239' severe O
'Sen239' acyclovir U-DRUG
'Sen239' overdose U-DOSAGE
'Sen239' who O
'Sen239' developed O
'Sen239' coma O
'Sen239' and O
'Sen239' nonoliguric O
'Sen239' renal O
'Sen239' failure O
'Sen239' . O

'Sen240' We O
'Sen240' report O
'Sen240' one O
'Sen240' case O
'Sen240' of O
'Sen240' non O
'Sen240' - O
'Sen240' Hodgkin O
'Sen240' lymphoma O
'Sen240' in O
'Sen240' a O
'Sen240' patient O
'Sen240' , O
'Sen240' with O
'Sen240' a O
'Sen240' 30-year O
'Sen240' history O
'Sen240' of O
'Sen240' rheumatoid O
'Sen240' arthritis O
'Sen240' , O
'Sen240' taking O
'Sen240' low U-DOSAGE
'Sen240' dose O
'Sen240' methotrexate U-DRUG
'Sen240' weekly O
'Sen240' over O
'Sen240' a O
'Sen240' 10-month O
'Sen240' period O
'Sen240' . O

'Sen241' We O
'Sen241' report O
'Sen241' a O
'Sen241' case O
'Sen241' of O
'Sen241' drug O
'Sen241' - O
'Sen241' induced O
'Sen241' Kaposi O
'Sen241' 's O
'Sen241' sarcoma O
'Sen241' ( O
'Sen241' KS O
'Sen241' ) O
'Sen241' on O
'Sen241' the O
'Sen241' sole O
'Sen241' of O
'Sen241' the O
'Sen241' right O
'Sen241' foot O
'Sen241' in O
'Sen241' a O
'Sen241' 71-year O
'Sen241' - O
'Sen241' old O
'Sen241' man O
'Sen241' , O
'Sen241' treated O
'Sen241' for O
'Sen241' 6 O
'Sen241' months O
'Sen241' with O
'Sen241' corticosteroid O
'Sen241' therapy O
'Sen241' ( O
'Sen241' prednisolone U-DRUG
'Sen241' 25 B-DOSAGE
'Sen241' mg I-DOSAGE
'Sen241' / I-DOSAGE
'Sen241' day L-DOSAGE
'Sen241' ) O
'Sen241' for O
'Sen241' pericardial O
'Sen241' effusion O
'Sen241' . O

'Sen242' Acute O
'Sen242' dystonic O
'Sen242' reaction O
'Sen242' with O
'Sen242' low U-DOSAGE
'Sen242' - O
'Sen242' dose O
'Sen242' pimozide U-DRUG
'Sen242' . O

'Sen243' This O
'Sen243' paper O
'Sen243' reports O
'Sen243' on O
'Sen243' a O
'Sen243' 6.9-year O
'Sen243' - O
'Sen243' old O
'Sen243' autistic O
'Sen243' male O
'Sen243' who O
'Sen243' developed O
'Sen243' repeated O
'Sen243' episodes O
'Sen243' of O
'Sen243' acute O
'Sen243' dystonic O
'Sen243' reactions O
'Sen243' associated O
'Sen243' with O
'Sen243' pimozide O
'Sen243' administration O
'Sen243' at O
'Sen243' the O
'Sen243' doses O
'Sen243' of O
'Sen243' 0.096 O
'Sen243' mg O
'Sen243' / O
'Sen243' kg O
'Sen243' / O
'Sen243' day O
'Sen243' and O
'Sen243' 0.032 B-DOSAGE
'Sen243' mg I-DOSAGE
'Sen243' / I-DOSAGE
'Sen243' kg I-DOSAGE
'Sen243' / I-DOSAGE
'Sen243' day L-DOSAGE
'Sen243' and O
'Sen243' 32 O
'Sen243' hours O
'Sen243' following O
'Sen243' pimozide U-DRUG
'Sen243' withdrawal O
'Sen243' , O
'Sen243' as O
'Sen243' well O
'Sen243' as O
'Sen243' during O
'Sen243' subsequent O
'Sen243' thioridazine O
'Sen243' administration O
'Sen243' . O

'Sen244' This O
'Sen244' paper O
'Sen244' reports O
'Sen244' on O
'Sen244' a O
'Sen244' 6.9-year O
'Sen244' - O
'Sen244' old O
'Sen244' autistic O
'Sen244' male O
'Sen244' who O
'Sen244' developed O
'Sen244' repeated O
'Sen244' episodes O
'Sen244' of O
'Sen244' acute O
'Sen244' dystonic O
'Sen244' reactions O
'Sen244' associated O
'Sen244' with O
'Sen244' pimozide O
'Sen244' administration O
'Sen244' at O
'Sen244' the O
'Sen244' doses O
'Sen244' of O
'Sen244' 0.096 B-DOSAGE
'Sen244' mg I-DOSAGE
'Sen244' / I-DOSAGE
'Sen244' kg I-DOSAGE
'Sen244' / I-DOSAGE
'Sen244' day L-DOSAGE
'Sen244' and O
'Sen244' 0.032 O
'Sen244' mg O
'Sen244' / O
'Sen244' kg O
'Sen244' / O
'Sen244' day O
'Sen244' and O
'Sen244' 32 O
'Sen244' hours O
'Sen244' following O
'Sen244' pimozide U-DRUG
'Sen244' withdrawal O
'Sen244' , O
'Sen244' as O
'Sen244' well O
'Sen244' as O
'Sen244' during O
'Sen244' subsequent O
'Sen244' thioridazine O
'Sen244' administration O
'Sen244' . O

'Sen245' How O
'Sen245' low O
'Sen245' can O
'Sen245' you O
'Sen245' go O
'Sen245' ? O
'Sen245' Use O
'Sen245' of O
'Sen245' very O
'Sen245' low U-DOSAGE
'Sen245' dosage O
'Sen245' of O
'Sen245' gold U-DRUG
'Sen245' in O
'Sen245' patients O
'Sen245' with O
'Sen245' mucocutaneous O
'Sen245' reactions O
'Sen245' . O

'Sen246' We O
'Sen246' have O
'Sen246' seen O
'Sen246' a O
'Sen246' case O
'Sen246' of O
'Sen246' terminal O
'Sen246' malignant O
'Sen246' melanoma O
'Sen246' in O
'Sen246' which O
'Sen246' clinical O
'Sen246' manifestations O
'Sen246' , O
'Sen246' indicative O
'Sen246' of O
'Sen246' anterior O
'Sen246' spinal O
'Sen246' artery O
'Sen246' syndrome O
'Sen246' , O
'Sen246' developed O
'Sen246' following O
'Sen246' the O
'Sen246' injection O
'Sen246' of O
'Sen246' 0.3 B-DOSAGE
'Sen246' ml L-DOSAGE
'Sen246' of O
'Sen246' 10 O
'Sen246' % O
'Sen246' phenol B-DRUG
'Sen246' - I-DRUG
'Sen246' glycerine L-DRUG
'Sen246' into O
'Sen246' the O
'Sen246' cervical O
'Sen246' subarachnoid O
'Sen246' space O
'Sen246' at O
'Sen246' the O
'Sen246' C4 O
'Sen246' - O
'Sen246' -C5 O
'Sen246' level O
'Sen246' for O
'Sen246' the O
'Sen246' control O
'Sen246' of O
'Sen246' severe O
'Sen246' right O
'Sen246' arm O
'Sen246' pain O
'Sen246' . O

'Sen247' The O
'Sen247' azathioprine U-DRUG
'Sen247' dose O
'Sen247' was O
'Sen247' low O
'Sen247' ( O
'Sen247' 1 B-DOSAGE
'Sen247' mg I-DOSAGE
'Sen247' / I-DOSAGE
'Sen247' kg L-DOSAGE
'Sen247' ) O
'Sen247' and O
'Sen247' pancytopenia O
'Sen247' occurred O
'Sen247' after O
'Sen247' 56 O
'Sen247' days O
'Sen247' therapy O
'Sen247' . O

'Sen248' The O
'Sen248' pharmaceutical O
'Sen248' company O
'Sen248' producing O
'Sen248' Halfan U-DRUG
'Sen248' has O
'Sen248' reported O
'Sen248' 8 O
'Sen248' cardiac O
'Sen248' arrests O
'Sen248' , O
'Sen248' leading O
'Sen248' to O
'Sen248' 6 O
'Sen248' deaths O
'Sen248' , O
'Sen248' when O
'Sen248' a O
'Sen248' higher U-DOSAGE
'Sen248' dose O
'Sen248' than O
'Sen248' recommended O
'Sen248' was O
'Sen248' used O
'Sen248' , O
'Sen248' there O
'Sen248' was O
'Sen248' recent O
'Sen248' or O
'Sen248' concomitant O
'Sen248' treatment O
'Sen248' with O
'Sen248' mefloquine O
'Sen248' , O
'Sen248' there O
'Sen248' was O
'Sen248' pre O
'Sen248' - O
'Sen248' existing O
'Sen248' prolongation O
'Sen248' of O
'Sen248' the O
'Sen248' QT O
'Sen248' interval O
'Sen248' or O
'Sen248' the O
'Sen248' patient O
'Sen248' had O
'Sen248' a O
'Sen248' thiamine O
'Sen248' deficiency O
'Sen248' . O

'Sen249' The O
'Sen249' pharmaceutical O
'Sen249' company O
'Sen249' producing O
'Sen249' Halfan O
'Sen249' has O
'Sen249' reported O
'Sen249' 8 O
'Sen249' cardiac O
'Sen249' arrests O
'Sen249' , O
'Sen249' leading O
'Sen249' to O
'Sen249' 6 O
'Sen249' deaths O
'Sen249' , O
'Sen249' when O
'Sen249' a O
'Sen249' higher U-DOSAGE
'Sen249' dose O
'Sen249' than O
'Sen249' recommended O
'Sen249' was O
'Sen249' used O
'Sen249' , O
'Sen249' there O
'Sen249' was O
'Sen249' recent O
'Sen249' or O
'Sen249' concomitant O
'Sen249' treatment O
'Sen249' with O
'Sen249' mefloquine U-DRUG
'Sen249' , O
'Sen249' there O
'Sen249' was O
'Sen249' pre O
'Sen249' - O
'Sen249' existing O
'Sen249' prolongation O
'Sen249' of O
'Sen249' the O
'Sen249' QT O
'Sen249' interval O
'Sen249' or O
'Sen249' the O
'Sen249' patient O
'Sen249' had O
'Sen249' a O
'Sen249' thiamine O
'Sen249' deficiency O
'Sen249' . O

'Sen250' FINDINGS O
'Sen250' : O
'Sen250' Six O
'Sen250' children O
'Sen250' with O
'Sen250' growth O
'Sen250' retardation O
'Sen250' noted O
'Sen250' after O
'Sen250' treatment O
'Sen250' with O
'Sen250' high U-DOSAGE
'Sen250' - O
'Sen250' dose O
'Sen250' fluticasone B-DRUG
'Sen250' propionate L-DRUG
'Sen250' were O
'Sen250' found O
'Sen250' to O
'Sen250' have O
'Sen250' adrenal O
'Sen250' suppression O
'Sen250' . O

'Sen251' Growth O
'Sen251' and O
'Sen251' adrenal O
'Sen251' suppression O
'Sen251' in O
'Sen251' asthmatic O
'Sen251' children O
'Sen251' treated O
'Sen251' with O
'Sen251' high U-DOSAGE
'Sen251' - O
'Sen251' dose O
'Sen251' fluticasone B-DRUG
'Sen251' propionate L-DRUG
'Sen251' . O

'Sen252' INTERPRETATION O
'Sen252' : O
'Sen252' When O
'Sen252' high U-DOSAGE
'Sen252' doses O
'Sen252' of O
'Sen252' fluticasone B-DRUG
'Sen252' propionate L-DRUG
'Sen252' are O
'Sen252' used O
'Sen252' , O
'Sen252' growth O
'Sen252' may O
'Sen252' be O
'Sen252' retarded O
'Sen252' and O
'Sen252' adrenal O
'Sen252' suppression O
'Sen252' may O
'Sen252' occur O
'Sen252' . O

'Sen253' METHODS O
'Sen253' : O
'Sen253' Growth O
'Sen253' retardation O
'Sen253' was O
'Sen253' observed O
'Sen253' in O
'Sen253' six O
'Sen253' severely O
'Sen253' asthmatic O
'Sen253' children O
'Sen253' after O
'Sen253' introduction O
'Sen253' of O
'Sen253' high U-DOSAGE
'Sen253' - O
'Sen253' dose O
'Sen253' fluticasone B-DRUG
'Sen253' propionate L-DRUG
'Sen253' treatment O
'Sen253' ( O
'Sen253' dry O
'Sen253' powder O
'Sen253' ) O
'Sen253' . O

'Sen254' Two O
'Sen254' case O
'Sen254' reports O
'Sen254' of O
'Sen254' bilateral O
'Sen254' granulomatous O
'Sen254' anterior O
'Sen254' uveitis O
'Sen254' are O
'Sen254' described O
'Sen254' in O
'Sen254' patients O
'Sen254' with O
'Sen254' open O
'Sen254' angle O
'Sen254' glaucoma O
'Sen254' treated O
'Sen254' with O
'Sen254' metripranolol U-DRUG
'Sen254' 0.6 U-DOSAGE
'Sen254' % O
'Sen254' eye O
'Sen254' drops O
'Sen254' . O

'Sen255' This O
'Sen255' case O
'Sen255' suggests O
'Sen255' that O
'Sen255' acyclovir U-DRUG
'Sen255' when O
'Sen255' given O
'Sen255' intravenously O
'Sen255' in O
'Sen255' doses O
'Sen255' of O
'Sen255' 10 B-DOSAGE
'Sen255' mg I-DOSAGE
'Sen255' / I-DOSAGE
'Sen255' kg L-DOSAGE
'Sen255' may O
'Sen255' result O
'Sen255' in O
'Sen255' increased O
'Sen255' serum O
'Sen255' lithium O
'Sen255' concentrations O
'Sen255' . O

'Sen256' This O
'Sen256' case O
'Sen256' suggests O
'Sen256' that O
'Sen256' acyclovir O
'Sen256' when O
'Sen256' given O
'Sen256' intravenously O
'Sen256' in O
'Sen256' doses O
'Sen256' of O
'Sen256' 10 B-DOSAGE
'Sen256' mg I-DOSAGE
'Sen256' / I-DOSAGE
'Sen256' kg L-DOSAGE
'Sen256' may O
'Sen256' result O
'Sen256' in O
'Sen256' increased O
'Sen256' serum O
'Sen256' lithium U-DRUG
'Sen256' concentrations O
'Sen256' . O

'Sen257' We O
'Sen257' describe O
'Sen257' 2 O
'Sen257' patients O
'Sen257' with O
'Sen257' cutaneous O
'Sen257' lupus O
'Sen257' erythematosus O
'Sen257' who O
'Sen257' developed O
'Sen257' severe O
'Sen257' dapsone U-DRUG
'Sen257' reaction O
'Sen257' after O
'Sen257' low U-DOSAGE
'Sen257' dose O
'Sen257' therapy O
'Sen257' , O
'Sen257' with O
'Sen257' a O
'Sen257' fatal O
'Sen257' outcome O
'Sen257' in O
'Sen257' one O
'Sen257' . O

'Sen258' A O
'Sen258' 17-year O
'Sen258' - O
'Sen258' old O
'Sen258' female O
'Sen258' patient O
'Sen258' who O
'Sen258' had O
'Sen258' been O
'Sen258' taking O
'Sen258' oral O
'Sen258' minocycline U-DRUG
'Sen258' ( O
'Sen258' 50 B-DOSAGE
'Sen258' mg I-DOSAGE
'Sen258' twice I-DOSAGE
'Sen258' daily L-DOSAGE
'Sen258' ) O
'Sen258' for O
'Sen258' 3 O
'Sen258' weeks O
'Sen258' for O
'Sen258' acne O
'Sen258' developed O
'Sen258' an O
'Sen258' eruption O
'Sen258' that O
'Sen258' progressed O
'Sen258' to O
'Sen258' an O
'Sen258' exfoliative O
'Sen258' dermatitis O
'Sen258' . O

'Sen259' The O
'Sen259' evidence O
'Sen259' of O
'Sen259' high O
'Sen259' plasmatic O
'Sen259' levels O
'Sen259' of O
'Sen259' CBZ O
'Sen259' and O
'Sen259' the O
'Sen259' absence O
'Sen259' of O
'Sen259' other O
'Sen259' aetiologic O
'Sen259' factors O
'Sen259' lead O
'Sen259' the O
'Sen259' authors O
'Sen259' to O
'Sen259' conclude O
'Sen259' that O
'Sen259' the O
'Sen259' overdose U-DOSAGE
'Sen259' of O
'Sen259' CBZ U-DRUG
'Sen259' could O
'Sen259' have O
'Sen259' represented O
'Sen259' the O
'Sen259' precipitating O
'Sen259' of O
'Sen259' the O
'Sen259' episode O
'Sen259' of O
'Sen259' acute O
'Sen259' pancreatitis O
'Sen259' . O

'Sen260' The O
'Sen260' evidence O
'Sen260' of O
'Sen260' high O
'Sen260' plasmatic O
'Sen260' levels O
'Sen260' of O
'Sen260' CBZ O
'Sen260' and O
'Sen260' the O
'Sen260' absence O
'Sen260' of O
'Sen260' other O
'Sen260' aetiologic O
'Sen260' factors O
'Sen260' lead O
'Sen260' the O
'Sen260' authors O
'Sen260' to O
'Sen260' conclude O
'Sen260' that O
'Sen260' the O
'Sen260' overdose U-DOSAGE
'Sen260' of O
'Sen260' CBZ U-DRUG
'Sen260' could O
'Sen260' have O
'Sen260' represented O
'Sen260' the O
'Sen260' precipitating O
'Sen260' of O
'Sen260' the O
'Sen260' episode O
'Sen260' of O
'Sen260' acute O
'Sen260' pancreatitis O
'Sen260' . O

'Sen261' Overdose U-DOSAGE
'Sen261' of O
'Sen261' magnesium O
'Sen261' sulfate O
'Sen261' in O
'Sen261' combination O
'Sen261' with O
'Sen261' renal O
'Sen261' insufficiency O
'Sen261' , O
'Sen261' hypocalcemia O
'Sen261' , O
'Sen261' or O
'Sen261' compromise O
'Sen261' of O
'Sen261' intestinal O
'Sen261' integrity O
'Sen261' may O
'Sen261' predispose O
'Sen261' horses O
'Sen261' to O
'Sen261' magnesium U-DRUG
'Sen261' toxicosis O
'Sen261' . O

'Sen262' Overdose U-DOSAGE
'Sen262' of O
'Sen262' magnesium B-DRUG
'Sen262' sulfate L-DRUG
'Sen262' in O
'Sen262' combination O
'Sen262' with O
'Sen262' renal O
'Sen262' insufficiency O
'Sen262' , O
'Sen262' hypocalcemia O
'Sen262' , O
'Sen262' or O
'Sen262' compromise O
'Sen262' of O
'Sen262' intestinal O
'Sen262' integrity O
'Sen262' may O
'Sen262' predispose O
'Sen262' horses O
'Sen262' to O
'Sen262' magnesium O
'Sen262' toxicosis O
'Sen262' . O

'Sen263' We O
'Sen263' thus O
'Sen263' concluded O
'Sen263' that O
'Sen263' an O
'Sen263' excessive U-DOSAGE
'Sen263' dose O
'Sen263' of O
'Sen263' AZ U-DRUG
'Sen263' had O
'Sen263' probably O
'Sen263' destroyed O
'Sen263' the O
'Sen263' gastric O
'Sen263' mucosal O
'Sen263' barrier O
'Sen263' or O
'Sen263' thrombocytopenia O
'Sen263' due O
'Sen263' to O
'Sen263' bone O
'Sen263' marrow O
'Sen263' disorder O
'Sen263' and O
'Sen263' thus O
'Sen263' eventually O
'Sen263' led O
'Sen263' to O
'Sen263' the O
'Sen263' development O
'Sen263' of O
'Sen263' hemorrhagic O
'Sen263' gastritis O
'Sen263' . O

'Sen264' On O
'Sen264' the O
'Sen264' next O
'Sen264' day O
'Sen264' , O
'Sen264' after O
'Sen264' a O
'Sen264' total O
'Sen264' dose O
'Sen264' of O
'Sen264' only O
'Sen264' 600 B-DOSAGE
'Sen264' mg L-DOSAGE
'Sen264' of O
'Sen264' danazol U-DRUG
'Sen264' , O
'Sen264' gingival O
'Sen264' bleeding O
'Sen264' and O
'Sen264' purpura O
'Sen264' occurred O
'Sen264' . O

'Sen265' We O
'Sen265' reported O
'Sen265' 3 O
'Sen265' patients O
'Sen265' who O
'Sen265' developed O
'Sen265' acute O
'Sen265' generalized O
'Sen265' dystonia O
'Sen265' and O
'Sen265' akinetic O
'Sen265' rigid O
'Sen265' syndrome O
'Sen265' following O
'Sen265' an O
'Sen265' initial O
'Sen265' therapy O
'Sen265' with O
'Sen265' d B-DRUG
'Sen265' - I-DRUG
'Sen265' penicillamine L-DRUG
'Sen265' 125 B-DOSAGE
'Sen265' - I-DOSAGE
'Sen265' 500 I-DOSAGE
'Sen265' mg I-DOSAGE
'Sen265' daily L-DOSAGE
'Sen265' . O

'Sen266' Ballistic O
'Sen266' movements O
'Sen266' due O
'Sen266' to O
'Sen266' ischemic O
'Sen266' infarcts O
'Sen266' after O
'Sen266' intravenous O
'Sen266' heroin U-DRUG
'Sen266' overdose U-DOSAGE
'Sen266' : O
'Sen266' report O
'Sen266' of O
'Sen266' two O
'Sen266' cases O
'Sen266' . O

'Sen267' Two O
'Sen267' heroin O
'Sen267' addicts O
'Sen267' , O
'Sen267' aged O
'Sen267' 34 O
'Sen267' and O
'Sen267' 19 O
'Sen267' years O
'Sen267' , O
'Sen267' developed O
'Sen267' ballistic O
'Sen267' movements O
'Sen267' after O
'Sen267' intravenous O
'Sen267' heroin U-DRUG
'Sen267' overdose U-DOSAGE
'Sen267' . O

'Sen268' We O
'Sen268' report O
'Sen268' a O
'Sen268' 76-year O
'Sen268' - O
'Sen268' old O
'Sen268' man O
'Sen268' who O
'Sen268' developed O
'Sen268' an O
'Sen268' acute O
'Sen268' blistering O
'Sen268' eruption O
'Sen268' following O
'Sen268' high U-DOSAGE
'Sen268' - O
'Sen268' dose O
'Sen268' penicillin U-DRUG
'Sen268' treatment O
'Sen268' for O
'Sen268' pneumococcal O
'Sen268' septicaemia O
'Sen268' . O

'Sen269' In O
'Sen269' case O
'Sen269' 1 O
'Sen269' , O
'Sen269' a O
'Sen269' total O
'Sen269' daily O
'Sen269' dose O
'Sen269' of O
'Sen269' 25 B-DOSAGE
'Sen269' mg L-DOSAGE
'Sen269' sertraline O
'Sen269' , O
'Sen269' with O
'Sen269' nondetectable O
'Sen269' sertraline O
'Sen269' and O
'Sen269' desmethylsertraline U-DRUG
'Sen269' blood O
'Sen269' levels O
'Sen269' , O
'Sen269' resulted O
'Sen269' in O
'Sen269' a O
'Sen269' doubling O
'Sen269' of O
'Sen269' the O
'Sen269' lamotrigine O
'Sen269' blood O
'Sen269' level O
'Sen269' with O
'Sen269' symptoms O
'Sen269' of O
'Sen269' toxicity O
'Sen269' . O

'Sen270' In O
'Sen270' case O
'Sen270' 1 O
'Sen270' , O
'Sen270' a O
'Sen270' total O
'Sen270' daily O
'Sen270' dose O
'Sen270' of O
'Sen270' 25 B-DOSAGE
'Sen270' mg L-DOSAGE
'Sen270' sertraline O
'Sen270' , O
'Sen270' with O
'Sen270' nondetectable O
'Sen270' sertraline O
'Sen270' and O
'Sen270' desmethylsertraline O
'Sen270' blood O
'Sen270' levels O
'Sen270' , O
'Sen270' resulted O
'Sen270' in O
'Sen270' a O
'Sen270' doubling O
'Sen270' of O
'Sen270' the O
'Sen270' lamotrigine U-DRUG
'Sen270' blood O
'Sen270' level O
'Sen270' with O
'Sen270' symptoms O
'Sen270' of O
'Sen270' toxicity O
'Sen270' . O

'Sen271' In O
'Sen271' case O
'Sen271' 1 O
'Sen271' , O
'Sen271' a O
'Sen271' total O
'Sen271' daily O
'Sen271' dose O
'Sen271' of O
'Sen271' 25 B-DOSAGE
'Sen271' mg L-DOSAGE
'Sen271' sertraline O
'Sen271' , O
'Sen271' with O
'Sen271' nondetectable O
'Sen271' sertraline O
'Sen271' and O
'Sen271' desmethylsertraline -
'Sen271' blood O
'Sen271' levels O
'Sen271' , O
'Sen271' resulted O
'Sen271' in O
'Sen271' a O
'Sen271' doubling O
'Sen271' of O
'Sen271' the O
'Sen271' lamotrigine O
'Sen271' blood O
'Sen271' level O
'Sen271' with O
'Sen271' symptoms O
'Sen271' of O
'Sen271' toxicity O
'Sen271' . O

'Sen272' In O
'Sen272' case O
'Sen272' 1 O
'Sen272' , O
'Sen272' a O
'Sen272' total O
'Sen272' daily O
'Sen272' dose O
'Sen272' of O
'Sen272' 25 B-DOSAGE
'Sen272' mg L-DOSAGE
'Sen272' sertraline O
'Sen272' , O
'Sen272' with O
'Sen272' nondetectable O
'Sen272' sertraline O
'Sen272' and O
'Sen272' desmethylsertraline -
'Sen272' blood O
'Sen272' levels O
'Sen272' , O
'Sen272' resulted O
'Sen272' in O
'Sen272' a O
'Sen272' doubling O
'Sen272' of O
'Sen272' the O
'Sen272' lamotrigine O
'Sen272' blood O
'Sen272' level O
'Sen272' with O
'Sen272' symptoms O
'Sen272' of O
'Sen272' toxicity O
'Sen272' . O

'Sen273' We O
'Sen273' report O
'Sen273' a O
'Sen273' case O
'Sen273' of O
'Sen273' pancytopenia O
'Sen273' in O
'Sen273' a O
'Sen273' 23-year O
'Sen273' - O
'Sen273' old O
'Sen273' man O
'Sen273' with O
'Sen273' Crohn O
'Sen273' 's O
'Sen273' disease O
'Sen273' who O
'Sen273' was O
'Sen273' treated O
'Sen273' with O
'Sen273' 5-aminosalicylic B-DRUG
'Sen273' acid L-DRUG
'Sen273' ( O
'Sen273' Pentasa O
'Sen273' ; O
'Sen273' Nisshin O
'Sen273' , O
'Sen273' Tokyo O
'Sen273' , O
'Sen273' Japan O
'Sen273' ) O
'Sen273' 3.0 B-DOSAGE
'Sen273' g I-DOSAGE
'Sen273' / I-DOSAGE
'Sen273' day L-DOSAGE
'Sen273' . O

'Sen274' We O
'Sen274' report O
'Sen274' a O
'Sen274' case O
'Sen274' of O
'Sen274' pancytopenia O
'Sen274' in O
'Sen274' a O
'Sen274' 23-year O
'Sen274' - O
'Sen274' old O
'Sen274' man O
'Sen274' with O
'Sen274' Crohn O
'Sen274' 's O
'Sen274' disease O
'Sen274' who O
'Sen274' was O
'Sen274' treated O
'Sen274' with O
'Sen274' 5-aminosalicylic O
'Sen274' acid O
'Sen274' ( O
'Sen274' Pentasa U-DRUG
'Sen274' ; O
'Sen274' Nisshin O
'Sen274' , O
'Sen274' Tokyo O
'Sen274' , O
'Sen274' Japan O
'Sen274' ) O
'Sen274' 3.0 B-DOSAGE
'Sen274' g I-DOSAGE
'Sen274' / I-DOSAGE
'Sen274' day L-DOSAGE
'Sen274' . O

'Sen275' 1 O
'Sen275' . O
'Sen275' Changes O
'Sen275' in O
'Sen275' the O
'Sen275' plasma O
'Sen275' cortisol O
'Sen275' level O
'Sen275' were O
'Sen275' reported O
'Sen275' in O
'Sen275' a O
'Sen275' male O
'Sen275' patient O
'Sen275' with O
'Sen275' panic O
'Sen275' disorder O
'Sen275' during O
'Sen275' the O
'Sen275' period O
'Sen275' of O
'Sen275' low U-DOSAGE
'Sen275' - O
'Sen275' dose O
'Sen275' alprazolam U-DRUG
'Sen275' treatment O
'Sen275' ( O
'Sen275' mean O
'Sen275' 0.62 O
'Sen275' + O
'Sen275' /- O
'Sen275' 0.15 O
'Sen275' mg O
'Sen275' / O
'Sen275' day O
'Sen275' ) O
'Sen275' compared O
'Sen275' with O
'Sen275' during O
'Sen275' the O
'Sen275' period O
'Sen275' of O
'Sen275' high O
'Sen275' - O
'Sen275' dose O
'Sen275' period O
'Sen275' ( O
'Sen275' mean O
'Sen275' 1.08 O
'Sen275' + O
'Sen275' /- O
'Sen275' 0.28 O
'Sen275' mg O
'Sen275' / O
'Sen275' day O
'Sen275' ) O
'Sen275' . O

'Sen276' We O
'Sen276' report O
'Sen276' on O
'Sen276' three O
'Sen276' patients O
'Sen276' with O
'Sen276' acute O
'Sen276' schizophrenia O
'Sen276' , O
'Sen276' who O
'Sen276' developed O
'Sen276' severe O
'Sen276' akathisia O
'Sen276' during O
'Sen276' treatment O
'Sen276' with O
'Sen276' olanzapine U-DRUG
'Sen276' ( O
'Sen276' 20 B-DOSAGE
'Sen276' - I-DOSAGE
'Sen276' 25 I-DOSAGE
'Sen276' mg I-DOSAGE
'Sen276' / I-DOSAGE
'Sen276' d L-DOSAGE
'Sen276' ) O
'Sen276' . O

'Sen277' A O
'Sen277' 65-year O
'Sen277' - O
'Sen277' old O
'Sen277' woman O
'Sen277' with O
'Sen277' angina O
'Sen277' pectoris O
'Sen277' presented O
'Sen277' with O
'Sen277' syncope O
'Sen277' after O
'Sen277' sublingual O
'Sen277' ingestion O
'Sen277' of O
'Sen277' isosorbide B-DRUG
'Sen277' dinitrate L-DRUG
'Sen277' ( O
'Sen277' 5 B-DOSAGE
'Sen277' mg L-DOSAGE
'Sen277' ) O
'Sen277' . O

'Sen278' In O
'Sen278' a O
'Sen278' postural O
'Sen278' challenge O
'Sen278' test O
'Sen278' after O
'Sen278' administration O
'Sen278' of O
'Sen278' isosorbide B-DRUG
'Sen278' dinitrate L-DRUG
'Sen278' ( O
'Sen278' 5 B-DOSAGE
'Sen278' mg L-DOSAGE
'Sen278' ) O
'Sen278' , O
'Sen278' blood O
'Sen278' pressure O
'Sen278' decreased O
'Sen278' from O
'Sen278' 120/67 O
'Sen278' to O
'Sen278' 65/35 O
'Sen278' mmHg O
'Sen278' , O
'Sen278' followed O
'Sen278' by O
'Sen278' syncope O
'Sen278' with O
'Sen278' a O
'Sen278' sudden O
'Sen278' decrease O
'Sen278' in O
'Sen278' pulse O
'Sen278' rate O
'Sen278' from O
'Sen278' 85 O
'Sen278' to O
'Sen278' 60 O
'Sen278' beats O
'Sen278' / O
'Sen278' min O
'Sen278' . O

'Sen279' High U-DOSAGE
'Sen279' - O
'Sen279' dose O
'Sen279' phosphate O
'Sen279' treatment O
'Sen279' leads O
'Sen279' to O
'Sen279' hypokalemia O
'Sen279' in O
'Sen279' hypophosphatemic -
'Sen279' osteomalacia O
'Sen279' . O

